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ABSTRACT 
 
JENNIFER LEIGH RAYNER 
 
Atrazine and Rat Mammary Gland Development 
(Under the direction of Louise M. Ball and Suzanne Fenton) 
 
The herbicide atrazine (2-chloro-4-ethylamino-6-isopropylamino-s-triazine, ATR) is 
used to control growth of broadleaf and grassy weeds.  It has been registered with the United 
States Environmental Protection Agency and is monitored to prevent unsafe levels of this 
possible endocrine disrupting compound from reaching human and animal populations via 
contaminated surface or ground water.  Life-time feeding studies on ATR have shown an 
increased incidence and decreased time to tumors in mammary glands (MG) of rats, via its 
long-term effects on the brain and altered estrous cyclicity.  This thesis focuses on changes 
observed in developing MG of female Long Evans rats (offspring and dam) exposed during 
late gestation to ATR.  It also explores possible confounders of observed effects including 
body weights, pubertal timing, and serum hormone concentrations.   
 Dams were gavage dosed with 100 mg/kg ATR during late gestation corresponding to 
fetal mammary bud development and outgrowth.  That exposure caused a delay in puberty 
and mammary development in female offspring.  From cross-fostered litters, it was 
determined that nursing from an ATR-treated dam delayed both puberty and mammary 
development.  However, a brief transplacental exposure to ATR caused delays only in MG 
development that persist into adulthood.  MG development was most delayed in offspring 
exposed during fetal mammary epithelial cell proliferation (GD17-19), but it was also 
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delayed in offspring exposed only by nursing from dams treated during that same time.  
These results suggested that ATR may reprogram fetal and neonatal MG development. 
 These findings suggested changes in dam MG development or lactation.  MG from 
ATR-exposed dams were developmentally different from those of controls at early 
timepoints.  ATR and its metabolites were detected in the urine, amniotic fluid, and serum of 
treated dams at several timepoints post exposure suggesting that ATR metabolites may be 
available to the developing offspring until at least PND11 when abnormal MG development 
has been detected in female pups.  These studies taken together suggest that ATR can have 
long-term effects on the MG of female offspring and dams without association of 
confounders. The effects of this brief exposure are persistent, extending into adulthood and 
affecting weight gain of future generations via the lactational effects.  
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CHAPTER 1 
 
INTRODUCTION TO ATRAZINE 
 
 
Atrazine (2-chloro-4-ethylamino-6-isopropylamino-s-triazine) is a widely used 
herbicide due to its cost effectiveness, persistence, and versatile application time.  It is used 
primarily on commercial corn, sorghum, sugar cane crops, and fruit crops but can also be 
used on cotton, Christmas trees, recreational turf (parks and golf courses), and on other crops 
to control broadleaf weeds and some grassy weeds (Gianessi et al, 1998).  Atrazine is broken 
down by plants, microbes, and animals to form four major metabolites; 2-chloro-4,6-
diamino-s-chlorotriazine DACT, hydroxyatrazine ATR-OH, 2-chloro-4-amino-6-
(isopropylamino)-s-triazine DEA, and 2-chloro-4-amino-6-(ethylamino)-s-triazine DIA (Wu 
et al., 1998).  The mercapturate forms of atrazine and its metabolites have recently been 
detected in urine (Norrgran et al., 2006).  Atrazine is a pesticide of concern because of 
detection of it and its metabolites in ground and surface water including those that serve as 
water sources for humans (Baker, 1998).      
 Atrazine was registered with the EPA by Geigy in 1958, later to become Ciba-Geigy, 
Novartis, and now Syngenta.  A Registration Standard asking for data to support continued 
registration of atrazine was issued in 1983 because of concerns regarding carcinogenic risk 
from drinking and using contaminated surface and ground water (Addendum IRED, 2004).  
A Data Call-In (DCI) was issued by the EPA in Sept 1990 for more data about atrazine.  
Along with other measures, Ciba-Geigy reduced application rates for corn and sorghum, 
deleted some crop uses, and classified atrazine-containing products as Restricted Use 
Pesticides in 1990 in response to groundwater contamination concerns (Addendum IRED, 
2004).  In 1991, the Office of Water set a Maximum Contaminate Level (MCL) for atrazine 
of 3 parts per billion in water under the Safe Drinking Water Act and required frequent 
monitoring of watersheds.  Another DCI was issued in 1992 and more steps were taken to 
reduce contamination, this time in surface waters.  These steps included reducing application 
for corn and sorghum, expansion of restricted use, and increased setback requirements 
(Addendum IRED, 2004). 
A Special Review of atrazine began in 1994 to examine the cancer risk of people 
exposed through their occupation, drinking water, or lawn treatments.  Two more DCIs were 
issued in March and October 1995.  Additional use restrictions were placed on atrazine in 
1996 including no applications within 66 feet of standpipes or in no-till fields unless residue 
management was being practiced (Addendum IRED, 2004).  Atrazine had a revised cancer 
characterization in 2000, preliminary risk assessments in 2001, and revised risk assessments 
in 2002 (Atrazine Background, 2003).  In the revised cancer characterization of 2000, 
atrazine was classified as not likely to be carcinogenic to humans.  However, its endocrine 
disrupting capabilities were noted with concern.  The Interim Re-registration Eligibility 
Decision (IRED) was extended by a Consent Decree between the EPA and the Natural 
Resources Defense Council to January 2003 with revisions due by October 2003 so that 
amphibian studies and cancer studies could be incorporated into the risk assessments 
(Addendum IRED, 2004).   
The Federal Insecticide, Fungicide, and Rodenticide Act Science Advisory Panel 
(SAP) met in July 2003 to discuss potential carcinogenic risk and amphibian gonadal 
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development.  Data from epidemiological studies concerning prostate cancer in workers at an 
atrazine manufacturing plant showed increased prostate cancer rates in those workers.  The 
SAP decided that atrazine was not likely to cause prostate cancer in those workers due to 
study confounders.  Using the SAP decision along with other data, the EPA decided that 
there is not a potential human cancer risk from atrazine exposure (Revised IRED, 2003).  
Studies concerning abnormal amphibian development in the presence of atrazine were also 
discussed at the SAP meeting.  There were studies that showed adverse amphibian effects in 
the presence of atrazine and other studies that showed no effect from atrazine exposure.  Due 
to conflicting results and insufficient data, no change was made to the January IRED.  
However, it was recommended that more studies be conducted on amphibians (Revised 
IRED, 2003).   
The October IRED was favorable and included an agreement with Syngenta to 
monitor 40 watersheds during a two year period.  If atrazine concentrations exceed the MCL, 
steps would be taken to remedy the situation.  The results from the monitoring studies will 
determine if further monitoring or mitigation efforts are needed in those watersheds.  Rural 
drinking wells are also being monitored in atrazine use areas.  Monitoring costs would be 
born by atrazine registrants.  Syngenta was also required to conduct studies to determine 
amphibian effects from atrazine exposure to reduce the uncertainty produced by earlier 
amphibian studies.  These studies include assessment of changes in developmental and 
gonadal morphology, steroid concentration, aromatase activity, and reproductive fitness of 
amphibian species (Revised IRED, 2003). 
In addition to being registered and regulated for use, atrazine is regulated to minimize 
environmental and health effects.  These regulations are set based on data from health effects 
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studies of animals and epidemiological studies including acute, chronic, teratogenicity, 
reproduction, and pesticide spray drift studies (Data Requirements, 2003).  Safety or 
uncertainty factors are included to produce exposure levels to protect humans and children 
from risk from various routes of exposure (Crawford-Brown, 1999). 
 Drinking water sources, food residues, and occupational exposures are areas of 
concern for human health.  There is very little atrazine residue on foods processed for human 
consumption and risk from food contamination do not exceed the level of concern for the 
EPA.  In areas of high use, such as the Midwest, atrazine concentrations in drinking water 
sources exceed the level of concern and so these sources have to be monitored and use of 
atrazine may be prohibited in these watersheds to lower concentrations.  Several studies have 
been conducted in these areas but the results have been inconclusive. 
 Recently the EPA finalized the IRED and completed the reregistration process for 
atrazine (Atrazine Finalization, 2006) prior to completing the cumulative risk assessment for 
other chlorinated triazine pesticides (Triazine, 2006).  The EPA determined that exposure to 
atrazine, simazine, and their chlorinated metabolites (DEA, DIA, and DACT) through 
drinking water, food residues, and non-occupational sources was not of concern and will 
cause no harm to the population (Atrazine Finalization, 2006).   
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CHAPTER 2 
 
RAT MAMMARY GLAND DEVELOPMENT 
 
 
The rat mammary gland is a two compartment structure that begins developing during 
gestation.  Growth is continuous throughout life with the majority of growth occurring during 
puberty under the influence of many hormones and growth factors.  When the animal reaches 
adulthood (sexual maturity), the gland enters a semi-resting state. 
The parenchyma and the mesenchyma are the two compartments of the mammary 
gland.  The parenchyma is derived from the ectoderm and commonly called the epithelial 
compartment.  The mesenchyme derives from mesoderm and is known as the stroma which 
includes the fat pad.  The compartments are separated by a basement membrane (Imagawa et 
al., 1994).  
 The epithelial compartment consists of the luminal epithelium and the 
myoepithelium.  The luminal epithelium is composed of epithelial cells that line the lumen of 
the ducts, end buds, alveoli, and lobules (Imagawa et al., 1990, Masso-Welch et al., 2000).  
Columnar and cuboidal epithelial cells line the ductal lumen and flattened epithelial cells line 
the alveolar lumen (Masso-Welch et al., 2000).  Basal epithelial cells of the myoepithelium 
form a sheath around the ducts and alveoli (Imagawa et al., 1999, Masso-Welch et al., 2000).  
These basal cells also form the basement membrane that separates the epithelial compartment 
from the stromal compartment (Masso-Welch et al., 2000). 
 
The stromal compartment is made of connective tissue and during fetal development, 
consists as two separate sections.  One section is formed from fibroblasts while the other is 
formed of fat pad precursor cells (Borellini and Oka, 1989; Imagawa et al., 1990).  During 
fetal mammary gland development a few layers of fibroblasts surround growing mammary 
epithelium and form the mesenchyme by packing densely together (Sakakura, 1987).  The fat 
pad precursor cells derive from fibroblast-like mammary stromal cells (Masso-Welch et al, 
2000) and form the fat pad by differentiating into white fat tissue after birth (Sakakura, 1987) 
which is incorporated into the stroma.  The connective tissue at the edge of the fat pad forms 
a boundary to which the mammary epithelial cells grow up to, but not past (Masso-Welch et 
al., 2000). 
Cellular Development 
Perinatal Development 
In the rat, at approximately gestation day (GD) 10, a single-layered ectoderm 
enlarges.  This layer, the mammary streak, extends from the anterior limb bud to the posterior 
limb bud on both sides of the animal (Sakakura, 1987; Imagawa et al., 1994; Hovey et al., 
2002).  Cells migrate along the mammary streak and form six pairs of mammary buds 
(Imagawa et al., 1994) which increase in size due to continued cell migration through GD13 
(Hovey et al., 2002).  From GD14 to GD16 there is little epithelial growth.  However, 
fibroblasts in the stroma begin to form concentric layers around the epithelial cells.  During 
this timeframe, the overlying epidermis is stimulated to form the nipple (Wysolmerski et al., 
1998).  From GD16-21, the epithelial cells proliferate rapidly forming a sprout or cord 
(Sakakura, 1987) that grows into the mesenchyme (Imagawa et al., 1990).  The cord 
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canalizes and branches, forming the mammary tree (Sakakura, 1987; Imagawa et al., 1994).  
In the stroma, lipids accumulate in the fat pad precursor cells (Hovey et al., 2002). 
Birth occurs in rats on approximately GD21.  Following birth, the mammary gland 
consists of 15-20 ducts branching off of a primary duct (Hovey et al., 2002).  The ends of the 
branching ducts are shaped liked clubs (Figure 1, 2; Imagawa et al., 1994; Hovey et al., 
2002).  Growth during this period of time is isometric meaning that the epithelium and the 
mesenchyme grow at the same rate as the body (Daniel and Silberstein, 1987; Borellini and 
Oka, 1989).  This growth is hormone independent (Imagawa et al., 1994).  During isometric 
growth, birth to postnatal day (PND) 22, the club shaped ends of the ducts regress but 
reappear during the peri-pubertal time period (Imagawa et al., 1994; Hovey et al., 2002). 
Peri-pubertal Development 
Following PND22, the approximate beginning of the peri-pubertal period, the 
mammary gland begins to grow allometrically (Figure 3A, B).  Allometric growth for 
mammary development is characterized by mammary growth that occurs at a rate two to 
three times faster than body weight (Borellini and Oka, 1989; Hovey et al., 2002).  The club 
shaped end buds reappear at this time.  The end buds or terminal end buds are clusters of 
epithelial cells, multiple layers thick (unlike other mammary gland epithelial structures) from 
which ductal elongation and branching occur (Masso-Welch et al., 2000).  Terminal end buds 
are very proliferative structures that consist of a basal surface and cuboidal epithelial cap 
cells (Daniel and Silberstein, 1987).  Cap cells are a type of stem cell that differentiates into 
luminal epithelial and myoepithelial cells (Masso-Welch et al., 2000), giving form to ductal 
structures (Imagawa et al., 1994). 
 7
During the early stages of puberty, the cells of the terminal end buds undergo mitosis 
and cell migration to form ductules (Figure 4, 5).  Apoptosis of the innermost cells occurs to 
form the lumen of the ductules (Masso-Welch et al., 2000).  This ductile elongation occurs 
until the ducts reach the end of the fat pad (Figure 6; Imagawa et al., 1990). 
As puberty ends, the terminal end buds bifurcate to form terminal ductules.  The 
terminal ductules cluster together to form alveolar buds (Masso-Welch et al., 2000).  With 
the progression of time, the number of alveolar buds increases and the buds differentiate into 
lobuloalveolar structures until the animal reaches sexual maturity (Figure 2.6). 
Adult Development 
After sexual maturity is reached, a cyclic remodeling takes place in the mammary 
gland that corresponds to the estrous cycle, but the gland is considered to be in a semi-resting 
state.  During the beginning of the cycle, diestrus I and diestrus II, the ductal ends are 
terminal end ductules.  During the middle of the cycle, proestrus, the ends differentiate into 
alveolar buds.  The end of the estrous cycle, estrus, is marked by lobuloalveolar structures 
and rapid apoptosis of these structures.  The terminal end ductules reappear at the beginning 
of the next cycle (Hovey et al., 2002).  This remodeling continues until pregnancy occurs or 
a constant state of estrus is reached in the aged rat. 
When pregnancy occurs, lobules and ducts grow to fill the fat pad.  In the early stages 
of pregnancy, ductal side branching and lobuloalveolar formation takes place.  Alveoli 
increase in number and size to fill the space between the ducts within the gland (Masso-
Welch et al., 2000).  As the epithelial structures grow and develop, the stromal adipose tissue 
reduces to thin strands (Imagawa et al., 1990, Masso-Welch et al., 2000).  During the late 
stages of pregnancy, the alveolar cells fill with lipids and luminal cells fill with a basophilic 
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substance.  The number of blood vessels increases to provide nutrients to the cells of the 
rapidly growing gland (Imagawa et al., 1990, Masso-Welch et al., 2000).  During this time, 
many endogenous substances are being transported to the mammary gland for milk 
production.  At parturition, alveolar cells are filled with lipid and lactose-containing secretory 
vesicles.  Crescent shaped cytoplasm enclosed milk fat globules containing lactose and milk 
proteins are expelled into the alveolar lumen.  Processes of the myoepithelial cells contract 
and push the contents of the lumen (milk) into draining ducts (Masso-Welch et al., 2000).   
Hormones and Growth Factors 
 Mammary gland development occurs through cell differentiation and migration, but 
this development is dependent upon several hormones and growth factors which are 
expressed during specific periods of growth in the developing mammary gland, mainly 
embryonic growth and peri-pubertal/pubertal growth.  The majority of hormone and growth 
factor knowledge comes from the study of transgenic mice, but can be extrapolated to rats. 
Parathyroid hormone-related protein (PTHrP) is expressed by mammary 
myoepithelial cells adjacent to the basement membrane beginning during GD14-16.  
Wysolmerski and colleagues (1998) showed that the embryos of PTHrP-null mice had 
normal appearing mammary buds but no primary ducts off the buds.  The fat pad of the 
PTHrP-null embryos was also smaller in size compared to that of control embryos.  The 
control embryos displayed an elongated primary duct extending into the fat pad with initial 
branches.  Closer examination showed degenerating epithelial duct cells in the PTHrP KO 
mice only in the upper dermis and they noted the absence of nipple sheath development.  The 
primary duct of the control embryos were surrounded by a well-developed nipple sheath 
(Wysolmerski et al., 1998).  At birth, the glands of the PTHrP-null mice were characterized 
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by remnants of degenerating ducts while the control mice had a normal duct system with 15-
20 branches elongating into the fat pad.    
During the peri-pubertal, pregnancy, and lactation periods many hormones and 
growth factors are expressed and play a major role in mammary gland development.  Ovarian 
estrogen stimulates ductal growth and stromal proliferation through a paracrine mechanism 
due to the fact that estrogen receptors are found in stromal fibroblasts and luminal epithelial 
cells in the end buds, but not cap cells of the end buds (Imagawa et al., 1990; Silberstein, 
2001; Hovey et al., 2002).    It is also required for lobuloalveolar development (Topper and 
Freeman, 1980).  Progesterone stimulates ductal side branching, terminal end bud formation 
(Atwood et al., 2000), and lobuloalveolar development (Silberstein, 2001).  Progesterone 
receptors are found in half of the cells of the terminal end buds, but not in myoepithelial cells 
(Atwood et al., 2000).  Growth hormone stimulates terminal end bud formation and ductal 
proliferation and prolactin stimulates ductal side branching and terminal end bud formation 
(Silberstein, 2001; Hovey et al., 2002).  
 Bocchinfuso and colleagues (2000) examined estrogen receptor-α (ERα) knockout 
mice to determine the role prolactin and estrogen play on mammary gland development.  
They found that ER-α knockout mammary glands displayed an immature mammary ductal 
structure and had low circulating serum prolactin levels.  With a pituitary graft replacing the 
source of prolactin, the ER-α knockout mice displayed a ductal network similar to that seen 
in control mice (Bocchinfuso et al., 2000).  They also found that exogenous estrogen and 
progesterone could increase ductal growth and alveolar development in ER-α knockout mice, 
and that prolactin could induce progesterone levels to enhance mammary growth.  Naylor 
and colleagues (2003) determined that prolactin exhibits its effect via an autocrine/paracrine 
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mechanism.  They showed that prolactin produced by mammary epithelial cells is not 
responsible for ductal side branching and alveolar bud formation, but that endocrine prolactin 
is responsible.  They determined that cell proliferation in lobuloalveoli was regulated by 
mammary-produced prolactin (Naylor et al., 2003).   
Epidermal growth factor (EGF) stimulates the proliferation of myoepithelial cells 
(Imagawa et al., 1994).  Transforming growth factor-β (TGFβ) inhibits mammary epithelial 
cell growth and appears to regulate ductal patterning through stromal receptors (Silberstein, 
2001).  Insulin-like growth factor I is required for mammary gland architecture and function, 
ductal growth, and terminal end bud formation (Imagawa et al., 1994).    It is stimulated by 
growth hormone which enhances its ability to stimulate terminal end bud formation 
(Kleinberg et al., 2000).  Insulin-like growth factor II is an effector of prolactin in alveolar 
development (Hovey et al., 2003).  Other growth factors, including hepatocyte growth factor, 
transforming growth factor-α, fibroblast growth factor, and keratinocyte growth factors, are 
also involved in mammary gland growth regulation but their mechanisms of action are not 
fully known. 
The role of growth hormone and EGF receptor in the mammary gland was examined 
by Gallego and others (2001).  Growth hormone receptor-null adult mice had retarded ductal 
outgrowth with limited ductal growth.  At a later timepoint, the ducts of these animals filled 
the fat pad but had limited side branching and thinner ducts than control mice.  Mammary 
glands taken from EGF-receptor null embryos at GD18 had only rudimentary ductal 
structures (Gallego et al., 2001).  Many other studies are ongoing to elucidate the role that 
the growth factors listed above along with other growth factors, activins, and hormones play 
in mammary gland development.  Mammary gland development is a very complex process 
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and the current knowledge that we have of the interplay of hormones and other factors 
necessary for growth is just beginning to be resolved. 
 12
Postnatal Day 4 Rat Mammary Gland (Whole Mount) 
 
LN 
FP 
BV 
 
 
Figure 2.1.  Early postnatal mammary gland development.  Whole mount of the PND4 rat 
inguinal mammary gland (4th) stained in carmine alum.  This gland has many initial ducts 
and branches and club-like end buds (arrow) growing toward the lymph node (LN arrow) in 
the top left corner.  Although more difficult to distinguish, blood vessels (BV) and lymphatic 
vessels are present in the fat pad/stroma (light pink stain, FP). 
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Histological Section of Postnatal Day 4 Rat Mammary Gland (H&E Stain) 
 
LN 
FP 
 
Figure 2.2.  H&E stain of the 4th inguinal mammary gland taken from PND4 rat.  The small 
round dark staining structures in the lower left of the slide are the club-like ducts (arrow).  
Blood vessels are also present within the fat pad (FP).  The lymph node (LN) is located in the 
middle left of the slide. 
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Postnatal Day 22 & 25 Rat Mammary Gland (Whole Mount) 
A      B       
TB 
 
Figure 2.3.  Isometric growth of the mammary gland. Whole mount carmine alum stain of 
the 4th inguinal rat mammary gland prepared on PND22 (A) and PND25 (B).  (A) Allometric 
growth has begun and there is extensive branching of the ducts.  Terminal end buds are 
prominent and ductal growth has reached the lymph node (arrow).  (B) In only a short period 
of time, terminal end buds (TB) are distended and side branches have elongated.   
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        Postnatal Day 33 Rat Mammary Gland (Whole Mount) 
                         
 
Figure 2.4.  Pubertal growth and development of the mammary gland. Whole mount carmine 
alum stain of the 4th inguinal rat mammary gland prepared on PND33.  This is approximately 
the timepoint when vaginal opening occurs.  The gland displays terminal end buds only on 
the most distal ends (arrows).  The fourth and fifth glands are shown growing together.  
When they reach each other, the terminal end buds will differentiate into alveolar buds and 
lobules, and rest in a semi-static state. 
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Histological Section of Postnatal Day 33 Rat Mammary Gland (BrdU Staining) 
                      
 
Figure 2.5.  Pubertal development of the rat mammary gland.  DAB, 3,3’-diamobenzidine, 
and hemotoxylin stain of a portion of the 4th inguinal rat mammary gland prepared on 
PND33.  BrdU is a cell proliferation marker taken into the DNA during the S-phase of the 
cell cycle.  Dark staining is BrdU labeled cells within ductule structures.  The ducts are 
surrounded by adipose tissue. 
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Histological Section of Postnatal Day 40 Rat Mammary Gland (BrdU Staining)                      
 
         
 
 
Figure 2.6.  Post-pubertal mammary gland development.  DAB, 3,3’-diamobenzidine,and 
hemotoxylin stain of a portion of the 4th inguinal rat mammary gland prepared on PND40.  Dark 
staining is BrdU labeled cells within ductule structures.  Fewer structures are labeled compared to 
Figure 2.5 because cell proliferation is slowing at this time.  The animal is nearing the end of puberty 
and the gland is about to enter the resting stage. 
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CHAPTER 3 
 
MAMMARY GLAND & ENDOCRINE DISRUPTING COMPOUNDS 
 
 
Endocrine disrupting compounds (EDCs) are chemicals that change endocrine 
function.  They can block or enhance the effect of endogenous hormones through mimicry or 
direct stimulation or inhibition of the endocrine system (Endocrine Primer).  Disturbing the 
endocrine system during major periods of growth and development can lead to adverse health 
effects later in life.  This is especially true of mammary tissue following EDC exposure 
during gestation and during the perinatal period.  
Several studies have shown that the developing mammary gland is sensitive to 
toxicant exposure.  Fenton and colleagues (Fenton et al., 2002) showed that the mammary 
glands of female offspring of Long-Evans dams exposed in utero to 2,3,7,8-
tetrachlorodibenzo-p-dioxin, a lipophilic aromatic hydrocarbon, on GD15 displayed 
persistently delayed development into adulthood.  The mammary gland epithelium of female 
offspring at several developmental time points had not migrated through the fat pad, lateral 
branching was reduced, and terminal end-buds were present for extended lengths of time 
suggesting a critical window of development during which the gland was susceptible to 
dioxin.  Foster et al., (2004) treated Sprague-Dawley dams from gestation day (GD) 9-16 
with a mixture consisting of organochlorines, chlorinated benzenes, and metals (Wade et al., 
2002) at their individual acceptable daily intake levels, with or without postnatal genistein. 
Female offspring receiving both the mixture and genistein had increases in female mammary 
gland morphological alterations including calcifications, epithelial hyperplasia, and cystic 
dilation compared to control and mixture groups.  Bisphenol A, compound used to 
manufacture plastic, was shown to alter the development of CD-1 mouse mammary gland 
when exposed beginning on GD9 and continuing throughout the pregnancy (Markey et al., 
2001).  Glands removed 1 month after birth from offspring of dams treated with 25 µg/kg 
showed increased ductal elongation while glands from dams treated with 250 µg/kg showed 
decreased elongation compared to control glands (possibly due to different signaling 
components for the low dose effect).  By six months of age both groups had significant 
increases in ductal and alveolar structures compared to control.  These studies taken together 
demonstrate that the fetal mammary glands of rats and mice are sensitive to the effects of 
environmental agents during the prenatal period of development, a probable critical period of 
development.  The delays in growth and development result in the presence of proliferating 
structures (terminal end buds) for a longer amount of time.  During this time, the mammary 
gland is more susceptible to ‘hits’ from carcinogens.   
Epidemiological studies concentrating on sexual maturation and growth have been 
conducted in populations accidentally exposed to endocrine disrupting compounds.  Pubertal 
development was assessed by Blanck et al., (2000) in girls exposed to polybrominated 
biphenyls (PBB) via maternal ingestion, either in utero or through breastfeeding.  The 
exposure occurred in 1973 after accidental contamination of Michigan dairy and animal 
products.  They found that females exposed to high estimated levels (> 7 parts per billion, 
ppb) in utero and through breastfeeding experienced menarche at an earlier age compared to 
females breastfed and exposed to low levels or females not breastfed.  Breast development in 
these females was not affected by exposure.  Blanck and colleagues (2002) also examined the 
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growth of these same females.  They found no association between height or weight and PBB 
exposure.  The did find that mothers who had higher (> 5 ppb) PBB exposure had female 
children who weighed less than those exposed to low levels of PBB.  den Hond et al., (2002) 
assessed Belgium adolescent populations in two suburbs exposed to polychlorinated aromatic 
hydrocarbons (PCAHs) and one rural control area.  The sources of exposure were a smelter, 
two waste incinerators, and a crematory.    Sixty percent of the population was females, and 
samples were taken from the adolescent participants.  They found that a significant number 
of females in one of the polluted sites (Wilrijk) had not reached the adult stage of breast 
development, by a mean age of 17.4 years, and pubic hair was less developed in these 
females.  They also noted that a higher serum concentration of dioxin-like compounds was 
associated with a lower stage of breast development.  Menarche was not different in the three 
populations.  These studies begin to suggest that endocrine disrupting compounds can disrupt 
puberty and mammary gland development through varying exposure routes, not only in 
rodents but in the human population as well.  
Atrazine (ATR) is a widely used herbicide applied to a variety of crops to control 
broadleaf and grassy weeds.  It is less expensive and persists longer in the soil than 
alternative herbicides, which leads more farmers to use ATR on their corn, cotton, citrus, and 
grape crops (Gianessi, 1998).  ATR levels higher than the Environmental Protection 
Agency’s (EPA) drinking water standard of 3 µg/L or 3 parts per billion have been detected 
in surface and groundwater (Baker, 1998).   
Stoker and colleagues (1999) found that at least 50 mg/kg ATR completely 
suppressed the suckling-induced prolactin release in lactating dams treated PND1-4.  The 
dam normally secretes prolactin into the milk for the developing pup which does not begin to 
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produce prolactin for itself until after PND5 (Hoeffler et al., 2002), and as previously stated, 
prolactin is needed for adequate mammary gland development during lactation.  ATR 
presumable prevented normal levels of prolactin from getting to the pups resulting in 
increased incidence of lateral prostate inflammation in adult male offspring.  They also 
suggest that the observed effects could be the result of suppressed immune response due to a 
transient period of hyperprolactinemia in the male offspring prior to puberty.  Other studies 
examined the effects of single ATR metabolites on puberty in female and male rats (Laws et 
al., 2003, Stoker et al., 2002).  They found that DACT delayed puberty in females and DIA, 
DEA, and DACT delayed puberty in male rats at relatively high levels.  They found the 
chlorinated metabolites to be as potent as ATR.  Cooper et al. (2000) showed that ATR 
specifically inhibits the estrogen-induced surges of luteinizing hormone (LH) and prolactin 
(PRL) in ovariectomized SD and LE rats and therefore disrupts hypothalamic-pituitary-
ovarian activity.     
Our early studies of late gestational exposure to high levels of ATR showed delayed 
mammary gland development in the female offspring.  Normal fetal mammary gland 
development is dependent upon hormones and growth factors directing cellular growth and 
migration.  It is possible that low prolactin levels or low levels or other hormones/growth 
factors in utero or in milk during a critical period of development could alter mammary 
growth. 
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CHAPTER 4 
 
ATRAZINE EXPOSURE DELAYS MAMMARY GLAND DEVELOPMENT 
 
Summary 
 
To evaluate the effects of time and duration of exposure to ATR on puberty in LE rats, these 
studies utilized brief gestational exposures and evaluated the effects on traditional pubertal 
indicators, as well as mammary gland development, in the female offspring.  Early studies 
suggested that gestational exposure to ATR affects both mammary gland development and 
VO in female offspring.  To evaluate whether these effects of ATR were via similar exposure 
parameters, offspring were cross-fostered at birth and evaluated for changes in pubertal 
indicators, reproductive tissue weights, and endocrine hormone status.  The exposure 
parameters were designed to determine if exposure-induced changes were the result of 
transplacental exposure to ATR (ATR-C), changes in milk composition, (C-ATR), or a 
combination of the two parameters (ATR-ATR).  Additionally, gene expression of local 
factors, previously suggested to affect mammary gland growth, was evaluated in tissues 
exposed to ATR under these described routes.    
Methods 
Animals- Time-pregnant Long Evans rats (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  The animals were housed one per cage 
and given food (Purina 5008 Rodent Chow, Ralston Purina Co., St. Louis, MO) and water ad 
libitum.  They were maintained in a room with a 14:10 hour light cycle, 20-24°C and relative 
humidity of 40-50%.  Animals were treated as approved by the National Health and 
Environmental Effects Research Laboratory, Institutional Animal Care and Use Committee. 
Dosing Solution and Procedures- Atrazine (Syngenta Crop Protection, Inc. Greensboro, NC, 
97.1% purity) was prepared as a suspension in 1.0% methyl cellulose (Sigma Chemical, St. 
Louis, MO) in distilled water.  Time pregnant rats were treated with 0 (vehicle) or 100 mg 
atrazine/kg BW by oral gavage in 5 ml/kg dosing volume.  The reference dose (100 mg/kg) 
was chosen due to consistent reproductive endpoint effects observed in previous studies 
(Stoker et al., 1999, Laws et al., 2000). 
Experimental Design- 40 pregnant LE dams were treated on gestational days (GD) 15-19 
with vehicle (control) or 100 mg/kg atrazine once daily (N=20 dams/treatment).  On 
postnatal day 1 (day of birth), litters were weighed and approximately half of each litter was 
cross-fostered with half of another litter from a control (C) or atrazine treated (ATR) dam, 
creating four exposure parameters (exposed dam-milk source; C-C, ATR-C, C-ATR, ATR-
ATR).  Pups remaining in the same litter were marked on the tail and/or front right paw with 
permanent ink.  Litters were weighed and equalized to 10 pups on PND4.  At weaning, 
PND22, animals were weighed and separated into unisexual sibling groups, 2-4 female rats 
per cage.  Some females were sacrificed on PND4, 22, 33, 40, and 58. Male pups were used 
in a separate study unrelated to this one (Appendix B).  The data from an exposed dam’s 
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offspring were evaluated with the dam (2 pups/dam or litter) as the experimental unit, with 
the exception of vaginal smears (see Statistical Analysis). 
Vaginal Opening and Cyclicity-Beginning on PND28, females (N>29/group) were evaluated 
for vaginal opening (VO).  The postnatal day of complete VO, and body weight on that day, 
were recorded.  Daily vaginal smears were collected beginning the day following VO for 
each animal.  Smears continued until PND 58. Vaginal smears were read wet for the presence 
of leukocytes (diestrus), nucleated epithelium (proestrus), or cornified epithelial cell (estrus) 
to determine cyclicity patterns on an American Optical low-power light microscope.  Smear 
data were plotted in Lotus 123 by assigning the value of 1 to diestrus, 5 to proestrus, and 10 
to estrus.  The graphs were observed for 4-5 day normal cycles and the number of 
consecutive normal cycles was recorded for each animal.  This was done to evaluate the 
effect of prenatal atrazine exposure on early cyclicity patterns following VO.  Episodes of 
persistent diestrus or estrus were also recorded and the number of episodes per animal was 
compared across treatment.  Irregular cyclicity was defined as those not presenting at least 
two consecutive normal cycles between VO and PND 58. 
Necropsy-Sufficient female pups were available that on PND58, females in the diestrus stage 
of their estrous cycle were decapitated, providing N=14 to16 for each of the four cross-
fostered groups.  Trunk blood was collected and centrifuged for 30 minutes at 3000rpm (4°C) 
for serum.  The pituitary gland, right and left ovaries, and uterus (wet) were removed and 
weighed.  The pituitary gland was frozen at -80°C and the uterus and ovaries were placed in a 
histology cassette and fixed in 10% buffered formalin.   
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Mammary Whole Mounts- The 4th and 5th mammary gland were removed, fixed, and stained 
in carmine as a whole mount as previously described (Fenton et al., 2002) on PNDs 4, 22, 33, 
40, and 58 (2-4 pups/dam).  Animals on PND 33 and 40 were decapitated and serum obtained 
for RIAs. Flattened whole mounts were visualized and subjectively scored on a scale of 1-4 
(1=poor development/structure and 4=normal development/structure for each age group) by 
two individual scorers, without knowledge of treatment, within age group (16% coefficient of 
variation).  Mean scores for each age group were computed and analyzed for differences due 
to treatment. Mammary glands representative of the mean score of the group were 
photographed on a Leica WILD M420 macroscope.   
BrdU Incorporation Assay- On PND 33 and 40, females in diestrus (N=5/exposure 
parameter) were injected IP with 50mg BrdU/kg BW 3 hours before decapitation.  A portion 
of the 4th mammary gland was fixed in methacarn (6:3:1, v:v:v, methanol, chloroform, and 
glacial acetic acid).  Tissues were processed by Veritas Laboratories, Inc., (Burlington, NC) 
as stated:  15 min 95% ethanol (EtOH), 3 hr methanol, 4 hr methanol, 1 hr 95% EtOH, 1 hr 
100% EtOH, 1 hr xylenes, 1 hr paraffin, 1 hr paraffin, and 3 hr paraffin.  The 5µm sections 
were either stained with hematoxylin and eosin (H&E) or used directly for 
immunohistochemical detection of BrdU. 
Immunohistochemistry- Unstained slides were deparaffinized in xylene (3 changes), hydrated 
in a series of graded ethanols, and rinsed in distilled water.  Sections were then incubated 
with anti-mouse BrdU (Dako, Carpinteria, CA) 1:40, and biotinylated rabbit anti-mouse IgG 
(Dako) 1:200, as described (McGinley et al., 2000).  Nuclei were stained with 3,3’-
diamobenzidine (DAB) (Sigma Chemical) and counterstained with Harris hematoxylin 
(Fisher Chemical, Fairlawn, NJ) to detect the presence of BrdU.   
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BrdU Scoring- Slides were visualized on an Olympus BH2 light microscope.   For scoring 
purposes, the total number of epithelial structures per slide was counted.  The total number of 
labeled structures per slide was counted to yield the percent of structures labeled.  A score 
was given to each slide based on the amount of labeling within the labeled structures (1=few 
cells labeled, 4=majority of cells labeled) and is presented as labeling score.  
Radioimmunoassays- Serum luteinizing hormone (LH), prolactin (PRL), and thyroid 
stimulating hormone (TSH) were analyzed by radioimmunoassay using materials supplied by 
the National Institute of Arthritis, Diabetes, Digestive, and Kidney Diseases.   All assays 
were run in duplicate with 100 µl of sera per animal.  These methods have been previously 
described in detail (Stoker et al., 2000). 
Real Time Polymerase Chain Reaction- The contralateral mammary glands of animals 
decapitated at PND33 and PND40 were frozen for RNA.  Total RNA was extracted from 
these glands using Tri Reagent as described by the manufacturer (Sigma Chemical), with two 
chloroform extractions, and dissolved in DEPC-treated H20.  RNA samples were digested 
with DNAse I (Promega Corporation, Madison, WI) and quantitated using RiboGreen 
quantitation reagent (Molecular Probes, Inc., Eugene, OR) according to manufacturer’s 
instructions.  After incubation with DNAse I, 0.5 µg of random hexamers (Promega Corp.) 
was added to each RNA sample (N=40 samples), heated to 70° for 5 minutes, incubated on 
ice, and added to the reverse transcription (RT) reaction.  RT reactions were prepared by 
mixing 4 µl of 5X ImProm-II buffer (Promega Corp.), 2 µl of 10 mM each dNTP, 2.4 µl of 
25 mM MgCl, 20U RNasin (Promega Corp.), 1 µl of ImProm-II Reverse Transcriptase and 
DEPC-treated H20  (q.s. 10 µl).  This RT reaction mix was added to each RNA sample and 
incubated according to ImProm II manufacturer’s instructions.  A 100 ng aliquot of each 
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reaction was then amplified by real-time polymerase chain reaction (PCR) in an iCycler 
(Bio-Rad Laboratories, Hercules, CA) with gene specific primers and dual-labeled (Fam and 
Black hole quencher-1) fluorescent probes synthesized by Integrated DNA Technologies 
(Coralville, IA) for aromatase and epidermal growth factor receptor (EGF-R).  Aromatase 
primers and probe used for PCR were: 5'-TCATTAACGAGAGCCTGCGG-3' F, 5'-
TTAACCGGGTAGCCGTCAATC-3' R, and 5'-TGTCGTGGACTTGGTCATGCGCA-3' 
probe.  EFG-R primers and probe used for PCR were: 5'-
TGAAGGGAAGTACAGCTTTGGTG-3' F, 5'-CTTCGTAGTAGTCAGGCCC ACAG-3' R, 
and 5'-TGCCCCCGAAACTACGTGGTGACA-3' probe.  The predicted size of the PCR 
amplified product was 90 bp for aromatase and 109bp for EGFR.  Each cDNA was amplified 
in reactions containing 2 µl of 10mM each dNTP, 5 µl of 10X Thermo buffer (Promega 
Corp.), 1.2 µl of 10 µM gene-specific reverse primer, 1.2 µl of 10 µM gene-specific forward 
primer, 0.125 µl of 10 uM dual-labeled probe, 1µl of Taq I polymerase (2.5U Taq, Promega 
Corp., mixed with 2.5U of Platinum Taq antibody, Invitrogen Corporation, Carlsbad, CA) 
and 25 mM MgCl (16 µl of 25 mM MgCl for aromatase or 8 µl of 25 mM MgCl for EGFR 
reactions) in a total reaction volume of 50 µl.  PCR cycling conditions were an initial 95° for 
3 minutes then multiple cycles of 95° for 15 seconds, 56° for 20 seconds and 72° for 10 
seconds.  Product size was confirmed using Agilent 2100 Bioanalyzer (Agilent Technologies, 
Palo Alto, CA).  Bands were not detected when reverse transcriptase was omitted, (data not 
shown) nor when water was the template.  Data were reported as threshold cycle and was 
obtained using manufacturer’s recommended settings for iCycler software, version three.  
Fold differences (induction values) were calculated by determining the differences in 
threshold cycles for each gene between the control and exposure parameters and log-
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transforming the values (exponent of the base 2), due to the exponential nature of PCR 
(Ginzinger, 2002).  Dam means were used as the unit of comparison. 
Statistical Analysis- Dam means (vs. litter means, because half litters were crossed) were 
calculated for body and tissue weights, mammary gland scores, VO day, serum hormones, 
and real time PCR (threshold and transformed data) and used as the unit of analysis. Means 
and adjusted means relative to body weight were calculated for organ weights and mammary 
gland scores.  Two-way analysis of variance (ANOVA, Statistical Analysis System (SAS), 
SAS Institute, Inc. Cary, NC) was performed for interaction effects of body weight, and VO 
day with treatment on mammary gland scores and tissue weights. There were no significant 
interactions found.  Body weights, mammary gland scoring, BrdU scoring, serum hormone 
concentrations, and PCR data were evaluated for treatment effects within each age group by 
one-way ANOVA.  Analysis of covariance was used to evaluate the effects of treatment on 
outcomes (mammary gland scores, tissue weights) while adjusting for any effect of body 
weight.  When there was an overall difference between treatment groups, a pair-wise 
comparison was made between treatment groups and control.  Estrous cyclicity data were 
compared by Mantel-Haenszel analysis (Nonzero Correlation and Row Mean Score test).  
Significant treatment effects were indicated by p<0.05 and specific p-values are indicated. 
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 Results 
Dam Weight Gain- Dam weight was recorded throughout the dosing period (GD15-19) and 
weight gain compared among the groups.  Mean body weight of the ATR dams on GD19 
(346.7+7g) was reduced 13% when compared to control dams (396.7+7g).  Control dams 
gained an average of 53.3+1.6g during the five-day dosing period and ATR-treated dams 
gained only 19.3+3.6g during the same time period. 
Body Weight, Puberty, and Cyclicity-The offspring of dams treated with ATR and crossed 
to an ATR dam during lactation were smaller (p<0.01) than offspring of all other groups at 
PND4 (Fig. 1A, 8.2+0.1 ATR-ATR vs. 8.7+0.1 C-C, 8.9+0.2 ATR-C, and 8.8+0.2 C-ATR).  
While found to be statistically significant, their mean weight was reduced only 5.7% from 
control animals, which is within normal range.  By weaning, PND22, body weights were not 
significantly different between groups (Figure 4.1B, C-C 54.7+0.8, ATR-C 52.7+0.7, C-ATR 
53.1+1.0, and ATR-ATR 53.8+1.0).  Furthermore, there was no difference in BW between 
groups at PND33, 40 (Figure 4.1C, 4.1D), or 58 (not shown). 
 The female offspring from dams (N>8/exposure parameter) were evaluated for 
physical signs of puberty, namely, VO and estrous cyclicity.  Control animals underwent VO 
on PND 33+0.4 (Figure 4.2A).  A significant delay in VO was seen only in those animals 
nursing from ATR treated dams (C-ATR 35.4+0.6, ATR-ATR 37.1+0.5, p<0.02 vs. C-C).  
Body weights of these animals on the day of VO were increased significantly in the ATR-
ATR, but not the C-ATR groups (Fig. 2B; ATR-ATR p<0.002 vs. C-C and ATR-C).   
Following VO, estrous cyclicity patterns of these animals were observed until they 
were necropsied.  The number of consecutive normal cycles (4-5 days) per animal were 
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determined and analyzed according to treatment (Table 4.1).  Abnormal cyclicity was 
designated to groups determined by their smear profiles: persistent estrus (PE), persistent 
diestrus (PD), or irregular (IR).  Animals that were PE and PD exhibited more than 4 
continuous days of estrus or diestrus, respectively.  Animals marked with IR did not cycle 
regularly, but could also display PE or PD.  Analysis of these data demonstrated no 
significant differences due to treatment in the number of consecutive normal estrous cycles 
between VO and PND 58.  The number of animals in each treatment group demonstrating PE 
or PD was also evaluated and no differences were found between treatment groups (data not 
shown).  We found 8% of all animals displayed a period of PE and 17% a period of PD 
during the first 3 to 4 weeks following VO.  We also found that 18% of female offspring did 
not demonstrate at least two consecutive normal cycles during this peri-pubertal period 
(consistently irregular).  
Mammary Gland Development- In addition to the traditional indicators of rodent puberty, 
we also evaluated mammary gland development in female offspring.  In order to evaluate the 
effects of atrazine following gestational and/or lactational exposures on mammary gland 
development in female offspring, whole mount analyses of the fourth and/or fifth mammary 
gland were compared on PND 4, 22, 33, 40, (Figure 4.3, Table 4.2) and 58 (not shown).  
Glands from PND4 females were examined to determine if epithelial development of the 
mammary gland was affected by the ATR exposure parameter.  Mammary glands from all 
ATR exposure parameters were smaller and displayed immature ductal structures compared 
to glands from C-C animals which showed a normal growth pattern, complete with strong 
branching.  Because the animals in the ATR-ATR group were smaller on average, we 
evaluated the mammary gland development data using body weight as the covariate and 
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found the development to be significantly different based on treatment alone (p<0.001).  This 
showed that body weight was not causal in the delayed development observed.  
At weaning, PND22, control females displayed normal branching with distended 
terminal ends and abundant lateral branching structures.  However, females from the ATR 
exposure groups displayed sparse branching patterns, fewer terminal ends, and delayed 
migration through the fat pad.  At the peripubertal timepoint, PND33, the glands from the 
animals that had suckled an ATR treated dam had terminal end buds on all sides and the 
fourth and fifth glands had not grown together.  The glands of C-C females had mostly 
grown together and only had terminal ends buds remaining on the distal ends.  By PND40, 
the glands from all ATR exposed animals had grown together but had not filled the majority 
of the fat pad, and still retained large numbers of terminal end buds on both ends compared to 
C-C animals in which few, if any, terminal end buds remained on the distal ends.  By 
PND58, there were only subtle differences between the groups in mammary gland 
development or structure.  Analysis of the mammary gland scoring at all later time points, 
using body weight as the covariate, found only exposure parameter-related effects (as 
indicated in Figure  4.3, Table 4.2). 
BrdU incorporation was used to measure the proliferation index (% cells per structure 
stained) of cells in the rapidly developing mammary gland of animals at PND33 and 40 
(McGinley et al., 2000; Table 4.3).  Immunohistochemical staining of PND33 gland sections 
showed no significant differences in staining in animals that had suckled from an ATR 
treated dam from those who had suckled from a control dam (Table 4.3), even though there 
were differences detected in the percent of structures labeled that varied from 10-22% higher 
than C-C.  An unusually large variability was seen in the mean % structures labeled, which 
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could be due to the section of the gland analyzed between animals (long ducts vs. end 
structures) or the small surges in growth that occur during transition through the estrous 
cycle. The number of cells labeled, per structure, at PND33 were approximately the same 
across the groups.  However, by PND40, those animals that had suckled from an ATR treated 
dam had twice the number of cells labeled per structure (p<0.005 vs. C-C and ATR-C) than 
those suckled from a control dam (Table 4.3).  These data reinforce the suggestion that final 
differentiation was delayed in the animals suckling an ATR treated dam. 
Gene Expression by RT-PCR- Several hormones and growth factors are known to be 
involved in mammary gland development.  Aromatase, which catalyzes the conversion of 
androgens to estrone and possibly plays a role in the amount of estrogen found in the breast, 
is expressed in normal mammary gland tissue as well as in some breast cancer tissue (Sasano 
and Harada, 1998).  Sanderson et al. (2000) reported the ability of ATR to induce aromatase 
mRNA in H295R human adrenocortical carcinoma cells.  Estrogen acts on its receptors in the 
stroma to stimulate growth factors, including EGF, which are needed for ductal growth 
(Silberstein, 2001).  Wiesen et al. (1999) found that EGFR is necessary to induce estrogen-
dependent ductal growth and branching morphogenesis to stimulate epithelial growth and 
development.  
To determine if ATR induces a change in aromatase or EGFR gene expression in 
vivo, RNA from the mammary gland was used for relative quantitation analysis (Ginzinger, 
2002), and product size confirmed when run on an Agilent DNA chip against molecular 
weight markers (Figure 4.4).    Threshold cycles for aromatase and EGFR were compared 
across exposure parameters (Table 4.4).  Threshold detection of aromatase at PND33 was not 
different when averaged across the exposure parameter groups.  However, when gene 
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expression was evaluated as fold induction, animals in the ATR-ATR group expressed 
significantly less aromatase when compared to C-C and ATR-C animals, meaning ATR-ATR 
offspring maintained less than half the gene copies present in controls (p<0.05).  At PND40, 
neither threshold detection nor induction values differed significantly among the groups, 
even though fold induction of aromatase was increased in the ATR in utero exposure group 
(ATR-C) only.   
Threshold detection for EGFR on PND33 in glands of ATR-ATR females was 
significantly different when compared to C-C and ATR-C levels, p<0.02.  Suckling from an 
ATR exposed dam decreased fold induction values by nearly 3-5 fold compared to C-C 
(p<0.01 vs. C-ATR and p<0.02 vs. ATR-ATR) showing that there were far fewer copies of 
these genes present in the glands of ATR exposed offspring (1/3 to 1/5 the number of 
copies).  By PND40 there were no statistical differences in threshold detection or fold 
induction values, but animals exposed to ATR in utero (ATR-C and ATR-ATR) had fold 
induction values of EGF-R two to nearly four times that of C-C animal. 
Serum Hormone Measurements- To determine if circulating hormone levels played a role 
in delayed mammary gland development, serum was separated from trunk blood of animals 
at PND33, 40, and 58.  Radioimmunoassays were performed to determine serum LH, PRL, 
and TSH concentrations.  No correlation could be made with serum hormone status and 
mammary gland development delays.  At PND33, the only change noted was a slight rise in 
the mean serum LH concentration (ng/ml) in ATR-C animals (0.78+0.00), when compared to 
C-C and ATR-ATR animals (0.44+0.06 and 0.47+0.06, p<0.01; mean serum LH for C-ATR 
animals was 0.60+0.08.), and although statistically significant, these LH values were within 
normal physiological range.  There were no exposure-induced differences in hormone 
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concentrations at PND40.  At PND58, TSH levels were decreased slightly in offspring of the 
ATR-ATR group (p<0.02 vs. C-C and ATR-C; Table 4.5).  The values in all exposure groups 
were within expected range.  
Reproductive Tissue Weights- Animals in diestrus were sacrificed on PND58.  Anterior 
pituitary glands and reproductive organs were removed and weighed.  All ATR exposure 
parameter groups had slightly increased pituitary weights, but only pituitary glands of 
animals in the ATR-ATR group were significantly increased (p<0.05 vs. C-C) when 
controlling for BW effects.  As seen in Table 6, there were no statistical differences between 
the groups in reproductive organ weights.  Even though the mean uterine weight (wet) of the 
ATR-ATR group was decreased nearly 10% from that of C-C group, it was not found to be 
statistically significant.  
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Discussion 
The results of the studies presented here demonstrate that a brief exposure to 
100mg/kg atrazine during the fetal period does delay mammary gland development in female 
offspring.  The mammary glands of offspring either exposed in utero and/or that had suckled 
from an exposed dam took longer to develop into mature glands than those of controls.  This 
was observed as early as PND4 and as late as PND40 when the control animals’ glands were 
filled and grown to a relatively static resting state. 
   The studies suggest that there may be a critical period of fetal mammary gland 
development between GD15 and GD19 in which the developing gland may be sensitive to 
the effects of ATR, and that continued exposure of the developing offspring to ATR is not 
required for exposure-induced delays in mammary gland development seen in LE rats.  
Specifically, mammary gland development was delayed by in utero exposure to ATR, 
without nursing an exposed dam, and those effects were detectable as early as PND4.  Low 
development scores were evident from PND 4-40 in the ATR-C group compared to controls.  
The results also suggest that ATR, either as a lactational exposure (ATR remaining after 
dosing exposure + breakdown products) or change in the composition of the milk received by 
the offspring, can negatively affect mammary gland development, as seen by the scores of 
the C-ATR group.  However, the gestational exposure combined with milk consumption 
from an ATR-exposed dam had the greatest impact on mammary gland development.  These 
data suggest that these effects are either length of exposure-dependent (assumes further 
exposure to ATR or its metabolites during lactation) or that ATR may be able to indirectly 
alter growth by impairing production of local or milk-mediated growth factors/hormones 
known to control mammary gland growth and development.    
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 Previous studies published on the effects of ATR evaluated pubertal endpoints and/or 
reproductive tissues in animals that had been exposed directly to ATR for at least 20 days.  
They found that ATR delayed puberty and decreased uterine weights (Laws et al., 2000, 
Ashby et al., 2002).  Ashby et al. (2002) and Eldridge et al. (1994) found that ATR exposure 
caused body, reproductive, and adrenal weights to be decreased.  Irregular cycles and 
increased cycle length were also reported due to ATR exposure (Eldridge et al., 1994, 
Cooper et al., 1996, Eldridge et al., 1999).  In these studies, dams were exposed for 5 days 
during the latter part of the gestation period.  There was a delay in VO seen in female 
offspring that suckled a treated dam coupled with higher BW of these animals.  This is 
similar to what was reported for Wistar and SD rats (Laws et al., 2000, Ashby et al., 2002).  
However, a similar delay in VO was triggered in the present study by merely suckling an 
ATR-exposed dam.  Limited differences in body or reproductive tissue weights were seen in 
the offspring exposed to ATR (10% decrease in wet uterine weight in ATR-ATR group 
compared to controls), which does not negate the possibility for effect in these tissues.  
Further, it does not appear that the short burst of atrazine during gestation alters development 
of normal estrous cyclicity patterns, or the number of animals demonstrating periods of 
constant diestrus or estrus, following VO.     
It has been hypothesized that BW can play a role in the development of the mammary 
gland of rodents.  However, only on PND4 were body weight differences detected (which 
were within normal range; reduced < 6%) and these were only found in the group born to and 
consuming milk from treated dams.  At no time point was weight considered a significant 
covariate in our analyses, and offspring from the other exposure parameters had less 
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developed glands at times when no difference in body weight was detected from the control 
offspring.     
Hormones are important to mammary gland development and changes in them could 
lead to altered mammary gland development.  Although serum LH levels were elevated in 
one group of ATR-exposed animals, and TSH was decreased in yet another (ATR-ATR), 
these changes, which were not deemed biologically significant, did not persist over time.  It 
appears that none of the endocrine endpoints evaluated contributed in a causal fashion to 
delayed mammary gland development.   
The developmental delays observed in mammary glands of ATR-exposed pups 
suggest that there may be critical windows of fetal and neonatal mammary gland 
development that are sensitive to ATR exposure.  We do not propose that ATR, per se, is 
directly responsible for altered growth of the pup gland early in life, but suggest that ATR 
causes changes in milk composition.  Body weight, endocrine hormone levels, and other 
pubertal endpoints were not particularly useful in predicting mammary gland development in 
LE rats exposed prenatally to ATR.     
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 Table 4.1 Effect of 100 mg/kg Atrazine on Estrous Cyclicity 
   # Normal Cycles 
 N IR 2 3 4 5
C-C* 31 7 4 9 5 6 
ATR-C 38 9 6 11 8 4 
C-ATR 25 6 9 3 5 2 
ATR-ATR 32 1 12 10 6 3 
*Dam-Milk Source, N= number of offspring, IR= irregular Cyclity, # Normal Cycles= Number of 
animals displaying consecutive normal cycles.  
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 Table 4.2. Effect of 100 mg/kg ATR on Offspring Mammary Gland Development 
Day C-C* ATR-C C-ATR ATR-ATR 
PND4 3.5 + 0.02 2.7 + 0.2a 1.8 + 0.2a 1.9 + 0.3a
PND22 3.2 + 0.3 2.1 + 0.3a 1.9 + 0.4b 1.8 + 0.5b
PND33 2.9 + 0.2 3.0 + 0.0 2.2 + 0.2 1.6 + 0.5c
PND40 3.1 + 0.2 2.4 + 0.2 2.5 + 0.2 2.0 + 0.2c
* Dam Milk Source. Data presented as dame mean + SE.  Scoring: 1=stunted growth pattern; 4= normal 
growth for age. Dam N=2-5, with > 5 offspring per exposure group at each time.  Significant treatment 
effect by ANOVA; a p<0.02 vs. C-C, b p<0.05 vs. C-C, c p<0.01 vs. C-C. 
 
 
 
 
Table 4.3.  Effect of 100 mg/kg ATR on BrdU Indices 
PND33 % Structures Labeled Labeling Score 
C-C* 26.0 + 6.04 1.7 + 0.35 
ATR-C 48.6 + 10.7 2.8 + 0.34 
C-ATR 36.4 + 4.67 1.7 + 0.49 
ATR-ATR 45.3 + 15.1 1.8 + 0.51 
   
PND40   
C-C* 54.9 + 34.5 1.2 + 0.16 
ATR-C 25.7 + 10.5 0.9 + 0.40 
C-ATR 47.6 + 4.83 2.1 + 0.12a 
ATR-ATR 53.2 + 4.83 2.1 + 0.14a 
*Dam-Milk Source. Data presented as dam mean + SE.  Labeling Score= subjective score for amount of 
labeling within structures; 1= lowest, 4= highest.  Dam N=2-5, with > 5 offspring per exposure group at 
each timepoint.  Significant treatment effect by ANOVA; a p<0.01 vs. C-C.  
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 Table 4.4. Effect of 100 mg/kg ATR on Aromatase and EGF-R Gene Expression 
 PND33  PND40  
Aromatase Threshold Induction Threshold Induction 
C-C* 34.2 + 0.4 1.00 + 0.0 35.2 + 0.5 1.00 + 0.00 
ATR-C 34.2 + 0.3 0.40 + 0.8 33.7 + 0.8 4.28 + 3.0 
C-ATR 34.5 + 0.3 -0.41 + 0.8 34.5 + 0.5 1.30 + 1.0 
ATR-ATR 35.2 + 0.4 -2.19 + 0.5a 34.7 + 0.2 1.10 + 0.5 
     
EGF-R     
C-C* 27.4 + 0.4 1.00 + 0.0 29.6 + 0.7 1.00 + 0.0 
ATR-C 27.7 + 0.2 -1.29 + 0.2 27.9 + 0.6 3.80 + 1.0 
C-ATR 28,6 + 0.4 -2.75 + 0.8b 29.2 + 1.0 0.77 + 2.0 
ATR-ATR 29.4 + 0.6c -5.25 + 2.0c 28.5 + 0.4 2.07 + 0.8 
*Dam-Milk Source. EGF-R= epidermal growth factor receptor.  Data presented as dam mean threshold 
cycle or fold induction value + SE.  Dam N=2-5, with > 5 offspring per exposure group at each timepoint.  
Significant treatment effect by ANOVA; a p<0.05 vs. C-C, ATR-C, b p<0.01 vs. C-C, c p<0.02 vs. C-C, 
ATR-C. 
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Table 4.5. Effect of 100 mg/kg ATR on Serum Hormone Concentrations (/ml) at PND58 
 C-C* ATR-C C-ATR ATR-ATR 
LH (ng) 0.57 + 0.06 0.61 + 0.1 0.58 + 0.1 0.49 + 0.06 
PRL (ng) 7.58 + 2.0 8.21 + 3.0 10.4 + 3.0 7.70 + 2.0 
TSH (ng) 2.62 + 0.2 2.81 + 0.4 2.41 + 0.2 1.81 + 0.2a
*Dam-Milk Source. LH= luteinizing hormone, PRL= prolactin, TSH= thyroid stimulating hormone.  
Animals sacrificed in diestrus on PND58. Data presented as dam mean + SE.  Dam N>6, with > 14 
offspring per exposure group. Significant treatment effect by ANOVA; a p<0.02 vs. C-C, ATR-C. 
 
 
 
 
Table 4.6. Effect of 100 mg/kg ATR on Reproductive Organ Weights 
 C-C* ATR-C C-ATR ATR-ATR 
Body Wt (g) 252 + 7.3 252 + 6.2 259 + 6.3 241 + 5.8 
Pituitary (mg) 9.55 + 0.48 10.1 + 0.45 10.7 + 0.54 10.9 + 0.33a 
Ovaries (mg) 110 + 3.8 112 + 2.9 101 + 5.6 106 + 3.5 
Uterus (mg) 284 + 11 275 + 17 264 + 7.3 258 + 8.9 
*Dam-Milk Source. Animals sacrificed in diestrus on PND58. Data presented as dam mean + SE.  Dam 
N>6, with > 14 offspring per exposure group. Significant treatment effect by ANOVA; a p<0.05 vs. C-C, 
adjusted for body weight. 
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Figure 4.1.  Body weight of pups exposed to ATR via exposure parameters and weighed on 
PND4, 22, 33, and 40.  Data are presented as mean + SE.  Groups listed as dam-milk source.  
Pups in the ATR-ATR group were statistically smaller than those in the control group on 
PND4.  * Significant treatment effect by ANOVA, p<0.01 vs. C-C (5.7%), ATR-C (7.9%), 
and C-ATR (6.8%).  Weights at other timepoints were not different. 
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Figure 4.2. (A) Age (days) at the time of vaginal opening.  Data are presented as mean + SE. 
Groups listed as dam-milk source. *Significant treatment effect by ANOVA (LSM) and 
significantly different from C-C and ATR-C (p<0.02). (B) Mean + SE of body weight (g) at 
the time of vaginal opening.  Significant treatment effect by ANOVA (LSM); * p<0.002 vs. 
C-C and ATR-C. 
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Mammary Glands
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Figure 4.3.  Mammary gland whole mount comparisons from female offspring following 
gestational exposure and cross-fostering. 1Dam-milk source; C-Control, ATR-Atrazine.  
Altered mammary gland development was apparent in glands from animals within treatment 
exposure parameters.  Pictures are representative of mean scores found in Table 3.  
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Aromatase and EGF-R PCR Products 
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Figure 4.4.  Products from real time(RT)-PCR.  Lane 1 is molecular weight marker in base 
pairs (bp).  Lane 2 is aromatase at expected size (90 bp).  Land 3 is EGF-R at expected size 
(109 bp).  Lane 4 is RT-PCR negative control (H20 template). 
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CHAPTER 5 
 
ATRAZINE AND CRITICAL PERIODS OF FETAL MAMMARY DEVELOPMENT 
 
Summary 
 
A 5-day exposure to 100 mg/kg/d ATR during GD15-19 in Long-Evans rats delayed 
mammary gland growth and development in female offspring.  To determine if there is a 
gestational critical period in which the developing mammary tissue is most sensitive to the 
effects of ATR, the studies presented here evaluated the effect of ATR on mammary gland 
development as well as traditional pubertal indicators after 3 or 7-day exposures during the 
latter period of gestation. The 3-day exposure periods bracket the proposed times of rat 
mammary bud formation, bud size increase, mesenchyme differentiation, and epithelial cell 
proliferation into the fat pad.  These studies also clarified that delayed offspring mammary 
growth and development following in utero ATR exposure is not caused by altered serum 
hormones or reduced mean fetal litter weights following what appears to be a period of 
maternal toxicity.   These persistent mammary gland effects of prenatal atrazine exposure 
resulted in decreased weight gain in the second generation litters born to prenatally exposed 
females, demonstrating the effects on the F1 mammary gland are adverse.  
Methods 
Animals-Time-pregnant Long Evans rats (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  The animals were housed in an 
AAALAC accredited facility, one per cage and given food (Purina 5008 Rodent Chow, 
Ralston Purina Co., St. Louis, MO) and water ad libitum.  They were maintained in a room 
with a 14:10 hour light cycle, 20-24°C and relative humidity of about 50%.  Animal 
protocols were reviewed and approved by the National Health and Environmental Effects 
Research Laboratory (NHEERL), Institutional Animal Care and Use Committee.  Animals 
were tested monthly for infectious diseases and remained negative for all NHEERL criteria. 
Dosing Solution and Procedures- Critical Period Study - ATR (Syngenta Crop Protection, 
Inc. Greensboro, NC, 97.1% purity) was prepared as a suspension in 1.0% methyl cellulose 
(Sigma Chemical, St. Louis, MO) in distilled water.  Timed-pregnant rats were treated in the 
morning and afternoon with 0 (vehicle) or 50 mg ATR/kg BW by oral gavage in 5 ml/kg 
dosing volume.  This ATR reference dose (100 mg/kg/d) was chosen due to consistent 
reproductive endpoint effects observed in previous studies (Laws et al., 2000; Rayner et al., 
2004; Stoker et al., 1999).  
Fetal Weight Study - ATR was prepared as a suspension in 1.0% methyl cellulose in distilled 
water.  Timed- pregnant rats were treated with 0 (vehicle), 25 mg/kg, 50 mg/kg, or 100 mg 
ATR/kg BW by oral gavage in 5 ml/kg dosing volume. 
Experimental Design- Critical Period Study-These studies were completed in two blocks.  In 
each block, 40 pregnant LE dams were treated with vehicle (control) or 50 mg/kg ATR twice 
daily (N=8 dams/ exposure period/treatment, equal to 100 mg/kg/d).  Control dams were 
dosed gestational days (GD) 13-19 and dams receiving ATR were dosed either on GD13-15, 
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GD15-17, GD17-19, or GD13-19.  Litters were weighed and randomly equalized to 10 pups 
(6 females, 4 males) on PND4.  At weaning, PND22 or 25, animals were weighed and 
separated into unisexual sibling groups, 2 female rats per cage.  Females, at least 2/dam and 4 
dams/group/block were sacrificed on PNDs 4 (from remaining pups following equalization 
of litters), 22, 25, 33, 46, and 67.  The second block was extended to PND67 due to persistent 
effects seen in Block 1 mammary glands (ended on PND 46).  Beginning on PND68, sibling 
females (N=4/group) of those sacrificed on PND67 and exhibiting normal estrous cycles 
were bred to control males.  Second generation litters were weighed and randomly equalized 
to 10 pups on PND4.  On PND11 of second generation, dams and pups were lactationally 
challenged (see below).  Dams and pups were sacrificed after challenge.  The data from an 
exposed dam’s offspring were evaluated with the dam (pups/dam) as the experimental unit.  
No block effects were detected. 
Fetal Weight Study- Forty pregnant LE dams were treated with vehicle (control), 25 mg/kg, 
50 mg/kg or 100 mg/kg ATR daily (N=8 dams/ treatment) on GD15-19 as previously 
described (Rayner et al., 2004).  On GD20, 24 hours after the last dose was received, dams 
were sacrificed.  Litters were removed from the dam and the sex and weight of each fetus 
were recorded.  One control dam died before necropsy and one dam in the 50 mg/kg ATR 
group was not pregnant.  The data from an exposed dam’s offspring were evaluated with the 
dam (litter) as the experimental unit.   
Vaginal Opening and Cyclicity-Beginning on PND29, female offspring (more than 24 
females/group) were evaluated for vaginal opening (VO).  The postnatal day of complete 
VO, and body weight on that day, were recorded.  Daily vaginal smears were collected in 
Block 2 females beginning on PND37 and continued until PND 67 to determine the effect of 
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prenatal atrazine exposure on early cyclicity patterns following VO. Vaginal smears were 
read wet for the presence of leukocytes (metestrus/diestrus), nucleated epithelium (proestrus), 
or cornified epithelial cells (estrus) to determine cyclicity patterns on an American Optical 
low-power light microscope (100X) and day of cycle was recorded.  Data were examined for 
4-5 day normal cycles and the number of consecutive normal cycles was recorded for each 
animal.  Episodes of persistent diestrus or estrus were recorded and the number of episodes 
per animal was compared across treatment.  Irregular cyclicity was defined as those not 
presenting at least two consecutive normal cycles between PND37 and PND 67. 
Necropsy- Necropsies were performed following an overnight and continued stay in a quiet 
holding area, and by using decapicones for animal transfer to reduce stress. 
Critical Period Study-On PND33, 46, or 67, >2 females/dam were weighed and decapitated.  
On PND33 (N=6 dams/treatment group), mammary glands were removed for whole mounts 
from female offspring that had undergone VO in all dose groups, so that differences in 
mammary gland development could be evaluated separately from other facets of puberty.  
Trunk blood was collected and centrifuged for 30 minutes at 3000rpm (4°C) for serum.  At 
PND46 (N>7 dams/group) mammary glands were removed for whole mounts.  On PND67 
(N>4 dams/group), trunk blood was collected and centrifuged for 30 minutes at 3000rpm 
(4°C) for serum from animals killed between 0800-1300 hours.  The pituitary gland, ovaries, 
and uterus (wet) were removed and weighed.  Mammary glands were removed for whole 
mounts.  Normal cycling female siblings remaining after PND67 were retained for breeding 
experiments. 
Fetal Weight Study-On GD20, dams (N>7/group) were decapitated, and trunk blood was 
collected and centrifuged as above for serum.  The 4th and 5th mammary glands of each dam 
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were removed.  Portions of these glands were processed for RNA, protein analyses, and 
histology.  The uterus of each dam was removed and opened.  The numbers of implantation 
sites and resorption sites were counted.  Fetuses were removed from the membranes, rinsed 
in room temperature phosphate buffered saline, and blotted to remove excess liquid before 
weighing.  After weight was recorded, the fetuses were decapitated and examined internally 
under a dissecting microscope to confirm their sex.   
Mammary Whole Mounts and Histology- The 4th and 5th mammary glands were removed, 
fixed, and stained in carmine alum as a whole mount as previously described (Fenton et al., 
2002) on PNDs 4, 22, 25, 33, 46, and 67 (2-4 pups/dam).  Mammary glands from second 
generation pups were removed and stained on PNDs 4 and 11.  Flattened whole mounts were 
visualized and the epithelial outgrowth was measured to the closest millimeter (mm).  Length 
measurements for area were taken from the nipple to the farthest point of branching.  
However, length measurements on PND46 were taken from the farthest branching of the 4th 
gland to the farthest branching of the 5th gland.  Width measurements for area were taken 
from the two longest points of outgrowth. The whole mounts were subjectively scored 
(scale=1-4; 1=poor development/structure and 4=normal development/structure for each age 
group) within an age group, by two individual scorers some knowledge of treatment.  
Mammary gland histology sections were scored for ductile dilation, lipid accumulation, and 
developmental score.  Scores ranged from 1 to 4 with 1 given to glands with ducts that are 
the least dilated, structures having the least lipid accumulation, and glands being the least 
developed and 4 given to glands having the most.  Mammary glands representative of the 
mean score of the group were photographed on a Leica WILD M420 macroscope. 
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Radioimmunoassay- Sera were obtained from offspring that were decapitated on PNDs 33 
and 67, and from dams at PND11 (second generation) for use in radioimmunoassays.  Serum 
total testosterone, androstenedione, corticosterone, and progesterone were measured using 
Coat-a-Count Radioimmunoassay Kits obtained from Diagnostic Products Corporation (Los 
Angeles, CA).  Serum estrone was measured using the DSL 8700 Estrone 
Radioimmunoassay kit and estradiol using the 3rd Generation Estradiol Radioimmunoassay 
kit from Diagnostic Systems Laboratories, Inc. (Webster, TX).  Serum prolactin (PRL) was 
analyzed by radioimmunoassay using materials supplied by the National Institute of Arthritis, 
Diabetes, Digestive, and Kidney Diseases.  All assays were run in duplicate.  Stage of the 
estrous cycle was known at the time of necropsy and was used as a model variable in data 
analysis (see below). 
Lactational Challenge- Dams and pups were moved to a quiet holding room on PND10.  On 
PND11, dams were removed, weighed, and placed in clean individual cages with food and 
water ad libitum.  Entire litters were weighed and pups individually weighed and allowed to 
remain in their own nest.  Two hours later, dams were placed back with their pups.  The 
amount of time it took for dams to nest on their young was recorded and dams were allowed 
to suckle their pups for 20 minutes after which dams were removed and decapitated.  Trunk 
blood was taken for serum collection.  The pituitary gland was removed, weighed, and 
discarded.  Portions of the mammary gland were removed and placed in 10% buffered 
formalin.  Litters were reweighed immediately, and mammary glands removed from female 
pups for whole mount analysis.  The uterus of dams was removed and implantation sites 
counted.  Male pups were euthanized. 
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Statistical Analysis- Dam means (pups/dam; litter as unit) were calculated for body and tissue 
weights, mammary gland scores, VO day, and serum hormones.  Means and adjusted means 
relative to body weight were calculated for organ weights.  Body weights, mammary gland 
scores, and serum hormone concentrations were evaluated for treatment effects within each 
age group by one-way analysis of variance (ANOVA, Statistical Analysis System (SAS), 
SAS Institute, Inc. Cary, NC).  Organ weights and hormone concentrations were analyzed 
with respect to day of cycle by Mixed Model ANOVA and interactions between day of cycle 
and group were evaluated.  Analysis of covariance, with body weight as a covariate, was 
used to evaluate the effects of treatment on mammary gland scores.  Estrous cyclicity data 
were compared by Mantel-Haenszel analysis (Non-zero correlation and Row Mean Score 
Test).  Resorption sites and pup death were analyzed in a contingency table using Fisher’s 
exact test in Graphpad Instat (Graphpad Software, San Diego, CA).   Block effects were 
evaluated but none were significant.  Significant treatment effects were demonstrated by 
p<0.05 and specific p-values are indicated throughout this manuscript. 
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Results 
Effects of Treatment on Dam and Fetal Weights: 
Critical Period Study-These studies were initiated to directly evaluate effects of prenatal 
ATR exposure on mammary gland development, because our previous work (Rayner et al., 
2004) demonstrated that a five-day ATR exposure (100 mg/kg BW/day) during late gestation 
could delay mammary gland development, as well as puberty.    
Dam weight was recorded throughout the dosing periods and weight gain compared 
among groups (Table 5.1).  During the GD13-15 exposure period, control dams (vehicle) 
gained an average of 20.4+3.4g.  Dams exposed to 100 mg/kg BW/day ATR during GD13-
15 and the first three days of GD13-19 gained no weight, significantly less than control 
dams, p<0.0001.  Dams dosed with ATR GD15-17 gained significantly less weight than 
control dams, with weight gain reduced 82%, (p<0.0001), and ATR GD13-19 dams had a 
35% reduced weight gain, (p<0.0007) on the middle three days of that exposure.  In the final 
dosing period, dams in the ATR GD17-19 group had a 90% reduction in weight gain, 
(p<0.0001) compared to control dams.  However, those exposed to ATR GD13-19 exhibited 
only a 26% reduction in weight gain during the GD 17-19 period, (p<0.0403).  During the 
entire dosing period GD13-19, control dams gained a total of 78.2+6.1g and ATR-exposed 
dams less than half of that amount (p<0.0001), with most of that weight gained in the latter 
stages of the 7 day dose period.  The dams treated with 100 mg/kg ATR gained significantly 
less weight than controls at all periods tested.  
 The combined mortality rates from PND4 (after equalizing litters) to weaning for 
both blocks were 24.6% for control, 33.2% for GD13-15, 40.5% for GD15-17, 30.0% for 
GD17-19, and 26.3% for GD13-19.  Because the dam is the unit of measurement, the larger 
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than expected pup loss necessitated running an additional block of these studies.  The cause 
of pup loss was unknown, but thoroughly investigated. It was not due to detectable illness, 
disease, or environmental stress.  Further, the weights of these pups were similar to those in 
our previous studies and block effects were evaluated in all statistical analyses.  
Fetal Weight Study- In utero exposure during gestation days (GD) 15-19 to100 mg ATR/kg 
maternal BW lead to lower pup weight just after birth (Rayner et al., 2004) when pups also 
nursed from ATR-exposed dams.  ATR-treated dams in this study exhibited significantly 
reduced weight gain during the exposure period when compared to vehicle-treated dams.  A 
pronounced lack of weight gain during the dosing period in the Critical Period study 
described, stimulated a further study to determine if this reduction in maternal weight gain 
(maternal toxicity) played a role in term fetus number or mean fetal body weight.  
Dam weight was recorded daily throughout the dosing periods and weight gain 
compared among groups.  During the exposure period GD15-19, control dams gained an 
average of 51.2+3.0g (Table 5.2).  Dams in the 25 mg/kg, 50mg/kg, and 100 mg/kg ATR, 
groups gained 6.1%, 42.0%, and 62.9%, less weight, respectively, than control dams during 
the exposure period.  Dams in the 50 mg/kg and 100 mg/kg gained significantly less weight 
than controls (p<0.002), and the 25 mg/kg dose had no effect.  Because the current mode of 
action of ATR includes altered serum prolactin, we evaluated the dam’s circulating prolactin 
levels at GD20 (24 hours after the last dose). There were no statistically significant exposure-
induced differences found in circulating prolactin levels among the groups (N>7 dams/group; 
9.38+2.22 C; 6.40+0.78 ATR 25 mg/kg; 8.44+1.84 ATR 50 mg/kg; and 4.78+0.48 ATR 100 
mg/kg), although the highest ATR dose reduced serum PRL to half that in controls.  
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Dam mammary glands were examined macroscopically to determine ductile dilation, 
lipid accumulation and developmental score at GD20.  The glands from dams in the 50 
mg/kg and 100 mg/kg groups had ducts that were dilated significantly more than those of 
control dams (p<0.05).  Lipid accumulation was increased in all ATR exposed groups, 
p<0.01.   Developmental scores were not found to be significantly different among the 
treatment groups.    
The mean number of live fetuses per dam at necropsy did not differ among the 
treatment groups.  The number of resorbed sites and dead fetuses were also evaluated (Table 
5.2).  Interestingly, dams treated with 100 mg/kg ATR had the greatest number of 
resorptions; a total of 13.  That was a significant increase compared to controls which had no 
recognizable resorption sites, p<0.001 (Table 5.2).  However, mean number of resorptions in 
controls of other species (0.82 resorptions/dam/study in Sprague Dawley rats; Charles River 
Laboratories, 1996) are typically higher than this (0) and therefore the increased loss in the 
ATR group may not be biologically relevant.  Mean number of resorptions in the 100mg/kg 
group were also significantly greater than the means for the 25 mg/kg (2 sites total) and 50 
mg/kg (3 sites total) groups, p<0.01 and p<0.03.  The total number of dead fetuses at 
necropsy did not differ among the treatment groups.   
The body weight of female fetuses was compared among groups (Figure 5.1) and no 
differences were found at GD20.  When female and male weights were both evaluated 
together, no differences were found.  These data taken together suggest that although ATR 
exposure during pregnancy may decrease maternal weight gain and increase the total number 
of reabsorbed fetuses, it had no effect on fetal weight gain, regardless of sex, over this short 
exposure period. 
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 Offspring Endpoints – Critical Periods Study 
Growth and Puberty- Body weight was compared among the female offspring of ATR 
treated dams at several time points.  At PND4, there were no differences in the body weights 
of female offspring (10.2+0.2g C, 10.0+0.2g GD13-15, 10.2+0.2g GD15-17, 9.7+0.2g 
GD17-19, and 10.4+0.2g GD13-19).  There were also no differences in body weight at PNDs 
22, 25, 33, or 46.  In fact, offspring from GD13-19 exposed dams weighed about the same as 
control offspring at PND4 (1.1% change vs. control), PND22 (1.7%), PND25 (1.3%), 
PND33 (7.0%) and PND46 (3.5%).  However, at PND67, both GD15-17 and GD13-19 
animals weighed significantly less than control, p<0.01. 
Vaginal opening and estrous cyclicity were evaluated as physical signs of female 
reproductive development (Figure 5.2).  Body weight at time of VO was not different among 
the treatment groups (panel A).  VO occurred in control animals at PND32.6+0.33 (panel B).  
The offspring exposed to ATR on GD13-19 displayed a significant delay in VO (34.5+0.36, 
p<0.0004), similar to that seen previously (Rayner et al., 2004).  VO was not significantly 
delayed in any other dose group (33.5+0.41 GD13-15; 32.9+0.31 GD15-17; and 33.2+0.36 
GD17-19).   
 Estrous cyclicity patterns of the female offspring were observed from PND37 to 
PND67.  The number of consecutive normal cycles (4-5 days) were determined and analyzed 
according to treatment for all animals.  The majority of animals in each group had three to 
four consecutive normal cycles, and less than two animals per group displayed persistent 
estrus.  No significant differences due to treatment were found in the number of consecutive 
normal cycles or irregular cycles among the treatment groups.   
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 Mammary Gland Development- Mammary glands were removed from female offspring in 
all groups on PNDs 4, 22, 25, 33, 46, and 67 and examined to determine if epithelial 
development of the mammary gland was affected by gestational ATR exposure.  Stained 
epithelia were measured (area (mm2) and length (mm)) to observe differences in outgrowth 
into the fat pad (Table 5.3).  Mammary gland development in female offspring was scored 
through whole mount analysis (Table 5.4, Figure 5.3).  
The area (mm2) of the mammary gland on PND4 in all 3-day ATR exposed groups 
was significantly smaller, p<0.001, compared to control offspring (22.5+2.7 mm2), with 
glands from the GD13-19 exposure group measuring less than half the size of controls 
(10.9+1.13 mm2).  As expected and repeating previously reported ATR-induced delays 
(Rayner et al., 2004), glands from offspring exposed GD15-19 (GD15-17, 17-19) and GD13-
19 were smaller and developmentally delayed in branching and ductal structures compared to 
glands taken from control offspring (Figure 5.3, Table 5.4).  There is no evidence that these 
mammary developmental deficits are due to overall growth inhibition of the pups (either 
during gestation or after birth) due to treatment.   
 Weaning occurred at either PND22 (Block 2) or 25 (Block 1), and mammary glands 
were taken from exposed offspring of equivalent BW.  The area of the fourth gland remained 
significantly smaller in exposed offspring at PND22, p<0.03 (Table 5.3), with the exception 
of GD13-15 offspring, but the distance between the fourth and fifth glands were not different. 
The mammary glands of GD17-19 and GD13-19 offspring displayed fewer terminal end buds 
and lateral branches, and had not migrated as far through the fat pad as controls (Table 5.4, 
Figure 5.4, top).  The area of the fourth gland remained significantly smaller in ATR-exposed 
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offspring at PND25 (Table 5.3), and the distance between the glands was greater than the 
same distance in the control females’ glands, p<0.04.  Control female offspring displayed 
normal mammary branching with distended terminal end buds and terminal ducts.  Glands of 
females in ATR-exposed groups were not as well developed.  Those glands had poor 
migration of epithelium into the fat pad, and were sparse in appearance with fewer lateral 
branches than control (Table 5.4, Figure 5.3).   
 By the peri-pubertal time point, PND 33, none of the ATR-exposed offspring glands 
were statistically significantly smaller in area than controls (Table 5.3).  Glands from control 
females displayed terminal end buds only on the most distal ends, lobules were present, and 
the fourth and fifth glands had grown close together (Figure 5.3).  Even though glands from 
exposed offspring were not smaller in area, the glands received lower developmental scores 
than controls.  ATR-exposed gland displayed abundant terminal end buds on 2-3 sides of the 
epithelial tree, limited lobules, and sparse branching (Table 5.4).  Figure 3 shows the distance 
between the fourth and fifth glands at PND33 in addition to terminal end buds.     
 At early adulthood, PND46, glands of ATR-exposed offspring were similar in length 
to controls (Table 5.3).  The 4th and 5th glands had grown together by that age and it was 
difficult to measure the area of each individual gland.  However, whole mount analysis of the 
mammary glands showed that developmentally, ATR-exposed glands were significantly 
different from controls.  Glands of control animals had very few terminal end buds left in the 
gland and the mammary gland was very dense with epithelial branching (Figure 5.4, bottom).   
Most glands of control animals resided in a resting state normally found in adult female rats.  
The development of mature gland structures was delayed in ATR-exposed offspring.  Glands 
from exposed offspring were less dense and still retained many terminal end buds with most 
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seen in GD17-19 and GD13-19 (arrows in Figure 5.4), leading to consistently low 
developmental scores (Table 5.4).  At a later point in adulthood when all females should have 
been sexually mature (PND67), ATR-exposed glands were still developmentally delayed and 
contained many large lobular units, with only moderate epithelial branching. Glands removed 
from female offspring in the GD17-19 and 13-19 groups received epithelial development 
scores that were statistically equivalent over time (PND4-67; Table 5.4).  Control glands had 
few complex lobules and dense branching throughout the gland and remained in the resting 
state described above (not shown). 
Serum Hormone Measurements-To determine if ATR exposure affected circulating 
hormone levels, serum was separated from trunk blood of animals at PND33 and 67.  At 
PND33, corticosterone concentrations were significantly increased in the GD15-17 group, 
p<0.009; 72.1+26.2, C vs. 193.9+21.8, GD15-17.  Although no stress events were noted, we 
realized this large increase could be due to an unknown environmental stressor prior 
to/during necropsy.  Total testosterone in GD13-19 animals was doubled compared to 
controls, p<0.04; 0.203+0.06, C vs. 0.419+0.08, GD13-19.  No additional differences in 
hormone concentrations evaluated at PND33 were found.   
At PND67 (Table 5.5), there were no consistent exposure-induced differences in 
hormone concentrations with respect to day of cycle, but there were some interesting trends 
observed when all animals were compared to control means.  Estrone and its precursor 
androstenedione were slightly decreased in GD17-19 and GD13-19 offspring.  Estradiol was 
slightly increased in GD15-17, GD17-19, and GD13-19 offspring, whereas its precursor 
testosterone was nearly doubled in GD13-19 ATR exposed animals (similar to that seen in 
PND 33 animals of the same dose group).  Steroid hormone ratios, particularly those 
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controlled by aromatase and 17-β hydroxysteroid dehydrogenase, were evaluated but no 
statistical differences among the groups were detected.  
Reproductive Tissue Weights-Females from each group were sacrificed on PND67 (one 
day before siblings were bred).  In addition to the previous data described, the ovaries and 
uterus were removed and weighed.  As seen in Table 5.5, there were no statistical differences 
among the groups in these organ weights with respect to day of cycle, even though there was 
a 14.3% to 38.9% increase in total ovary weight in the ATR-exposed animals versus controls.  
There was also a 19.4% to 57.7% increase in wet uterine weight compared to controls in the 
ATR-exposed females.   
Consequences of brief prenatal ATR exposure on 2nd Generation  
The offspring of control and ATR-treated dams were bred to control LE males 
(beginning PND68) to determine if the females exposed gestationally to ATR, and exhibiting 
delayed mammary gland development, would have difficulty sustaining their young.  Of the 
20 normal cycling females chosen to breed (4/group), only one female in the GD17-19 group 
did not conceive.  One female in the GD13-19 group conceived, delivered 2 pups, but dam 
and pups died before PND4.  On PND4 post partum, individual pups in each litter (N>3) 
were weighed and the sex of each was determined.  Litters were equalized to 10 pups if 
possible.  On PND11, dams were removed from their pups for two hours during a lactational 
challenge as described.   
Female pups in the groups GD17-19 and GD13-19 were significantly smaller than 
those of control (p<0.003 and 0.02), with reduction in body weight of 14.8% and 12.5%, 
respectively.  Male pups in these same groups were also smaller than control, p<0.002 and 
0.0001, and had body weight reduction of 15.6% and 16.7% (Figure 5.4 A).  Mammary 
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glands were removed from the female pups at PND4 and scored for development and the 
area of the gland measured.  Whole mount analysis of the fourth and fifth mammary gland at 
PND4 showed that mammary epithelial development of pups taken from GD17-19 and 
GD13-19 dams had few ductal buds from lateral branches and were undersized compared to 
glands taken from other groups.  Control, GD13-15, and GD15-17 offspring glands displayed 
small buds on primary branches and moderate branching within the gland, and received 
similar developmental scores.  When mammary gland scores were compared using body 
weight as a cofactor, glands from GD17-19 and 13-19 were no longer considered 
significantly different.  The areas of the 4th mammary gland were not different among the 
groups.  It should be mentioned that the mean body weight of pups on PND 4 in the GD13-
15 and GD15-17 ATR exposure group (male and female) were significantly greater than the 
control group.  The development of mammary glands in female siblings from both ATR 
exposure groups was known to be similar to controls when they were mated.      
 There were no differences in dam body weight across group (Table 5.6).  The anterior 
pituitary glands (source of prolactin and decreased weight from ATR exposure, Laws et al., 
2000) were removed and weights were found to be similar across dose group.  Although 
highly variable, dam nesting time was not different and litter weight gain during the nursing 
period was not different among the treatment groups (not shown).  Estradiol, progesterone, 
and prolactin concentrations were measured from serum taken from the trunk blood of dams 
at PND11.  Lower concentrations of estradiol were found in GD13-15 and GD13-19 dams, 
p<0.0006 and 0.02, respectively.  No other differences were found in hormone concentration 
among the groups, even though some values were quite varied (e.g. PRL GD17-19). 
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Body weights of the pups were recorded at PND11, and again GD17-19 and GD13-19 
had dramatically reduced weight in both sex groups; female p<0.0001 (25%) and 0.0003 
(23.8%), male p<0.0001 (23.9%) and 0.002 (13%) (Figure 5.4 B).  Mammary glands 
removed from females at PND11 were scored and measured.  Glands taken from GD13-15, 
GD17-19, and GD13-19 scored significantly lower than control and GD15-17 glands.  The 
areas of glands from GD17-19 and GD13-19 were reduced.  As noted above, the pups from 
GD17-19 and GD13-19 dams were smaller at PND11.  This led us to evaluate mammary 
gland scores and area using body weight as the covariate.  Mammary gland development was 
not found to be significantly different on this basis, demonstrating that body weight may 
have been causal in the delayed development observed at this time point, unlike the delays in 
F1 mammary development where body weight was not a significant factor in mammary gland 
size or developmental score.  Delays in mammary gland development were not evaluated 
past PND11 in the F2, but have the potential to exacerbate the effects of a brief prenatal ATR 
exposure in two generations of offspring to a third.   
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Discussion 
 The results of the studies presented here demonstrate that exposures as brief as three 
days to 100 mg/kg atrazine during late gestation caused delayed mammary gland 
development in the female offspring.  These results also suggest that the fetal mammary 
gland may be most sensitive to the effects of ATR during the latter part of pregnancy, during 
the time of epithelial outgrowth.  The mammary glands of offspring exposed GD17-19 took 
longer to develop into mature glands.  This developmental deficit was observed as early as 
PND4 and as late as PND67, when the animals were sexually mature. 
 These studies suggest that GD17-19 may be the most important period of fetal 
mammary gland development, showing sensitivity to ATR that was consistent with the 7-day 
exposure.  The previous chapter showed that a five-day in utero exposure to ATR during 
GD15-19 delayed mammary gland development in the female offspring.  It was reported that 
gestational exposure combined with milk consumption from an ATR-treated dam (ATR-
ATR) led to more severely delayed mammary glands than those exposed only in utero or 
lactationally.  In the present study, a three-day in utero exposure, especially during GD17-19, 
caused mammary gland developmental delays similar to that found in the five-day ATR-ATR 
exposed, and the GD13-19 offspring (7-day exposed; this study), framing the narrowest 
sensitive period of mammary gland development to non-lipophilic environmental agents to 
date.   
 It has been suggested that maternal/fetal weight gain and/or early pup weight gain 
might play a role in offspring reproductive tissue development, and in this case, specifically 
the mammary gland. The previous chapter and data presented here demonstrate that F1 
offspring body weight at GD20, PND4 or after was not a significant variable influencing 
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mammary gland developmental delays induced by ATR.  The present fetal weight study 
showed that dams treated with 50 mg/kg or 100mg/kg of ATR during GD15-19 gained 
significantly less weight than control dams, but was without effect on litter sizes or fetal/pup 
weight.  During the critical period study, dams treated with 100 mg/kg BW/day ATR during 
the three-day exposure period gained significantly less weight than control dams during the 
same time period, in fact, during early treatment periods they gained no weight.  Dams 
treated during GD13-19 were reduced in weight gain by almost half of control dams, but 
there were no differences in female offspring weight in any of the groups following birth.  
However, differences in F1 (specifically) mammary gland development were apparent in 
groups exposed to ATR, even after three days.  Further, as noted in Table 5.6, there was no 
significant weight difference in F1 dams used in the breeding study. Importantly, however, 
those same animals with delayed mammary gland development at breeding (to generate the 
F2 offspring) raised pups that were significantly (from 12-25%) smaller than controls, 
suggesting that the GD17-19 and 13-19 ATR-exposed dams were not able to produce quality 
and/or quantity of milk necessary to sustain the body weight of their offspring. 
 In an unpublished study prepared by Ciba-Geigy and accepted by the EPA (Mainiero 
et al., 1987), rats were exposed to ATR over 2-generations.  Male and female rats were 
treated through their diet with approximately 0.5, 5, and 50 mg/kg/day ATR prior to mating 
and then females were treated during gestation and lactation.  The first generation of pups 
were weaned and treated through the diet for 12 weeks prior to mating.  The only changes 
noted in both sets of parents were weight reductions at the high dose, but no changes were 
noted in the offspring due to treatment in the reproductive parameters evaluated including 
fertility, postnatal mortality, or developmental delays.  This study, over two generations, 
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consisted of treating only F0 pregnant dams 3 or 7 days with ATR by oral gavage.  Female 
offspring displayed persistent delayed mammary gland development (an end point not 
evaluated in NTP-like 2-generational studies) but appeared to have no changes in fertility or 
litter size.  It was noted that F2 litters in the GD17-19 and GD13-19 ATR exposure groups 
were significantly reduced in body weight at PND4 and PND11.  The mammary glands of 
these F2 offspring were also smaller and less developed than the other groups and this was 
found to be due to reduced body weight.  These data suggest that late gestational ATR 
exposure has an indirect adverse effect on body weight of the next generation.  The 
differences in results of the two studies mentioned above may be due to inconsistencies in 
time of breeding or differences in dose.  Delayed mammary gland development was observed 
in the siblings of the females bred on PND68.  It is possible that F2 effects may not have 
been seen if the females had been bred at a later time, such as 90-120 days as is typically 
seen in 2-generational studies.  There is no proof that this effect is permanent, just long-
lasting. 
 In conclusion, mammary gland developmental delays observed in all groups of ATR-
exposed pups suggest that GD17-19 is a sensitive window of fetal mammary gland 
development.  While traditional endpoints were measured (body weight, puberty, and serum 
hormone concentrations), they were not associated with mammary gland development effects 
in LE rats.   
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Table 5.1. Critical Period Study: Effect of 100 mg/kg ATR on Maternal Weight Gain (g)
 N GD13-15 GD15-17 GD17-19 GD13-19 
Control 15 20.4 + 3.4 27.3 +1.4 30.5 + 2.2 78.2 + 6.1 
ATR GD13-15 16 0.18 + 1.8a    
ATR GD15-19 16  4.85 + 2.2a   
ATR GD17-19 16   3.02 + 3.3a  
ATR GD13-19 16 -0.28 + 1.5a 17.7 + 1.7a 22.7 + 2.0b 40.1 + 3.4a
N=number of dams dosed on gestations days (GD) as shown. Data shown as dam mean + SE. Significant 
treatment effect by ANOVA, a p<0.01, b p<0.04  
 
 
 
 
Table 5.2. Treatment Effects on Dam Weight Gain and Fetal Outcome on GD20. 
  Maternal  Litter Resorbed Dead 
 N Weight Gain Means Fetus Fetus 
Control 7 51.2 + 3.0 13.7 + 1.0 0 + 0.0 0 +0.0 
25 mg/kg ATR 8 48.1 + 3.9 14.6 + 0.5 0.25 + 0.2 0.12 + 0.12 
50 mg/kg ATR 8 29.7 +  6.7a 13.9 + 0.6 0.43 + 0.2 0 + 0.0 
100 mg/kg ATR 7 19.0 + 3.2a 11.1 + 1.0 1.62 + 1.0c 0.24 + 0.25 
N=number of dams. Weight gain during GD15-19 dosing period. *Dead but not resorbed fetus.  Data 
presented as litter mean + SE.  Significant treatment effect by ANOVA, a p<0.01 vs. Control. Significant 
effect by Firsher’s exact test; two sided p<0.001 vs. Control. 
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 Table 5.3 Effect of 100 mg/kg ATR on 4th Mammary Gland Areas (mm2) PNDs4-33 and 
Epithelial Length (mm) at PND46. 
Day Control GD13-15 GD15-17 GD17-19 GD13-19 
PND4 22.5 + 2.7 14.3 + 1.2a 14.0 + 1.3a 21.7 + 0.84a 10.9 + 1.1a
PND22 77.4 + 9.0 69.2 + 13 43.4 + 2.9a 48.5 + 10b 30.6 + 6,8a
PND25 126 + 12 85.4 + 5.2a 75.5 + 8.3a 67.6 + 6.2a 57.7 + 11a
PND33 193 + 11 176 + 9.8 196 + 11 175 + 9.1 152 + 8.7 
PND46 52.2 + 0.62 49.2 + 1.2 50.0 + 0.80 52.4 + 1.8 48.8 + 1.3 
PND=postnatal day. Dam > 8, with > 5 offspring per group at each timepoint.  Data presented as dam 
mean + SE. Significant treatment effect by ANOVA, a p<0.001 vs. Control, b p<0.03 vs. Control. 
 
 
 
 
Table 5.4. Effect of 100 mg/kg ATR (Evaluated by Subjective Scoring) on Mammary 
Gland Development 
Day Control GD13-15 GD15-17 GD17-19 GD13-19 
PND4 3.2 + 0.2 2.8 + 0.2 2.3 + 0.2a 1.9 + 0.2a 2.1 + 0.1a
PND22 3.2 + 0.3 2.7 + 0.4 2.4 + 0.2 2.0 + 0.1a 1.6 + 0.2a
PND25 3.3 + 0.2 2.7 + 0.1b 2.4 + 0.2a 2.2 + 0.2a 2.2 + 0.2a
PND33 3.5 + 0.1 3.0 + 0.1a 2.7 + 0.1a 2.7 + 0.1a 2.6 + 0.1a
PND46 3.7 + 0.1 3.0 + 0.1a 3.0 + 0.1a 2.9 + 0.1a 2.7 + 0.1a
PND67 3.4 + 0.1 2.8 + 0.2b 2.8 + 0.2b 2.6 + 0.2a 2.4 + 0.1a
GD=gestation day, PND=postnatal day. Dam > 8, with > 5 offspring per group at each timepoint.  
Scoring: 1=stunted growth pattern; 4= normal growth for age. Data presented as dam mean + SE. 
Significant treatment effect by ANOVA, a p<0.01 vs. Control, b p<0.05 vs. Control. 
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 Table 5.5. Lack of Effect of 100 mg/kg ATR on Reproductive Organ Weights and 
Serum Hormone Concentrations (/ml) at PND67. 
 Control GD13-15 GD15-17 GD17-19 GD13-19 
Body Wt (g) 273 + 3.5 261 + 10 235 + 5.3a 257 + 5.0 244 + 5.7a
Ovaries (mg) 116 + 8.4 149 + 10 146 + 15 161 + 21 132 + 4.7 
Uterus (mg) 310 + 31 370 + 35 430 + 57 489 + 112 418 + 36 
Progesterone (ng) 8.80 +2.7 7.60 + 2.2 5.40 + 2.5 11.6 + 7.8 6.50 + 1.6 
Corticosterone (ng) 128 + 17 119 + 31 107 + 11 113 + 42 128 + 22 
Androstenedione (ng) 0.60 + 0.19 0.64 + 0.12 0.46 + 0.19 0.39 +0.08 0.35 +0.08 
Estrone (pg) 57/3 + 9.1 58.3 + 5.6 68.7 +8.3 43.6 + 14 54.8 + 5.0 
Testosterone (ng) 0.16 + 0.04 0.19 + 0.07 0.20 + 0.10 0.15+ 0.09 0.29 + 0.05 
Estradiol (pg) 51.7 + 2.3 46.6 + 3.9 70.7 + 33 59.3 + 15 56.3 + 4.8 
Prolactin (ng) 6.90 + 2.9 3.60 + 0.30 4.50 + 2.1 9.40 + 4.3 8.80 + 4.9 
GD=gestation day. Dam N > 4 (>2 pups/dam). Data presented as dam mean + SE. Significant treatment 
effect by ANOVA; a p<0.01 vs. Control. 
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Table 5.6. Effect of 100 mg/kg ATR on Lactational Challenge and Serum Hormone 
Concentrations (/ml) at PND11 
 Control GD13-15 GD15-17 GD17-19 GD13-19 
Body Wt (g) 393 + 19 386 + 16 401 +15 353 + 16 391 + 13 
Pituitary (mg) 15.7 + 0.7 12.5 + 1.0 15.4 +2.0 13.7 + 0.4 16.9 + 2.4 
Nesting Time (sec) 287 + 111 638 + 121 390 + 71 297 + 68 307 + 61 
Estradiol (pg) 49.1 + 2.9 32.0 +  1.4a 43.9 + 6.3 41.9 + 2.9 33.6 + 2.3a
Progesterone (ng) 58.8 + 15 62.9 + 4.8 44.7 +10 42.9 + 21 62.2 + 2.4 
Prolactin (ng) 141 + 50 109 +27 144 + 68 21.0 + 7.3 107 + 57 
GD=gestation day, PND=postnatal day. Data presented as dam mean + SE.  Significant treatment effect 
by ANOVA, a p<0.02 vs. Control. 
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Figure 5.1. Litter mean (N>7/group) body weights (g) of GD20 pups exposed to increasing 
concentrations of atrazine during GD15-19 (25, 50, and 100 mg/kg).  Data are presented as 
litter mean + SE.  Weights at this timepoint were not reduced compared to control in any 
dose group. 
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Figure 5.2.  Effect of gestational exposure to 100 mg atrazine/kg BW/day on female pubertal 
body weights and age at time of vaginal opening (VO).  (A) Litter mean (N>4 litters) body 
weight (g) at the time of vaginal opening. (B) Litter mean age (days) at the time of vaginal 
opening.  Data are presented as mean + SE. Significant treatment effect by ANOVA (LSM) 
and significantly different from control (p<0.0004).  
a
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Figure 5.3.  Critical window for effects of prenatal exposure to 100 mg atrazine/kg BW/day 
on mammary gland development.  Mammary gland whole mounts were prepared from 
female offspring on postnatal days (PND) 4, 22, 25, 33, and 46 following ATR exposure on 
gestational days (GD) 13-15, 15-17, 17-19, or 13-19.  Photos demonstrate the mean scores 
found in Table 5.4.  
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Figure 5.4. Enlarged picture of PND 22 mammary gland from control, GD17-19, and GD13-
19, demonstrating fewer branches, delayed migration through the fat pad, and sparse 
appearance of atrazine exposed glands (top).  Enlarged picture of PND 46 mammary gland 
from control, GD17-19, and GD13-19 (bottom).  Glands taken from GD17-19 animals 
presented numerous terminal end buds (arrows) compared to few to none in control animals.  
The glands from the 3-day exposure period (GD17-19) closely resembled the glands from 7-
day exposure (GD13-19).      
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Figure 5.5.  Decreased mean body weight (BW, g) following gestational exposure to 100 mg 
atrazine/kg BW/day of 2nd generation pups (F2) on postnatal days (PND) 4 and 11. Data are 
presented separately for male and female pups as litter mean + SE. N>3 dams with >8 
pups/dam (A) BW on PND4. Significant treatment effect by ANOVA (LSM) and reduction 
in BW; different from control a= p<0.01 (14.8%); b= p<0.02 (12.5%); c= p<0.01 (15.6%); 
d= p<0.0001 (16.7%).  (B) BW on PND11. Significant treatment effect by ANOVA (LSM) 
and reduction in BW; different from control a= p<0.001 (25%); b= p<0.003 (23.8%); c= 
p<0.001 (23.9%); d= p<0.01 (13%). 
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CHAPTER 6 
 
ATRAZINE AND EXPOSURE PARAMETERS WITHIN CRITICAL PERIODS OF DEVELOPMENT 
 
 
Summary 
 
The previous chapters examine the effects of gestational versus residual lactational atrazine 
(ATR) exposure and the critical three-day window of susceptibility in mammary gland 
development.  The studies reported here evaluate the exposure parameters within each 
critical window to determine if residual lactational ATR exposure plays a role in the 
observed early mammary gland developmental delays.  
 
 
Methods 
Animals-Time-pregnant Long Evans rats (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  The animals were housed in an 
AAALAC accredited facility, one per cage and given food (Purina 5008 Rodent Chow, 
Ralston Purina Co., St. Louis, MO) and water ad libitum.  They were maintained in a room 
with a 14:10 hour light cycle, 20-24°C and relative humidity of 40-50%.  Animal protocols 
were reviewed and approved by the National Health and Environmental Effects Research 
Laboratory, Institutional Animal Care and Use Committee. 
Dosing Solution and Procedures- ATR (Syngenta Crop Protection, Inc. Greensboro, NC, 
97.1% purity) was prepared as a suspension in 1.0% methyl cellulose (Sigma Chemical, St. 
Louis, MO) in distilled water.  Timed-pregnant rats were treated in the morning with 0 
(vehicle) or 100 mg ATR/kg BW by oral gavage in 5 ml/kg dosing volume.  This ATR 
reference dose (100 mg/kg/d) was chosen due to consistent reproductive endpoint effects 
observed in previous studies (Laws et al., 2000; Rayner et al., 2004; Stoker et al., 1999). 
Experimental Design -Fifty pregnant LE dams were treated with vehicle (control) or 100 
mg/kg atrazine once daily (N=25 dams/treatment).  Control and ATR dams were dosed on 
either gestational days (GD) 13-19, 13-15, 15-17, or 17-19.  On postnatal day 1 (day of 
birth), litters were weighed, equalized to 10 pups, and each full litter was cross-fostered with 
another litter from a control (C) or atrazine treated (ATR) dam, creating 10 exposure 
parameters (exposed dam-milk source; C-C GD13-19, ATR-C 13-19, C-ATR13-19, ATR-C 
13-15, C-ATR13-15, ATR-C 15-17, C-ATR15-17, ATR-C 17-19, C-ATR17-19, and ATR-
ATR13-19).   
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Necropsy- Necropsies were performed following an overnight and continued stay in a quiet 
holding area, and by using decapicones for animal transfer to reduce stress.  All dams, 
female, and male pups were sacrificed on PND4. 
Mammary Whole Mounts- The 4th and 5th mammary glands of female offspring were 
removed, fixed, and stained in carmine alum as a whole mount as previously described 
(Fenton et al., 2002) on PND4.    Flattened whole mounts were visualized and the epithelial 
outgrowth was measured to the closest millimeter (mm).  Width measurements for area were 
taken from the two longest points of outgrowth. The whole mounts were subjectively scored 
(scale=1-4; 1=poor development/structure and 4=normal development/structure for each age 
group) within an age group, by two individual scorers without knowledge of treatment.   
Statistical Analysis- Dam or litter means were calculated for body weights and mammary 
gland scores.  Body weights and mammary gland scores were evaluated for treatment effects 
within each age group by one-way analysis of variance (ANOVA, Statistical Analysis 
System (SAS), SAS Institute, Inc. Cary, NC).  Analysis of covariance, with body weight as a 
covariate, was used to evaluate the effects of treatment on mammary gland scores.   
Significant treatment effects were demonstrated by p<0.05 and specific p-values are 
indicated throughout. 
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Results 
Dam Weight Gain- As observed in previous studies, all dams exposed to ATR failed to gain 
as much weight as control dams.  Weight gain between control and treated dams was similar 
when treated dams were not being dosed with ATR (Table 6.1).  During their respective 
dosing periods ATR GD13-15 gained 3.9 + 2.6 g. ATR GD15-17 gained 5.3 + 10.3g, ATR 
GD17-19 gained 12.7 + 4.6 g, and ATR GD13-19 gained 41.1 + 4.1g.  All were significantly 
different when compared to control, p<0.002 and when compared to control cohorts.  The 
lack of weight gain significantly reduced their total weight gain over the seven day period, 
p<0.02. 
Growth of offspring- The differences in dam weight gain did not affect litter size or weights 
on PND1 (Table 6.2), but the ATR litters tended to weigh less than control litters and have 
slightly fewer pups.  However, the average weight per pup was similar among all treatment 
groups.  Differences in weight were noted in some females born to ATR dams at PND4 
(Table 6.3).  Females in the ATR-C GD13-15, ATR-C GD13-19, and ATR-ATR GD13-19 
groups, had statistically different weights (6.7, 8.6, and 8.5% of control, respectively).   
Offspring mammary gland development- Mammary glands were removed from offspring 
at PND4, scored for development, and measured as described in Chapter 5 (Table 6.4).  All 
offspring born to an ATR-treated dam displayed delayed mammary gland development in the 
fourth and fifth mammary gland (ATR-C and ATR-ATR groups).  They received lower 
scores based on lateral branching off of the primary ducts and branches and the inappropriate 
absence of terminal buds.  Females born to ATR dams displayed decreased branching and 
decreased number of terminal buds.  Females nursing from ATR dams dosed either GD17-19 
or GD13-19 also consistently scored significantly lower in development than controls.  Their 
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glands were similar in appearance to those of ATR born offspring in that they displayed 
moderate branching and budding. The fourth gland seems to be most sensitive to ATR effects 
as glands of animals born to a control dam and nursed from an ATR dam treated GD13-15 
and GD17-19 were smaller in area compared to control glands (Table 6.4).  However, the 
lateral and longitudinal growth effects of those treatments were not seen in the fifth 
mammary gland.  Mammary glands from offspring born to ATR dams treated GD15-19 were 
significantly smaller in area in the fourth and fifth glands.  These data suggest that the critical 
time of ATR exposure for effects on the developing MG are in utero.  The effects, judging by 
MG developmental scores and size of the glands are worse as the ATR exposure gets closer 
to the time of parturition. 
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Discussion 
The results of these studies demonstrate that a brief exposure to 100 mg/kg ATR/d 
during the latter part of gestation only is enough to delay mammary gland development in the 
female offspring regardless of the milk source.  The results also suggest a residual lactation 
effect of ATR if dams were dosed during GD17-19.  The glands of the offspring nursed by an 
ATR treated dam dosed during GD17-19 (including dams dosed GD13-19) were delayed in 
development.  These results confirm that gestational ATR exposure does not alter litter 
weights at birth, and caused inconsistent decreases in weight on PND4.  Only the earliest 
three day (GD13-15) and longest seven day (GD13-19) exposure was associated with 
decreased weight at PND4, but only in female offspring.         
Mammary gland development in the offspring begins during the latter part of 
gestation and isometric growth of the gland continues until puberty (Imagawa et al., 1994; 
Sakakura, 1987).  The gestational ATR exposure in these studies coincided with different 
developmental events of fetal mammary gland development (bud formation, differentiation, 
and epithelial proliferation) and appeared to act directly on the mammary gland during those 
events.  The mammary gland effects of the in utero exposure were not rescued by milk from 
a control dam suggesting that the gestational exposure (in all exposure groups) caused 
permanent changes to the developing fetal mammary gland.  The most severe delays were 
observed in animals exposed for the entire seven day period suggesting a cumulative or 
additive effect from continued exposure.   
Early postnatal mammary gland development is characterized by epithelial branching 
and growth into the fat pad (Sakatura, 1987; Imagawa et al., 1994).  The offspring nursed 
from GD17-19 and GD13-19 ATR treated dams displayed reduced branching and 
 81
differentiation.  These animals were only exposed through lactation, adding evidence to the 
idea ATR alters the amount of parent compound and/or metabolites found in milk that can be 
transferred to the pup or cause a change in milk composition (i.e. lower protein or fat levels).   
The results support the preceding chapter’s evidence that maternal /fetal weight gain 
and early pup weight gain do not play a role in offspring mammary gland development.  
When exposed to 100 mg/kg ATR, dams do not gain as much weight at control dams, and it 
appears that ATR may act as an appetite suppressant.  Because, when exposure ended, in the 
case of the three day exposure, weight gain approached that of controls.  Weight gain in the 
GD13-19 dams began to approach controls after the first three days of dosing suggesting that 
over time the animals were able to cope with the exposure.  The lack of weight gain had no 
effect on the offspring.  The body weights of the offspring were not different when the pups 
were born and body weight did not influence mammary gland development at PND4.    
Acute in utero exposure to 100 mg/kg ATR alone consistently delays offspring 
mammary gland development.  In addition to the effects ATR appears to have 
transplacentally, in the dam, late gestational ATR exposure (specifically exposures occurring 
after GD17) may cause changes in the milk that directly affect the female offspring 
mammary glands or may additionally expose the pups to residual ATR metabolites in the 
milk.  These effects occur when dams are dosed GD17-19 suggesting that this is the sensitive 
window of fetal mammary gland development as well as dam milk production/transference.     
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 Table 6.1. Effect of 100 mg/kg ATR on Dam Weight Gain. 
Group N GD13-15 GD15-17 GD17-19 GD13-19* 
GD13-19 C 9 24.6 + 2.1 39.2 + 2.5 43.0 + 2.6 67.6 + 3.5 
GD13-15 C 5 33.3 + 2.6 39.6 + 3.7 39.4 + 3.8 72.7 + 6.4 
GD15-17 C 5 21.3 + 4.7 28.1 + 8.2 38.3 + 10.5 59.6 + 15 
GD17-19 C 6 30.2 + 3.0 42.7 + 1.7 44.6 + 1.7 74.9 + 3.6 
GD13-15 A 5 3.92 + 2.6a 40.8 + 3.9 40.4 + 3.4 44.3 + 4.3b
GD15-17 A 4 5.50 + 5.6a 5.32 + 10.3a 27.4 + 9.7 32.9 + 15b
GD17-19 A 6 26.5 + 3.6 20.1 + 5.7a 12.7 + 4.6a 39.2 + 7.0a
GD13-19 A 9 7.74 + 2.3a 30.5 + 3.6 33.3 + 2.4 41.1 + 4.1a
ATR= atrazine, GD= gestation day.  Data presented as dam mean + SE. * Accumulating weight gain with 
overlap.  Significant treatment effect by ANOVA, a p<0.01 vs. GD13-19 C and control cohort C, b p<0.05 
vs. GD13-19 C and control cohort C. 
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 Table 6.2.  Effect of 100 mg/kg ATR on Litter Weight and Size at PND1. 
Group N Litter Weight (g) Ave # of Pups Weight per Pup
GD13-19 C 8 75.5 + 3.3 13.5 + 0.80 5.7 + 0.27 
GD13-15 C 5 74.5 + 5.9 14.0 + 1.0 5.3 + 0.03 
GD15-17 C 4 79.6 + 3.3 14.5 + 0.50 5.5 + 0.17 
GD17-19 C 6 73.9 + 2.9 13.5 + 0.62 5.5 + 0.13 
GD13-15 A 5 69.8 + 4.0 12.8 + 0.86 5.5 + 0.15 
GD15-17 A 3 67.7 + 2.5 12.3 + 0.67 5.5 + 0.22 
GD17-19 A 6 69.2 + 4.1 12.8 + 0.75 5.4 + 0.17 
GD13-19 A 8 71.3 + 3.0 12.9 + 0.64 5.6 + 0.12 
ATR= atrazine, GD= gestation day, PND= postnatal day.  Data presented as dam mean + SE.  
 
 
 
Table 6.3.  Effect of 100 mg/kg ATR on Offspring Weight at PND4. 
Group Female Male 
GD13-19 C-C1 8.80 + 0.18 8.75 + 0.46 
GD13-15 C-ATR 8.78 + 0.14 9.17 + 0.39 
GD15-17 C-ATR 9.55 + 0.16 9.53 + 0.32 
GD17-19 C-ATR 9.63 + 0.12 9.99 +0.18 
GD13-19 C-ATR 8.80 + 0.24 9.34 + 0.39 
GD13-15 ATR-C 8.21 + 0.16a 8.93 + 0.18 
GD15-17 ATR-C 8.20 + 0.27 8.49 + 0.27 
GD17-19 ATR-C 8.52 + 0.17 8.90 + 0.21 
GD13-19 ATR-C 8.04 + 0.18b  8.16 + 0.18 
GD13-19 ATR-ATR 8.05 + 0.46c 8.86 + 0.22 
ATR= atrazine, PND= post natal day.  Data presented as dam mean + SE. 1Dam-Milk source. Significant 
treatment effect by ANOVA, a p<0.05 vs. C-C, b p<0.01 vs. C-C, c p<0.02 vs. C-C. 
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 Table 6.4. Effect of 100 mg/kg ATR on Mammary Glands and Area (mm2) at PND4. 
Group Gland 4 Score Gland 4 Area Gland 5 Score Gland 5 Area 
GD13-19 C-C1 3.1 + 0.3 9.1 + 0.6 3.1 + 0.2 8.7 + 0.7 
GD13-15 C-ATR 2.7 + 0.1 6.7 + 0.5a 2.9 + 0.1 7.5 + 0.5 
GD15-17 C-ATR 3.3 + 0.1 9.6 + 0.7 2.8 + 0.1 9.0 + 0.8 
GD17-19 C-ATR 2.5 + 0.1a 6.6 + 0.5a 2.4 + 0.1a 7.8 + 0.6 
GD13-19 C-ATR 2.3 + 0.2a 7.5 +0.7 2.5 + 0.2a 8.3 + 1.0 
GD13-15 ATR-C 2.4 + 0.1a 6.0 + 0.4a 2.3 + 0.1b 7.1 + 0.6 
GD15-17 ATR-C 2.1 + 0.2a 5.7 + 0.6a 2.1 + 0.1a 6.1 + 0.4a
GD17-19 ATR-C 2.5 + 0.1a 6.1 + 0.1a 2.2 + 0.1b 5.7 + 0.4a
GD13-19 ATR-C 1.8 + 0.1b 4.4 + 0.4b 1.8 + 0.1b 6.0 + 0.5a
GD13-19 ATR-ATR 1.9 + 0.1b 5.1 + 0.6b 1.7 + 0.1b 4.7 + 0.6b
ATR= atrazine, PND= post natal day.  Data presented as dam mean + SE. 1Dam-Milk source. Significant 
treatment effect by ANOVA,a p<0.01 vs. C-C, b p<0.0001 vs. C-C. 
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CHAPTER 7 
 
ATRAZINE ALTERS DAM MAMMARY GLAND DEVELOPMENT 
 
Summary 
 
Atrazine (ATR) was shown to delay early mammary development in female rat offspring 
following a brief gestational exposure.  ATR can also cause developmental effects via 
nursing, as shown in Chapters 4 and 6.  Because it is not known if the lactational effects of 
ATR are due to changes in quality, amount of milk transferred, or to actual ATR exposure,  I 
hypothesized that ATR would adversely affect pregnancy-related dam mammary gland 
differentiation.  On the contrary, the studies presented here test this hypothesis and suggest 
that exposure to ATR during pregnancy causes precocious dam mammary gland 
development.  The proper development of dam mammary glands during pregnancy is very 
important to the well-being of the offspring and could play a role in the delayed mammary 
gland development observed in the offspring.  
 
Methods 
Animals-Time-pregnant Long Evans rats (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  The animals were housed in an 
AAALAC accredited facility, one per cage and given food (Purina 5008 Rodent Chow, 
Ralston Purina Co., St. Louis, MO) and water ad libitum.  They were maintained in a room 
with a 14:10 hour light cycle, 20-24°C and relative humidity of 40-50%.  Animal protocols 
were reviewed and approved by the National Health and Environmental Effects Research 
Laboratory, Institutional Animal Care and Use Committee. 
Dosing Solution and Procedures- Atrazine, ATR, (Syngenta Crop Protection, Inc. 
Greensboro, NC, 97.1% purity) was prepared as a suspension in 1.0% methyl cellulose 
(Sigma Chemical, St. Louis, MO) in distilled water.  The environmentally based mixture 
(EBM) was prepared as a suspension in 1.0% methyl cellulose (Sigma) in distilled water.  
The EBM is a mixture of atrazine and its metabolites developed from the data accumulated 
from the North Carolina State Extension office and based on the highest measured levels of 
atrazine metabolites.  It consists of atrazine (25%), 2-chloro-4, 6-diamino-s-chlorotriazine 
(DACT 35%), hydroxyatrazine (HA 20%), 2-chloro-4-amino-6-(isopropylamino)-s-triazine 
(DEA 15%), and 2-chloro-4-amino-6-(ethylamino)-s-triazine (DIA 5%).  Time pregnant rats 
were treated in the morning with 0 (vehicle), EBM (total concentration equal to 8.7 mg/kg or 
250 ppm), or 100 mg atrazine/kg BW by oral gavage in 5 ml/kg dosing volume.  This 
reference dose (100 mg/kg/d) was chosen due to consistent reproductive endpoint effects 
observed in previous studies (Stoker et al., 1999, Laws et al., 2000, Rayner et al., 2004). 
Experimental Design- One hundred two pregnant LE dams were treated with vehicle 
(control), 8.7mg/kg EBM, or 100 mg/kg ATR daily (N>24 dams/ exposure period/treatment).  
Control and EBM dams were dosed gestational days (GD) 13-19, and dams receiving ATR 
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were dosed either GD17-19, or GD13-19.  Dams and litters were sacrificed on GD20 (N= 5 
dams/group), GD21 (N> 4 dams/group), PND1 (N=5 dams/group), PND4 (N>5 
dams/group), and PND11 (N= 4 dams/group).  On PND4, remaining litters were weighed 
and randomly equalized to 10 pups (6 females, 4 males).  On PND11, dams and pups were 
lactationally challenged (Appendix A).  Dams and pups were sacrificed immediately after 
challenge.  .   
Necropsy- Necropsies were performed following an overnight stay in a quiet holding area 
and by using decapicones for animal transfer to reduce stress.  At all necropsies, trunk blood 
was collected and portions of the 4th and 5th mammary glands of each dam were removed and 
processed for RNA and histology.  For RNA, mammary gland was placed in 1 mL Tri 
Reagent (Sigma).  Glands were placed in histology cassettes in 10% buffered formalin.  
These glands were sectioned and stained with hemotoxylin and eosin for developmental 
scoring.  
On GD20 and 21, dams were decapitated, and trunk blood was collected and 
centrifuged for 30 minutes at 3000rpm (4°C) for serum.  The uterus of each dam was 
removed and opened.  Fetuses were counted and decapitated.  On PNDs1 and 4, dams were 
sacrificed and treated as above.  The uterus of each dam was removed and implantation and 
resorption sites were counted.  The weight and sex of each pup was recorded and the pups 
discarded after mammary gland removal from female offspring.  Remaining litters were 
culled to 10 pups. 
Mammary Whole Mounts- The 4th and 5th mammary glands were removed from pups, fixed, 
and stained in carmine alum as a whole mount as previously described (Fenton et al., 2002) 
on PNDs4 and 11.  Flattened whole mounts were visualized and the epithelial outgrowth was 
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measured to the closest millimeter (mm).  Length measurements for area were taken from the 
nipple to the farthest point of branching.  Width measurements for area were taken from the 
two longest points of outgrowth.   
Mammary Gland Scoring- Dam mammary glands and offspring whole mounts were 
subjectively scored (scale=1-4; 1=poor development/structure and 4=normal 
development/structure for each age group; operating procedure available upon request) 
within an age group, by two individual scorers without knowledge of treatment.  For dam 
developmental scores, a higher score was given to advanced development of the gland.  Dam 
mammary glands were also scored for ductal dilation and lipid accumulation in the same 
manner.  Mammary glands representative of the mean score of the group were photographed 
on a Leica WILD M420 macroscope. 
Radioimmunoassay- Serum was obtained from dams that were decapitated on GDs 20, 21, 
PNDs 1, 4, and 11 for use in radioimmunoassay.  Serum corticosterone and progesterone 
were measured using Coat-a-Count Radioimmunoassay Kits obtained from Diagnostic 
Products Corporation (Los Angeles, CA).  Serum estrone was measured using the DSL 8700 
Estrone Radioimmunoassay kit from Diagnostic Systems Laboratories, Inc. (Webster, TX).  
Serum prolactin (PRL) was analyzed by radioimmunoassay using materials supplied by the 
National Institute of Arthritis, Diabetes, Digestive, and Kidney Diseases.  All assays were 
run in duplicate.   
Statistical Analysis- Group means and dam means (pups/dam; litter as unit) were calculated 
for body weights, mammary gland scores, and serum hormones and were evaluated for 
treatment effects within each age group by one-way analysis of variance (ANOVA, 
Statistical Analysis System (SAS), SAS Institute, Inc. Cary, NC).  Analysis of covariance 
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was used to evaluate the effects of treatment on mammary gland scores while adjusting for 
any effect of body weight.  Significant treatment effects were indicated by p<0.05 and 
specific p-values are indicated. 
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Results 
Dam weight gain- As seen in our previous studies, dam weight gain during dosing in the 
ATR group was reduced when compared to weight gain of dams from the control and EBM 
groups.  From GD13-17, control, EBM, and ATR GD17-19 (dosed only one day during this 
period of time) dams gained a similar amount of weight (~38.9 grams, g).  Dams in ATR 
GD13-19 group averaged a gain of -2.6 + 6.9 g (p<0.0001) over the same time period.  The 
ATR GD17-19 dams were dosed starting on GD17 and gained an average of 5.2 + 2.2 g 
(p<0.0001) during their three day dosing period, while dams in the remaining groups gained 
an average of 27 grams during this period of dosing.  Throughout the entire dosing period, 
GD13-19, both GD17-19 and GD13-19 ATR groups, gained significantly less weight than 
control dams (66.5 + 2.2 g); 44.7 + 3.8 g ATR GD17-19 and 24.4 + 6.7 g ATR GD13-19 
(both p< 0.001).  This reduced weight gain did not affect litter size as the number of pups per 
litter was not different in any of the groups on GD20, GD21, or in the number of 
implantation sites at PND1, 4, or 11.  Following dosing, the remaining dam weights were 
recorded at PND 1 and found not to be different among the groups.  At PND4, dams in the 
ATR GD13-19 groups weighed significantly less than control dams (p<0.02, 265.2 + 8.2 g 
ATR GD13-19 vs. 303.5 + 9.3 g Control).  By PND11, dam weights between the dose groups 
were no longer different.    
Dam serum hormone concentration- To determine if ATR exposure affected circulating 
hormone levels during this developmentally important period, serum was separated from 
trunk blood of dams on GD20, 21, PND1, 4, and 11 (Table 7.1).   Progesterone, 
corticosterone, estrone, and prolactin were chosen because of their role in mammary gland 
development, pregnancy maintenance, and lactation.  At GD20, progesterone levels were 
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found to be significantly lower in ATR GD17-19 dams (p<0.02 vs. Control).  No other 
hormones were found to be statistically different at this time or any other timepoint, but 
interesting trends were noted among treatment groups.  However, progesterone levels in ATR 
GD17-19 remained low at GD21.  Corticosterone levels remained high throughout the end of 
pregnancy and early lactation and lowered by PND11 except in the two ATR groups.  
Estrone levels were higher in the two ATR groups the day before parturition and remained 
high after birth.  Prolactin levels were similar across the groups.  Hormone ratios were not 
found to be different (date not shown).    
Dam mammary gland development- Dam mammary glands were removed on GD20, 21, 
PND1, 4, and 11 and scored for development, ductal dilation, and lipid accumulation (Table 
7.2, Figures 7.1-7.5).  Developmental scoring was based on how much of the gland had filled 
with lobuloalveolar units and the size of the units.  Advanced or precocious development, 
different from controls (p<0.004), was observed in the glands of ATR GD13-19 dams at the 
first two timepoints.  Glands from ATR GD17-19 were only statistically different at GD21, 
p<0.005, and developmentally, glands from EBM were not different from controls at any 
timepoint.  Following parturition, development was not statistically different from controls in 
ATR GD13-19.   
 Ductal dilation was characterized by enlarged ductal structures occurring throughout 
the gland.  This was not expected and highly abnormal.  Oddly, glands from ATR GD13-19 
dams had a significant increase in ductal dilation than controls at the first three timepoints, 
p<0.003 (Figures 7.1-7.3).  Strangely, ATR GD17-19 and EBM also displayed these 
abnormal ductal and were scored significantly different from controls at GD21 and PND1, 
p<0.02.  None of the groups were different from controls at PNDs 4 and 11 (Table 7.2, 
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Figures 7.4-7.5).  There was an increased amount of lipid in the lobuloalveolar structures in 
the ATR GD13-19 glands at GD20, GD21, and PND1 (p<0.02), that was consistent with 
precocious development.  Coincident with abnormal ductal dilation and precocious 
development on GD21, lipid accumulation in the ATR GD17-19 and EBM glands were 
different at GD21, p<0.002, but not at any other timepoint.  Mammary glands from all treated 
groups displayed inflammatory cells within the ducts and in the glands at PND4 (Figure 7.4).  
Apoptotic bodies were noted in ATR exposed glands at PND11 (Figure 7.5).    
Offspring Effects- 
Offspring growth- Body weights were compared among the offspring of all groups at 
PND1, 4, and 11.  At PND1, female pup weights were not different, but male pups from ATR 
GD17-19 weighed significantly less than control males (p<0.003, but only a 6.3% reduction).  
Consistent with our previous work (Chapter 4), females in both ATR groups weighed 
significantly less than control females by PND4 (p<0.001, 7.3% ATR GD17-19 and 9.1% 
ATR GD13-19).  Their male siblings from the EBM group and both ATR groups weighed 
significantly less than control males (p<0.02, 4.8% EBM, 11.5% ATR GD17-19, and 8.1% 
ATR GD13-19).  Only female offspring from ATR GD13-19 weighed significantly less than 
control at PND 11(p<0.001, 11.6% reduction).  Male offspring weights were not found to be 
different at this timepoint. 
Offspring mammary gland development- Female offspring mammary glands removed on 
PNDs4 and 11 were scored for development and measured for epithelial area (Table 7.3).  At 
PND4, glands from all groups were significantly reduced from control in development and 
size, p<0.0001.  While all glands scored lower in development than control, there were some 
issues that separated each group.  Glands from EBM offspring had a great amount of 
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variability, but the number and density of lateral branching was reduced consistently 
throughout all the glands.  Lack of branching was an issue in the ATR GD17-19 glands and 
branching and budding were reduced in the ATR GD13-19 glands. 
  By PND11, developmental scores were still significantly lower than controls for all 
ATR-exposed groups, but the area of EBM and ATR GD17-19 glandular epithelium was not 
statistically different from control in the fourth gland or for EBM in the fifth gland.  EBM 
glands still displayed density and branching detriments.  ATR GD17-19 and GD13-19 had 
similar defects, with ATR GD13-19 having weak branching patterns and poor epithelial 
outgrowth.  
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Discussion 
The results of the studies presented here demonstrate that gestational exposure to a 
low dose (8.7 mg/kg) mixture of ATR and its metabolites or to 100 mg/kg ATR/d altered 
development of the dams’ mammary gland.  As observed in previous studies and expected in 
these; mammary gland development was delayed in the offspring of the ATR treated dams as 
well as in the low dose mixture group.  The delays were first observed at PND4, but 
remained until at least PND11.   
We hypothesized that ATR would delay pregnancy-related mammary gland 
differentiation in a manner similar to that observed in the offspring leading to under-
developed glands as pregnancy continued.  In the offspring, ATR appears to act most directly 
when the glands are going through the epithelial proliferation stage which starts around 
GD17 and continues after birth.  As the dam enters the final stages of pregnancy and begins 
to prepare for birth, the epithelial structures proliferate and differentiate to fill the fat pad and 
form lobuloalveolar structures (Masso-Welch et al., 2000).    In this study, instead of 
delaying dam mammary gland development, ATR appeared to accelerate it especially in the 
GD13-19 ATR treated dams which filled the fat pad much earlier with lobulalveolar 
structures than controls.  ATR exposure, either in low dose mixture or parent compound, also 
altered the ducts of the dam mammary gland by greatly increasing their size and distension 
within the gland.  This occurred during late gestation through the day the pups were born.  
Coupled with the accelerated development, this ductile dilation suggests action on 
proliferating cells or active transfer of compound from the blood stream into the MG prior to 
beginning lactation. 
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   The observed effects in the dam mammary gland occurred with only subtle changes 
in serum hormone concentrations.  Hormones change very rapidly when transitioning from 
pregnant to lactating.  With the exception of one group at one timepoint, we observed no 
differences in serum hormones.  With the accelerated development and ductile dilation, we 
expected differences in estrone, progesterone, and prolactin concentrations as these are all 
known to be involved in lobuloalveolar differentiation and secretory development (Borellini 
and Oka, 1989; Imagawa et al., 1994; Silberstein, 2001; Topper and Freeman, 1980).  We did 
see corticosterone levels decrease following birth as pregnancy maintenance was no longer 
required.  We also saw prolactin levels increase during mid-lactation due to the lactational 
challenge.  Based on these data, the mammary gland alterations observed in the dams 
following exposure to ATR were not associated with changes in hormone concentrations.   
As seen in the previous studies, offspring mammary gland development was delayed 
at early timepoints in all ATR exposed groups, even the low dose (8.7 mg/kg) mixture.  Their 
developmental scores were very similar to the two ATR groups at PND4.  This delayed 
development was mirrored by stunted area of the entire gland.  By PND11, the  8.7 mg/kg 
EBM group had caught up to controls with respect to area of the gland but still displayed 
delayed development in the gland with scores only slightly higher than the two ATR groups.  
The mixture appears to be a very potent modulator of early mammary gland development. 
In conclusion, gestational exposure to ATR, as well as a low dose mixture of ATR 
and its metabolites, not only delays offspring mammary gland development, but accelerates 
lactogenesis in the dam without affecting serum hormone concentrations.  Therefore, these 
data suggest that decreased milk production and/or quality (lipid content) do not explain the 
mammary gland effects observed in females nursing from ATR-exposed dams.  Further 
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studies evaluating milk transfer during a timed feeding and maternal behavior confirm this 
conclusion (Appendix B).     
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Table 7.1.  Effect of 8.7 mg/kg EMB and 100 mg/kg ATR on Dam Serum Hormone 
Concentrations (/ml) Over Time. 
GD 20 Progesterone 
(ng) 
Corticosterone 
(ng) 
Estrone (pg) Prolactin (ng) 
Control 51.6 + 10 573 + 116 42.9 + 4.8 4.80 + 1.7 
EBM 26.6 + 11 332 + 70 29.6 + 5.6 2.94 + 0.36 
ATR GD17-19 15.5 + 6.6a 321 + 72 45.6 + 9.0 11.4 + 7.1 
ATR GD13-19 53.8 + 9.7 371 + 52 49.5 + 10 4.26 + 1.0 
     
GD21     
Control 19.3 + 7.9 517 + 120 29.0 + 3.5 60.4 + 14 
EBM 16.9 + 7.2 674 + 80.3 57.0 + 18 63.7 + 5.1 
ATR GD17-19 8.79 + 2.8 407 + 137 53.1 + 6.8 61.8 + 11 
ATR GD13-19 13.0 + 3.1 453 + 114 64.8 + 24 42.2 + 18 
     
PND1     
Control 23.7 + 6.1 639 + 84 55.1 + 6.6 5.81 + 1.9 
EBM 33.0 + 5.4  554 + 47 39.5 + 5.2 5.63 + 1.9 
ATR GD17-19 34.4 + 11 576 + 46 167 + 68 7.78 + 2.4 
ATR GD13-19 32.7 + 11 452 + 77 80.7 + 34 4.24 + 0.67 
     
PND4     
Control 48.0 + 8.8 437 + 138 98.4 + 22 6.65 + 3.24 
EBM 51.9 + 6.4 498 + 108 73.9 + 12 4.34 + 0.74 
ATR GD17-19 62.8 + 6.7 516 + 87 148 + 44 3.99 + 1.0 
ATR GD13-19 47.8 + 8.1 407 + 127 193 + 110 3.73 + 1.3 
     
PND11     
Control 47.3 + 8.4 51.0 + 10 62.1 + 12 127 + 6.2 
EBM 53.0 + 12 82.6 + 25 50.3 + 2.8 109 + 14 
ATR GD17-19 68.5 + 6.7 136 + 14 105 + 40 101 + 12 
ATR GD13-19 47.8 + 12 110 + 41 150 + 39 128 + 13 
EBM= environmentally based mixture 8.7 mg/kg, ATR= atrazine, GD=gestation day, PND= post natal 
day.  Data presented as dam mean + SE. GD20, PND1- Dam N=5 per group, GD21- Dam N> 4  per 
group, PND4- Dam N> 5 per group, PND11- Dam N=4 per group. Significant treatment effect by 
ANOVA, a p<0.02 vs. Control. 
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Table 7.2. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on Dam Mammary Gland 
Development, Ductal Dilation, and Lipid Accumulation over Time. 
Development   
Group Control EBM ATR GD17-19 ATR GD13-19 
GD20 1.9 + 0.1 2.1 + 0.3 1.9 + 0.4 3.4 + 0.2* 
GD21 2.3 + 0.2 2.6 + 0.2 3.4 + 0.2* 3.5 + 0.3* 
PND1 2.2 + 0.4 2.7 + 0.3 3.1 + 0.3 3.4 + 0.2* 
PND4 2.9 + 0.4 2.4 + 0.1 2.8 + 0.3 3.4 + 0.2 
PND11 2.5 + 0.2 3.2 + 0.5 3.2 + 0.4 3.2 + 0.5 
     
Ductal Dilation 
GD20 2.0 + 0.3 2.6 + 0.4 1.2 + 0.2 3.6 + 0.2* 
GD21 1.2 + 0.2 3.2 + 0.4* 2.6 + 0.4* 3.0 + 0.4* 
PND1 1.6 + 0.2 2.8 + 0.4* 2.6 + 0.2* 3.4 + 0.2* 
PND4 2.6 +0.2 2.6 + 0.3 2.7 + 0.4 3.2 + 0.4 
PND11 2.5 + 0.3 3.0 + 0.0 3.0 + 0.0 2.7 + 0.2 
     
Lipid Accumulation 
GD20 1.2 + 0.2 1.8 + 0.3 1.7 + 0.25 3.6 + 0.2* 
GD21 1.8 + 0.2 3.2 + 0.4* 3.4 + 0.2* 3.7 + 0.2* 
PND1 3.0 + 0.0 3.2 + 0.2 3.0 + 0.3 3.8 + 0.2* 
PND4 3.2 + 0.2 2.7 + 0.2 2.9 + 0.3 3.6 + 0.2 
PND11 2.5 + 0.2 2.5 + 0.6 2.7 + 0.2 3.7 + 0.2 
EBM= environmentally based mixture 8.7 mg/kg, ATR= atrazine, GD=gestation day, PND= post natal 
day.  Data presented as dam mean + SE. GD20, PND1- Dam N=5 per group, GD21- Dam N> 4  per 
group, PND4- Dam N> 5 per group, PND11- Dam N=4 per group. Significant treatment effect by 
ANOVA, * p<0.02 vs. Control. 
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Table 7.3. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on Offspring Mammary Gland 
Development (4th and 5th gland) and Area (mm2) 
PND4 Control EBM ATR GD17-19 ATR GD13-19 
Gland 4 Score 3.3 + 0.1 2.4 + 0.1* 2.4 + 0.1* 2.3 + 0.1* 
Gland 4 Area 9.0 + 0.4 6.5 + 0.4* 5.5 + 0.3* 6.6 + 0.4* 
Gland 5 Score 3.3 + 0.1 2.2 + 0.1* 2.3 + 0.1* 2.1 + 0.1* 
Gland 5 Area 9.2 + 0.5 6.4 + 0.4* 6.0 + 0.3* 6.0 + 0.4* 
     
PND11     
Gland 4 Score 3.5 + 0.1 2.4 + 0.2* 2.2 + 0.2* 2.0 + 0.2* 
Gland 4 Area 20.4 + 1.4  19.0 + 2.7 15.7 + 2.0 12.3 + 2.1* 
Gland 5 Score 3.6 + 0.1 2.7 + 0.2* 2.4 + 0.2* 2.2 + 0.2* 
Gland 5 Area 18.9 + 1.0 18.7 + 1.7 12.9 + 2.1* 12.3 + 1.6* 
EBM= environmentally based mixture, ATR= atrazine, PND= post natal day.  Data presented as dam 
mean + SE. PND4- Dam N> 5 per group, PND11- Dam N> 3 per group. Significant treatment effect by 
ANOVA, * p<0.01 vs. Control. 
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Control 8.7 mg/kg EBM
ATR GD13-19ATR GD17-19 
 
Figure 7.1. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on dam mammary gland 
development at GD20.  ATR GD13-19 glands displayed increased development, ductal 
dilation, and lipid accumulation, p<0.02 vs. Control.  8.7 mg/kg EBM not statistically 
significant at this timepoint. 
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ATR GD17-19 ATR GD13-19
 
Figure 7.2. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on dam mammary gland 
development at GD21.  All treated dam glands displayed increased ductal dilation, and lipid 
accumulation, p<0.02 vs. Control.  ATR GD17-19 and GD13-19 scored higher in 
development than controls, p<0.02. 
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Figure 7.3. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on dam mammary gland 
development at PND1.  All treated dam glands displayed increased ductal dilation.  ATR 
GD13-19 had increased lipid accumulation at this timepoint, p<0.02 vs. Control and very 
little adipose was evident in glands of these animals.  
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Figure 7.4. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on dam mammary gland 
development at PND4.  No statistical differences were found for development, ductal 
dilation, and lipid accumulation.  Ducts of control animals were now also filled with 
secretory materials.  Inflammatory cells were found in the glands and ducts of the ATR 
treated animals (arrow). 
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Figure 7.5. Effect of 8.7 mg/kg EBM and 100 mg/kg ATR on dam mammary gland 
development at PND11.  No statistical differences were found for development, ductal 
dilation, and lipid accumulation.  However, the fat pads appear to be totally filled with 
epithelium in treated animals when compared with control.  Apoptotic bodies were noted in 
the glands of the ATR treated animals. 
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CHAPTER 8 
 
DETECTION OF ATRAZINE IN THE PREGNANT AND LACTATING DAM 
 
Summary 
Atrazine (ATR) causes precocious lactogenesis and mammary gland development in Long-
Evans dams following a brief gestation exposure as short as three days at 100 mg/kg or 
following a seven day low dose exposure (8.7 mg/kg).  ATR is reported to have a half-life of 
less than 1 day in adult non-pregnant rats. However, control pups nursing from dams exposed 
to ATR have altered MG development and delayed puberty.  We hypothesized that ATR 
disposition in the pregnant and lactating rat may differ from that in the adult non-pregnant rat 
resulting in residual ATR metabolite transference to pups both transplacentally and via milk. 
The studies presented here test this hypothesis and determine if ATR and its metabolites are 
found in milk, urine, serum, and amniotic fluid at different time points following dosing.  
The results showed that ATR and its metabolites can de detected in the dam at least 6 days 
post dosing.  These results suggest that even though exposure to the pregnant dam ended on 
GD19, ATR metabolites may be available to the developing offspring until at least PND4 
when abnormal mammary gland development has been detected in female pups, and 
neurological centers in the brain responsible for central nervous system control of puberty are 
suggested to be developing. 
Methods 
 
The animals and methods in this study were the same as used in the previous chapter except 
where noted below.   
Experimental Design- A subset of dams were dosed with vehicle, 8.7 mg/kg EBM, or 100 
mg/kg ATR on PND4 (exactly as they had been dosed prenatally) and sacrificed three hours 
post dosing.  .   
Milking and Urine Collection- On GD21, PND1, and PND4 dams were milked prior to 
sacrifice.  Dams were injected with Oxytocin (5 IU/ml IM injection, Sigma).  Dams were 
then injected with Ketamine:Xylazine (35:5 mg/kg IP injection).  A milking device was 
created using the building’s vacuum system, a side-arm flask with a one holed rubber 
stopper, and tubing from a commercial breast pump.   Urine was collected from live animals 
five and 8 hours post dosing on GD19. 
Necropsy- Necropsies were performed following an overnight stay in a quiet holding area 
and by using decapicones for animal transfer to reduce stress.  At all necropsies, trunk blood 
was collected for serum and portions of the 4th and 5th mammary glands of each dam were 
removed and processed for extraction of ATR and metabolites.  For tissue homogenate, 
mammary gland was weighed and placed in 1 mL 37% methanol and later homogenized and 
centrifuged to collect the supernatant.  Urine from each dam was collected from the bladder 
with a syringe on GD20, 21, PNDs1, 4, and 11 at necropsy. 
On GD20 and 21, dams were sacrificed after attempted milk collections.  Dams (N=5) were 
decapitated, and trunk blood was collected and centrifuged for 30 minutes at 3000rpm (4°C)  
for serum.  Uteri were removed intact and amniotic fluid from each dam at GD20 and 21 was 
collected, sonicated, and centrifuged to collect supernatant.  On PNDs1, 4, and 11, dams 
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(N=5, PND1; N>7, PND4, N=5, PND11) were sacrificed and treated as above.  Urine, 
amniotic fluid, serum, milk extract, and milk were sent to the Centers for Disease Control for 
ATR and metabolite detection.   
Detection of Atrazine and Metabolites- Urine, amniotic fluid, and serum samples from 
control and ATR-dosed dams were analyzed by isotope dilution high performance liquid 
chromatography tandem mass spectrometry for the presence of hydroxyl-, dealkyl- and 
mercapturate ATR metabolites.  The method can accurately quantify 10 ATR-related 
metabolites and qualitatively analyze two additional mercapturate metabolites with limits of 
detections ranging from 0.1-1 ng/ml.  Values listed at 0 were below the limit of detection.  
The process was divided into three phases including sample loading, reverse phase separation 
and strong cation exchange separation and re-equilibration of reverse phase columns.  Two 
hundred ul of sample were used and 2 ion pairs monitored for each metabolite.  Detected 
metabolites include 2-chloro-4, 6-diamino-s-chlorotriazine DACT, hydroxyatrazine ATR-
OH, 2-chloro-4-amino-6-(isopropylamino)-s-triazine DEA, and 2-chloro-4-amino-6-
(ethylamino)-s-triazine DIA, and the mercapturate forms of ATR and DEA.  The parent 
compound, ATR, was detected as well.     
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Results 
Detection of ATR and/ or its metabolites 
Urine- Urine was collected from exposed dams on GD19 as well as all the timepoints 
mentioned above.  ATR and metabolites were detected in urine at all timepoints, including 
PND11 (Figures 1-4).  There was very little ATR detected among the groups compared to 
what they were actually given orally, but ATR metabolites were still being excreted as long 
as 13 days post dosing.  The major metabolites detected in EBM dams were ATR-OH > 
DACT > DEAM.  In dams treated with ATR parent compound, DACT and DEAM were the 
major metabolites detected.  During the last two days of gestation, the metabolite profile for 
ATR GD17-19 contained a fair amount of ATR-OH, but following birth, ATR-OH levels 
were very low.  
All treated dams had a decrease in ATR and metabolites in the three hours between 
the collection periods on GD19 (Figures 8.1-8.3).  A continued decrease was evident in urine 
of EBM treated dams on GD20, but a slight increase was observed in the dams on GD21 
(Figure 8.1).  Both ATR GD17-19 and GD13-19 showed an increase in detected components 
on GD20 and a decrease on GD21.  Levels of metabolites increased on PNDs1 and 4 in the 
ATR GD13-19 dams followed by a decrease on PND11.  Both EBM and ATR GD17-19 
showed an increase in levels after parturition.  It is not clear how these levels correlate with 
changes in creatinine in the urine.  The reason for the large postnatal increase is unknown.  
On PND4, a subset of dams were dosed with the compound they were prenatally 
exposed to and killed three hours later.  Urine collected at that time demonstrated a dose-
related increase in detected metabolite totals.  ATR-OH was very similar to DACT in the 
EBM and DACT > DEAM in the dams dosed with the parent compound.    
 109
Amniotic fluid- To measure the ATR metabolites present, amniotic fluid was removed from 
dams at GD20 and 21, and fluid collected.  DACT was the only metabolite detected in the 
amniotic fluid of EBM dams at GD20 and GD21 (very low levels).  In the ATR GD17-19 
dams, DACT was the major metabolite detected, but DIA, DEA, DEAM, and even the parent 
compound were also detected in lower concentations.  ATR, ATRM, and ATR-OH were not 
detected in the ATR GD13-19 dams.  From GD20 to GD21, DACT concentration in EBM 
females had decreased but was still detectable.  ATR-OH and DIA were not detected in ATR 
GD17-19, but all forms were found in ATR GD 13-19 females on GD21. 
Serum- Serum was analyzed at all timepoints for the presence of free ATR and its 
metabolites.  Very little free metabolite was detected in serum relative to other body fluids 
evaluated.  DACT was the major metabolite found in EBM dam serum on GD20.  There was 
very little HA and DEA present and no other metabolites detected.  DACT was the only 
metabolite detected at GD21 and PND1 in decreasing amounts.  No serum analytes were 
detectable on PNDs4 and 11.  Surprisingly, in both the ATR GD17-19 and GD13-19 groups, 
ATR-OH was the major available metabolite detected with DEAM, DIA, DACT, and DEA 
present at very low levels on GDs 20, 21, and PND1.  By PND4, very little metabolite 
remained, but mostly ATR-OH was present in both groups.  Although the levels were very 
low, ATR GD17-19 was the only group presenting any metabolites (ATR-OH and DEAM) 
on PND11.   
 A subset of dams was given one dose of vehicle, 8.7 mg/kg EBM, or 100 mg/kg ATR 
on PND4 and necropsied three hours later.  The distribution of metabolites was similar to 
what was seen in animals dosed only during gestation.  In the EBM dams, DACT was the 
major metabolite followed by ATR-OH, DEA and DIA.  No DEAM or ATRM was detected.  
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In the ATR dosed dams, the metabolites order from greatest to least was ATR-OH, DEAM, 
DIA, and DACT.  DEA was not detected in ATR GD17-19 but ATRM and ATR were found.  
DEA, ATRM, and ATR were detected in low amounts in ATR GD13-19 serum. 
 111
Discussion 
 The results of the studies presented here demonstrate that ATR and its metabolites 
can be detected in the urine, amniotic fluid, and serum of pregnant and lactating dams and is 
detectable six to thirteen days after exposure.  Levels and ratios of analytes are different 
depending upon the starting exposure and exposure length.  The results also demonstrated 
that the parent compound and a mixture of ATR + metabolites present different profiles in 
the fluids mentioned above. 
 Many studies have examined ATR in the virgin non-pregnant rats and found it to be 
rapidly eliminated (Atrazine Toxicology).  The results of these studies suggest that this is not 
the case for the pregnant and lactating rat.  In the urine, ATR and metabolites increased 
following birth of the offspring suggesting storage of the compounds during pregnancy and a 
subsequent release or a change in metabolism following parturition.     
 It is also possible that postnatal increase in levels of metabolites could be attributed to 
the maternal behavior of the dams.  When the offspring are less than 10 days old, dams 
routinely groom them by licking their anogenital region (Smith et al., 2004), to aid the pups 
in urination during this time.  While doing this, the dams ingest urine and possible feces 
containing ATR metabolites.   
 In examining the profiles of urine, amniotic fluid, and serum in the exposed dams, we 
were surprised to observe that the amount of metabolites in the 8.7 mg/kg EBM dams were 
different from those found in the dams treated with only ATR.  ATR-OH was found in 
relatively high levels in the urine, but was only 20% of the administered dose, suggesting that 
the metabolism of ATR-OH is slow.  In amniotic fluid, DACT was the main metabolite 
detected in all groups, and it decreased over the two day period post dosing.  However, this 
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data shows that the developing fetus is exposed to DACT and low amounts of other 
metabolites.  Surprisingly, DACT in the EBM group, and ATR-OH in ATR treated group, 
were major metabolites found in serum, especially given that ATR-OH was a major 
metabolite in 8.7 mg/kg EBM dam urine.   
The metabolite profiles could be due to preferential binding of the metabolites to 
proteins or amino acid residues in the fluids in which they were detected (Dooley et al., 
2006; Wu et al., 1998).  Recent work by Dooley and colleagues (2006) identified a 
hemoglobin adduct in Sprague-Dawley rats exposed to ATR they speculate to be DACT.  
This could explain why the serum metabolite profiles of the two ATR groups were majority 
ATR-OH.  It does not explain the DACT levels in the 8.7 mg/kg EBM dams.  The different 
profiles could also be due to metabolism pathway saturation at the higher doses.  Either way, 
these data demonstrate that ATR metabolites are available to the neonate via the exposed 
dam, both transplacentally as DACT or via the milk, which would recruit metabolites from 
blood.  
In conclusion, ATR and its metabolites can be detected in urine, amniotic fluid, and 
serum many days post dosing in the pregnant and lactating rat.  The data show that 
metabolites of ATR do reach the placenta, and potentially therefore the fetus.  Dose and 
length of exposure appear to play a role in the distribution of the metabolites within each 
media tested.  The difference in the ratio of metabolites may be the reason that EBM induces 
developmental delays in mammary glands of offspring at such low doses.                 
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Figure 8.1.  Levels of ATR and metabolites in urine from 8.7 mg/kg EBM dams over time.  
Metabolites in GD19 and GD19U were detected from samples taken 5 and 8 hours post 
dosing.  The major metabolites detected include ATR-OH and DACT. 
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Figure 8.2.  Levels of ATR and metabolites in urine from ATR GD17-19 dams over time.  
Metabolites in GD19 and GD19U were detected from samples taken 5 and 8 hours post 
dosing.  The major metabolites detected include DACT and DEAM.
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Figure 8.3.  Levels of ATR and metabolites in urine from ATR GD13-19 dams over time.   
Metabolites in GD19 and GD19U were detected from samples taken 5 and 8 hours post 
dosing.  The major metabolites include DACT and DEAM.
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Figure 8.4.  Levels of ATR and metabolites in urine three hours after dosing on PND4.  
Metabolites in GD19 and GD19U were detected from samples taken 5 and 8 hours post 
dosing.  Levels of ATR-OH and DACT are similar in the EBM group, but DACT was the 
major metabolite in the ATR GD17-19 and GD13-19. 
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Figure 8.5.  Levels of ATR and metabolites in Environmentaly Based Mixture (8.7 mg/kg) 
dam amniotic fluid over time.  DACT was the only metabolite detected for this group of 
animals. 
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Figure 8.6.  Levels of ATR and metabolites in ATR GD17-19 amniotic fluid over time.  
DACT was the major metabolite detected but others are present in small amounts.  Some 
parent compound was detected. 
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Figure 8.7.  Levels of ATR and metabolites in ATR GD13-19 amniotic fluid over time.  
DACT was the major metabolite detected in these animals, but DIA was noticeably present. 
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Figure 8.8.  Levels of ATR and metabolites in EBM serum over time.  In these animals, 
DACT was the major metabolite detected. 
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Figure 8.9.  Levels of ATR and metabolites in ATR GD17-19 serum over time.  In contrast 
to urine and amniotic fluid, ATR-OH was the major metabolite found in these animals. 
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Figure 8.10.  Levels of ATR and metabolites in ATR GD13-19 serum over time.  Similar to 
ATR GD17-19, ATR-OH was the major metabolite detected in the serum. 
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Figure 8.11.  Levels of ATR and metabolites in serum three hours after dosing on PND4.  
The profiles were very similar to that detected over time.  EMB animals had mostly DACT 
while the two ATR groups had high levels of ATR-OH and DEAM.    
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CHAPTER 9 
CONCLUSIONS 
 
  
A gestational exposure to ATR has been shown to delay mammary gland 
development in the offspring of Long-Evans rats.  It has also been shown to alter the 
pregnancy-related mammary gland differentiation in the exposed dams.  The effects appear 
to be due to small amounts of ATR as well as ATR metabolites which have been detected in 
the urine, amniotic fluid, and serum of the dams days after the exposure period has ended. 
In these studies, we used the rat dam as the experimental unit of analysis because the 
dam was given the treatment dose.  At this time, it is unknown how much of the actual dose 
and what form (parent compound or metabolites) are present and biologically active in the 
offspring, but the compounds do appear to reach them both transplacentally and via the milk.  
The exposure period ended 2 days before the dams gave birth and any exposure to ATR 
occurring during lactation should have been far less than the dose given to the dam as the 
compound is thought to be rapidly metabolized and excreted.  We hypothesize that a 
sufficient dose of ATR can occur via the milk following a prenatal exposure to cause the 
effects seen in the male offspring in this study.  Alternatively, ATR exposure to the dams 
could have inhibited milk production or quality resulting in decreased nutritive value of the 
milk.   
Although a relatively high dose of atrazine (100 mg/kg) is used in these studies, with 
the exception of the low dose EBM, one must remember that each pregnant rat contains in 
her an average of 144 developing fetal mammary buds during the time of exposure (12 buds 
per rat and an average of 12 pups/litter).  Some dams contained as many as 204; possibly 
contributing to the litter to litter variation.  This is in comparison to the 2 mammary buds 
developing in the average pregnant woman (lower average variation).    
From the small amount of published information available on ATR disposition in the 
rat, it has been shown that C14-labelled ATR is absorbed into plasma with a rate constant of 
0.2 to 1 hr (McMullin et al., 2003) and it has been reported that approximately 85% of 
radioactivity, administered as C14-labeled atrazine, is excreted in the urine and feces of the rat 
in the first 72 hours after dosing (Bakke et al., 1972), with the majority of that excretion (85-
95%) in the first 24 hours.  These excretion values are very similar to the values reported in 
the milk goat (Robbins et al., 1968), where they further estimated that very limited amounts 
of labeled propazine, structurally related to ATR, were detected in milk.  Furthermore, recent 
attempts to measure atrazine in 10 breastmilk samples found either no detectable compound 
or metabolite (7/10; below the limit of detection), or concentrations at (1/10) or below (2/10) 
the assay quantitation limit (1.0 µg/l; Balduini et al., 2003).  
Even though we do not yet know if ATR or its metabolites are transferred in the milk 
or changing the composition of the milk, we do know that gestational exposure to ATR or a 
metabolite mixture changes the dam’s mammary gland development.  We know that ATR 
and its metabolites are present in the dam as late as PND11 as evidenced by urine metabolite 
levels and PND4 in serum.  We also have preliminary evidence that metabolites are detected 
in mammary gland tissue from pregnant and lactating ATR treated dams suggesting that 
ATR or at least its metabolites are transported into the tissue or the milk during gestational 
exposure.   
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You and colleagues (1999) demonstrated that 1,1-dichloro-2,2-bis(p-chlorophenyl) 
ethylene (DDE) was stored in the mammary glands following in utero exposure and released 
during nursing.  When litters were cross-fostered, the lactational DDE exposure to the pups 
proved greater than that of the in utero exposure.  There are many pathways through which 
endogenous and exogenous substances enter milk including membrane or glucose transport, 
through mammary epithelial cell lipid secretion, or active transport mechanisms 
(McManaman and Neville, 2003).  You and colleagues (1999) suggested DDE, a lipophilic 
compound, associated with fatty acids or lipoproteins in mammary tissue used for milk 
production.  It is possible that ATR acts in a similar manner, being stored in the dam’s body 
and released with milk production.  We have observed delayed mammary gland development 
in offspring only exposed in utero or only through nursing in the exposure parameters studies 
as well as in the cross-fostering within each critical period studies. 
We suggest that ATR exposure to the pregnant dam may alter her milk composition.  
It has been shown that 100 mg/kg/d ATR inhibits suckling-induced prolactin surges in Wistar 
rats (Stoker et al., 1999).  From the number of papers evaluating hormonal control of 
development of the mouse mammary gland (reviewed in Rosen et al., 1994 and Silberstein, 
2001), it is known that many hormones and growth factors contribute to the correct 
development of the rodent mammary gland.  Disruption of one or several of those factors 
(many of which are milk-borne) may contribute to the delay in development seen in these 
studies.  Additionally, it is possible that hormone production other than those we evaluated 
contribute to our findings.  However, we do not suspect that altered maternal behavior or a 
lack of milk production by the dam is the moderator of effect since a relatively small change 
in body weight was seen in the offspring due to treatment.  Further, we see these as early 
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effects, interrupting local growth factor-regulated development of the mammary bud, or early 
neonatal outgrowth of the gland as the effects of exposure are apparent as early as PND 4. 
It did not appear that the mammary gland delays observed in the offspring were the 
result of changes in puberty in the animals.  Early mammary gland development is controlled 
by many hormones and local growth factors.  As stated earlier, estrogen, progesterone, and 
prolactin are important to the proper growth and development of the mammary gland.  
Growth hormone acts on stromal cells to stimulate end bud formation and mammary 
epithelial proliferation.  EGF and insulin-like growth factor-I and II play essential roles in 
mammary gland development.  Members of the transforming growth factor-β family have 
been found to be involved in both ductal and lobuloalveolar development (Silberstein, 2001).  
Even though we did see a delay in VO and mammary development, our statistical analyses 
did not show an interaction between these endpoints, suggesting that the delay in VO was not 
associated with the developmental delays seen in the mammary gland.  We propose, rather, 
that an early imprinting effect, either via transplacental exposure to atrazine or early 
lactational exposures may be the cause of the delays seen in peripubertal mammary 
development. 
From puberty to adulthood, the rodent mammary gland undergoes allometric growth, 
characterized by the mammary gland growing nearly 4 times faster than body surface area.  
This growth is dependent on ovarian hormone and local factors (Daniel and Silberstein, 
1987).    Sanderson et al. (2000) reported the induction of aromatase by ATR in a human cell 
line and Yue et al. (2001) reported the moderate down-regulation of aromatase activity in 
breast cancer cells by estrogen suggesting that estrogen plays a role in regulating aromatase 
in the breast.  Oka et al. (1991) suggests that EGFR numbers in the mammary gland are high 
 128
during proliferative phases and low when the gland is in its resting state.  Growth factors and 
enzymes that bind EGFR, in addition to endocrine factors that regulate its expression, may be 
important in controlling mammary gland growth and development via stromal-epithelial 
interactions.  Wiesen et al. (1999) reported that EGFR is essential to induce estrogen-
dependent ductal growth and branching morphogenesis.  From this, they suggest that EGFR-
mediated signaling, via estrogen action, is required for stimulation of epithelial growth and 
development.  During this period of time, PND33, we found that animals within the ATR 
exposure parameters had less aromatase and EGFR RNA expressed in their mammary 
glands.  Our data suggest that ATR exposure can decrease aromatase and EGFR expression 
in the mammary gland, but the mechanism by which these events occur is unknown. 
The mode of action of atrazine for the developmental delays in the rat mammary 
gland is unknown.  There were no changes in puberty or hormones that could be associated 
with delayed mammary gland development in our study.  However, we know that body 
weight is not the answer.  Only the offspring from dams dosed GD13-19 in the critical period 
study exhibited delayed VO, indicating again that VO is not altered in a time/dose paradigm 
similar to ATR-induced mammary gland development delays.  Delayed VO seems to require 
longer ATR exposures than does the notable mammary changes.  This situation is 
reminiscent of pubertal changes in U.S. girls, where the timing of breast development and 
menses do not necessarily go hand-in-hand.  Data from over 17,000 girls (Herman-Giddens 
et al., 1997) and the Third National Health and Nutrition Examination Survey (Sun et al., 
2002) demonstrated that breast and pubic hair development are beginning earlier in both 
African-American and Caucasian populations and taking longer to conclude.  However, 
menses occurs at an age similar in these populations as that seen 30 years ago (Chumlea et 
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al., 2003). Many theories exist on the effect of the environment on these changes in sexual 
maturity. In our critical period study, the hormone concentrations measured from serum did 
not differ consistently among the groups, even when considered by stage of the estrous cycle.  
Statistical differences in hormone concentrations at PND33 did not persist to PND67 and 
were not outside the biologically normal value ranges.  This further indicates that serum 
hormone levels are not a direct causal factor in delaying mammary gland development 
following ATR exposure.  Once again, we go back to the possibility that the effect of ATR is 
an early imprinting effect and that the programmed growth pattern of the mammary 
epithelium was altered by the prenatal or early postnatal exposures. 
The effect of ATR on puberty could be explained by many different theories 
including hormonal changes or early postnatal brain development (specifically in the median 
eminence), critical to regulating the timing of vaginal opening, were altered by ATR and led 
to delays.  Atrazine may affect the enzymes or local growth factors in the median eminence 
that regulate LHRH release (Ojeda et al., 2000), the levels of ghrelin (a negative regulator of 
LH secretion and a marker of energy insufficiency; Fernandez-Fernandez et al., 2005), or 
possibly the circulating levels of leptin in the offspring were altered due to decreased appetite 
in the dams during the perinatal period.  Plasma leptin levels correlate with pubertal timing in 
rats (Leonhardt et al., 2003).  Altered maternal prolactin following ATR-exposure (Cooper et 
al., 2000) may influence these or other critical elements of pubertal timing in the offspring. 
Although we have no data to support any of these potential mechanisms of action for 
perinatal ATR exposure on pubertal delays, they are all consistent with known ATR modes 
of action (CNS and appetite-related effects). 
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 Either low levels of ATR or its metabolites are readily present in the milk of these 
animals or the milk quality of ATR-exposed dams is sufficiently compromised to cause the 
puberty delays. From the lactational challenge studies (Appendix B) we know that the ATR-
exposed pups are getting similar amounts of milk.  Atrazine metabolism follows first-order 
kinetics, and is reported to be rapidly eliminated from the body of adult non-lactating rats.  
For example, in adult female Sprague-Dawley rats given 100 mg/kg radio-labeled ATR 
(orally), 100% of the compound was recovered in 3 days (Atrazine Toxicology, 2002).  
Whether or not rapid elimination takes place in the pregnant and lactating dam is still in 
question. The mode and mechanism of action of atrazine on pubertal timing is unknown and 
deserves further investigation, focusing on exposure during the early postnatal period. 
In conclusion, my studies on Long Evans rats exposed to ATR prenatally have shown 
that brief in utero exposures to ATR, parent compound and/or low dose mixture, delays 
mammary gland development in the female offspring as early as PND4.  The mammary 
gland effects are not associated with body weight changes, puberty or serum hormone 
concentrations later in life.  I have shown that a critical window of susceptibility (GD17-19) 
exists during fetal mammary gland development.  During this time, the fetus of ATR treated 
dams is exposed to DACT and other metabolites in the amniotic fluid.  When the gland is 
exposed to ATR during this time, it leads to delayed mammary gland development that 
persists into adulthood.  These animals then have difficulty providing enough milk for their 
offspring.  I have also shown that ATR and/or metabolite associated changes 
(ATR/metabolites in milk or milk composition changes) in the dam dosed during late 
gestation (after GD17) can be transferred to naïve offspring and yield similar delayed 
mammary gland development as those seen in gestationally exposed offspring.  These studies 
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have shown that ATR accelerates pregnancy-related dam mammary gland development, and 
its metabolites can be detected in the dam as late as 13 days post dosing suggesting that 
metabolism of ATR is different in the pregnant and lactating rat than in the virgin rat.  From 
these data, it can be suggested that regulatory attention be given to ATR metabolites, some of 
which are known to be breakdown products of other chlorinated triazine pesticides.   
These studies have aided the Centers for Disease Control in achieving excellent 
quality standards and protocols for measuring ATR and metabolites in the human population.  
As well, they give insight into possible wildlife implications (low dose exposure) especially 
with respect to lactation and adverse effects on future generations.     
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APPENDIX A 
 
ATRAZINE AND METABOLITE CONCENTRATIONS  
 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in EBM GD13-19 Dam 
Urine 
 GD19 GD19U GD20 GD21 PND4 PND11 
DACT 36 27 24 10 70 8.6 
ATR-OH 38 15 2.5 10 11 0.70 
ATRM 0.27 0.06 0.17 0.10 0.004 0 
DEA 0.71 0.04 0.31 0.13 0.05 0 
DEAM 7.7 2.3 0.85 5.5 0.71 0 
DIA 1.0 0.1 1.3 0.50 0.24 0 
ATR 0.84 0 0.004 0 0 0 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in GD ATR17-19 Dam 
Urine 
 GD19 GD19U GD20 GD21 PND4 PND11 
DACT 73 26 124 34 1.7 173 
ATR-OH 30 13 6.3 0.43 0.32 4.5 
ATRM 2.0 0.94 1.0 0.032 0.22 0.57 
DEA 4.4 2.6 1.1 0.12 0.19 0.15 
DEAM 27 38 13 0.22 1.5 7.7 
DIA 12 6.4 3.5 0.10 0.64 1.9 
ATR 3.2 1.4 0.62 0.009 0.41 1.1 
Value of 0 indicates concentration below the limits of detection. 
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Millimolar Concentration of Atrazine Metabolites Detected in GD ATR13-19 Dam 
Urine 
 GD19 GD19U GD20 GD21 PND1 PND4 PND11
DACT 157 52 134 48 41 150 13 
ATR-OH 9.8 4.0 0.73 9.7 2.6 6.2 2.1 
ATRM 1.4 1.4 0.18 0.14 1.0 1.3 0.28 
DEA 5.5 2.8 0.80 0.90 5.6 3.4 1.0 
DEAM 27.4 22 2.8 1.6 18 17 4.3 
DIA 9.5 8.0 0.87 1.9 14 7.2 1.1 
ATR 2.2 1.4 0.15 0.083 3.6 2.1 0.44 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in Dam Urine on PND4 
3 Hours Post-dosing 
 Control EBM GD13-19 GD17-19 GD13-19 
DACT 0 23 71 294 
ATR-OH 0 18 3.7 11 
ATRM 0 0.15 1.1 2.2 
DEA 0 0.26 2.1 7,1 
DEAM 0 1.6 8.3 15 
DIA 0 0.42 6.1 9.1 
ATR 0 0.007 2.7 3.3 
Value of 0 indicates concentration below the limits of detection. 
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Millimolar Concentration of Atrazine Metabolites Detected in EBM GD13-19 Dam 
Amniotic Fluid 
 GD20 GD21 
DACT 2.1 0.28 
ATR-OH 0 0 
ATRM 0 0 
DEA 0 0 
DEAM 0 0 
DIA 0 0 
ATR 0 0 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in ATR GD17-19 Dam 
Amniotic Fluid 
 GD20 GD21 
DACT 48 6.2 
ATR-OH 0.026 0 
ATRM 0 0.005 
DEA 0.32 0.051 
DEAM 0.065 0.13 
DIA 1.0 0 
ATR 0.023 0.024 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in ATR GD13-19 Dam 
Amniotic Fluid 
 GD20 GD21 
DACT 21 10 
ATR-OH 0 0.11 
ATRM 0 0.015 
DEA 0.16 0.10 
DEAM 0.038 0.081 
DIA 0.11 2.3 
ATR 0 0.11 
Value of 0 indicates concentration below the limits of detection. 
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Millimolar Concentration of Atrazine Metabolites Detected in EBM GD13-19 Dam 
Serum 
 GD20 GD21 PND1 
DACT 1.9 0.34 0.035 
ATR-OH 0.008 0 0 
ATRM 0 0 0 
DEA 0.001 0 0 
DEAM 0 0 0 
DIA 0 0 0 
ATR 0 0 0 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in ATR GD17-19 Dam 
Serum 
 GD20 GD21 PND1 PND4 PND11 
DACT 0.013 0.24 0 0 0 
ATR-OH 14 4.9 0.29 0.025 0.032 
ATRM 0.017 0.011 0 0.001 0 
DEA 0.002 0.038 0 0 0 
DEAM 1.2 0.88 0 0.002 0.005 
DIA 0.43 0.18 0 0 0 
ATR 0.026 0.017 0 0.002 0 
Value of 0 indicates concentration below the limits of detection. 
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Millimolar Concentration of Atrazine Metabolites Detected in ATR GD13-19 Dam 
Serum 
 GD20 GD21 PND1 PND4 
DACT 0 0.002 0.022 0 
ATR-OH 9.7 3.0 0.26 0.013 
ATRM 0.003 0.023 0 0 
DEA 0 0 0 0 
DEAM 0.034 0.28 0.002 0 
DIA 0.086 0.072 0 0.025 
ATR 0.004 0.037 0 0.020 
Value of 0 indicates concentration below the limits of detection. 
 
 
 
 
Millimolar Concentration of Atrazine Metabolites Detected in Dam Serum on PND4 
3 Hours Post-dosing 
 Control EBM GD13-19 GD17-19 GD13-19 
DACT 0 5.7 0.008 0.13 
ATR-OH 0 0.12 10.6 9.9 
ATRM 0 0 0.13 0.040 
DEA 0 0.081 0 0.061 
DEAM 0 0 4.1 1.8 
DIA 0 0.071 1.2 0.87 
ATR 0 0.08 0.21 0.063 
Value of 0 indicates concentration below the limits of detection. 
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APPENDIX B 
ATRAZINE AND MATERNAL BEHAVIOR 
 
During the dosing period, dams are monitored closely to determine if treatment is having an 
adverse effect on the dam.  Dams are monitored following dosing to determine treatment 
effects on parturition and maternal behavior.  We observed ATR dams and their offspring, 
and hypothesized that ATR may alter maternal behavior leading to reduced weight gain of 
their offspring.     
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Methods 
These studies were performed within previous experiments. 
Animals-Time-pregnant Long Evans rats (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  The animals were housed in an 
AAALAC accredited facility, one per cage and given food (Purina 5008 Rodent Chow, 
Ralston Purina Co., St. Louis, MO) and water ad libitum.  They were maintained in a room 
with a 14:10 hour light cycle, 20-24°C and relative humidity of 40-50%.  Animal protocols 
were reviewed and approved by the National Health and Environmental Effects Research 
Laboratory, Institutional Animal Care and Use Committee. 
Dosing Solution and Procedures- ATR (Syngenta Crop Protection, Inc. Greensboro, NC, 
97.1% purity) was prepared as a suspension in 1.0% methyl cellulose (Sigma Chemical, St. 
Louis, MO) in distilled water.  The environmentally based mixture (EBM) was prepared as a 
suspension in 1.0% methyl cellulose (Sigma) in distilled water.  The EBM is a mixture of 
atrazine and its metabolites developed from the data accumulated from the North Carolina 
State Extension office and based on the highest measured levels of atrazine metabolites.  It 
consists of atrazine (25%), 2-chloro-4, 6-diamino-s-chlorotriazine (DACT 35%), 
hydroxyatrazine (HA 20%), 2-chloro-4-amino-6-(isopropylamino)-s-triazine (DEA 15%), 
and 2-chloro-4-amino-6-(ethylamino)-s-triazine (DIA 5%).  Time pregnant rats were treated 
in the morning with 0 (vehicle), EBM (total concentration equal to 8.7 mg/kg), or 100 mg 
atrazine/kg BW by oral gavage in 5 ml/kg dosing volume.  This ATR reference dose (100 
mg/kg/d) was chosen due to consistent reproductive endpoint effects observed in previous 
studies (Laws et al., 2000; Rayner et al., 2004; Stoker et al., 1999). 
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Experimental Design- Ninety six pregnant LE dams were treated with vehicle (control), 8.7 
mg/kg EBM, or 100 mg/kg ATR daily (N>9 dams/ exposure period/treatment).  Control and 
EBM dams were dosed gestational days (GD) 13-19 or GD15-19, and dams receiving ATR 
were dosed GD17-19, GD15-19, or GD13-19.  On PND4 remaining litters were weighed and 
randomly equalized to 10 pups.  On PND11, dams and pups were lactationally challenged. 
Lactational Challenge- On PND10 dams and pups were moved to a quiet holding room.  On 
PND11, dams were removed, weighed, and placed in clean individual cages with food and 
water ad libitum.  The bellies of the pups were rubbed to encourage urination, and then pups 
were individually weighed and placed back in their own nest.  Three hours later, dams were 
placed back with their pups.  The amount of time it took for dams to nest on their young was 
recorded, and dams were allowed to suckle their pups for 30 minutes after which dams were 
removed and decapitated.  Litters were reweighed immediately and euthanized. 
Mammary Gland Scoring- Dam mammary glands were subjectively scored.  Dam 
developmental scores were based on the percentage of the gland filled with lobuloalveolar 
units, the size of the units within each structure, and the amount of distention (by 
lobuloalveolar units) within the gland.  When the lobuloalveolar units were not empty, a 
score was given to the amount of secretory product present and the location of the product.   
Statistical Analysis- Group means and dam means (pups/dam; litter as unit) were calculated 
for body weights and time-to-nest and were evaluated for treatment effects within each age 
group by one-way analysis of variance (ANOVA, Statistical Analysis System (SAS), SAS 
Institute, Inc. Cary, NC).   
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Results  
Maternal Behavior- When dams were placed back into their cages after a three hour 
separation, they were watched and timed closely to determine the amount of time to settle 
over their litters in the arched-back crouched position and allow the pups to nurse.   The 
time-to-nest was not found to be different among the different treatment groups.  These data 
demonstrated that ATR does not change this aspect of maternal behavior. 
Although litters were culled to 10 pups on PND4, the average number of pups 
remaining on PND11 was 9.5 pups per litter per treatment group.  Litter weights prior to 
lactational challenge were not found to be statistically different among groups.     Following 
nursing, litters were weighed again to determine weight gain.  No statistical differences were 
found in litters weights or weight gain post nursing.  Weigh gain per pup were similar for all 
groups.  These data suggest that dam milk quantity is not altered in ATR treated dams.   
Pregnancy related dam mammary gland development- Dam mammary glands were 
examined for changes related to treatment following the lactational challenge.  They were 
scored for different developmental components as well as for content in the lobuloalveolar 
units.  No differences were found among the groups for development or content.  This data 
suggest that there are no dam mammary gland differences at PND11.   
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APPENDIX C 
 
ATRAZINE-INDUCED REPRODUCTIVE TRACT ALTERATIONS AFTER TRANSPLACENTAL 
AND/OR LACTATIONAL EXPOSURE IN MALE LONG-EVANS RATS 
 
These studies examine the effects observed after short-term prenatal exposure to ATR in 
Long Evans rats on pubertal timing, reproductive tissues, and hormone levels in the male 
offspring.  The effects on their female siblings were reported elsewhere.  Exposure 
parameters were designed to determine if exposure-induced changes were the result of 
transplacental or lactation exposure to ATR, or both.  We report male reproductive tissue 
effects following gestational exposure.  We have also evaluated the effects on the prostate via 
myeloperoxidase assays and pathological examination at both postnatal days 120 and 220.  
Our results suggest that late gestational exposure to atrazine and/or the resulting lactational 
effects of the prenatal exposure can influence prostate weight, hormone levels, and 
inflammation, long after the exposure has occurred, presumably due to its effects on 
developing tissues at the time of the exposure. 
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Methods 
Animals- Time-pregnant Long-Evans rats (LE) (sperm positive=Day 0) were purchased from 
Charles River Breeding Laboratories (Raleigh, NC).  Dams were housed one per cage in an 
AAALAC-International accredited facility and provided food (Purina 5008 Rodent Chow, 
Ralston Purina Co., St. Louis, MO) and water ad libitum.  The rats were maintained in a 
room with a 14:10 hour light cycle, 20-24°C and relative humidity of approximately 50%.  
Animal protocols were reviewed and approved by the National Health and Environmental 
Effects Research Laboratory (NHEERL), Institutional Animal Care and Use Committee.  
Animals tested negative for infectious diseases prior to beginning the study. 
Dosing Solution- Atrazine (Syngenta Crop Protection, Inc. Greensboro, NC, 97.1% purity) 
was prepared as a suspension in 1.0% methyl cellulose (Sigma Chemical, St. Louis, MO) in 
distilled water.  Timed-pregnant rats were treated with vehicle or 100 mg ATR/kg BW by 
oral gavage in 5 ml/kg dosing volume.  The dose of ATR was chosen based on consistent 
results on reproductive tissues in previous studies (Laws et al., 2000; Rayner et al., 2004; 
Stoker et al., 1999a). 
Experimental Design- The general study design has previously been reported (Rayner et al., 
2004).  Briefly, 40 pregnant LE dams were treated on gestational days (GD)15-19 (time 
period during which reproductive tissues are developing) with vehicle, C, or 100 mg/kg 
ATR/BW.  On PND1 (day of birth), litters were weighed and half litters were cross-fostered 
with half of another litter from a vehicle or ATR treated dam, creating four exposure 
parameters: dam born to or gestational exposure only (ATR-C), milk source or lactational 
exposure only (C-ATR), exposure both pre- and postnatal (ATR-ATR), or neither (C-C).  
Pups were individually identified.  Litters were weighed and randomly equalized to 10 pups 
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on PND4.  At weaning, PND22, animals were weighed and separated into unisex sibling 
groups, with two male rats per cage.  Males were singly housed if aggressive behavior was 
observed within a cage.  Males were euthanized and necropsied on PND120 or 220.   
Preputial Separation- Beginning on PND 37, male offspring (N>18 males/group) were 
evaluated for puberty. The separation of the foreskin of the penis from the glans (preputial 
separation, PPS) was used to determine if an animal had gone through puberty (Korenbrot et 
al., 1977).  The day of complete PPS and body weight on that day were recorded. 
Necropsy- Necropsies were performed following an overnight and continued stay in a quiet 
holding area, and by using decapicones for animal transfer to reduce stress.  Males were 
euthanized on either PND120 (N=10/group) or 220 (N>8/group).  Following decapitation, 
trunk blood was collected into serum separator tubes and centrifuged for 30 minutes at 3000 
rpm (4ºC) to obtain serum for hormone assays.  The pituitary gland, testes, lateral and ventral 
prostates, and seminal vesicles of each animal were removed and individually weighed.  
Gross lesions were recorded.  The right lateral and ventral prostates were fixed in 10% 
neutral buffered formalin for routine histology.  Pituitary glands and left lateral prostates 
were placed on dry ice, frozen, and stored at -80°C.   
Radioimmunoassays- Sera obtained from male offspring PNDs 120 and 220 were analyzed 
for prolactin levels by radioimmunoassay using materials supplied by the National Institute 
of Arthritis, Diabetes, Digestive, and Kidney Diseases.  The prolactin assay was run as 
previously described in detail by Stoker et al., (2000).  Total serum testosterone and 
androstenedione were measured using Coat-a-Count Radioimmunoassay Kits obtained from 
Diagnostic Products Corporation (Los Angeles, CA).  Serum estrone was measured using the 
DSL 8700 Estrone Radioimmunoassay kit from Diagnostic Systems Laboratories, Inc. 
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(Webster, TX).  All assays were run in duplicate following manufacturer’s directions.  Inter-
assay coefficients of variation for the prolactin, testosterone, adrostenedione, and estrone 
assays were 5.2%, 4.7%, 4.4%, and 4.9% respectively. 
Myeloperoxidase Assay- The left lateral prostates collected on PNDs120 and 220 were 
analyzed for myeloperoxidase (MPO) activity.  Tissues were homogenized and prepared as 
described in detail by Stoker et al., (1999a) for myeloperoxidase assays.  The supernatant 
(250 µl) of the tissue homogenate was assayed using the APLCO Myleperoxidase ELISA kit 
(American Laboratory Products Company, Windham, NH) following the manufacturer’s 
directions.  Duplicate samples were loaded onto a 96-well plate coated with anti-MPO 
antibody.  A peroxidase-conjugated polyclonal anti-MPO antibody was added followed by 
tetramethylbenzidine and a stop solution.  The plate was read on a Spectra Max Plus 
Microplate Reader (Molecular Devices Corporation, Sunnyvale, CA) at an excitation 
wavelength of 450 nm.  The standard curve used in the assays had correlation coefficients of 
R=0.99 (PND120) and R=1.0 (PND220).  The data was used to calculate the MPO 
concentration in each sample according to the manufacturer’s directions. 
Histology and Pathology- The right lateral and ventral prostates which were fixed in 10% 
neutral buffered formalin, and were processed by routine methods to paraffin block.  Five 
slides were prepared from each gland; 5 µm sections were taken following step-sectioning 
through the gland (skipping 20 µm segments). They were stained with hemotoxylin and eosin 
(H&E) for microscopic examination.  All 5 slides from a single prostatic lobe were examined 
without knowledge of treatment and graded based on the distribution (% of gland affected) 
and severity (magnitude of cellular infiltrate) of the inflammation.  Distribution scores were 
as follows: 0- none, 1 - 10% or less of gland affected, 2 – approximately 25%, 3 – 
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approximately 50%, 4 – 75% or greater of the gland affected.  For severity of inflammation 
in organ: 0 – no infiltration of inflammatory cells, 1 - minimal interstitial infiltration of 
inflammatory cells, 2 - moderate interstitial inflammation with or without focally marked 
accumulations of perivascular collections of inflammatory cells, 3 - early micro-abscess 
formation, mild numbers of inflammatory cells in acinus with some degradation of colloid, 4 
– micro-abscess, 5- micro-abscess with moderate to marked interstitial inflammation.  If two 
or more slides per gland were found to have inflammation a score was given and averaged 
according to the most severe lesion per slide.  No score was given if a lesion was found on 
only one slide.  In addition, the cellular component of the inflammatory process was 
identified.  Lymphocytes were most commonly present.  If neutrophils made up more than 
10% of the inflammatory cell population then both the diagnosis of lymphocytes and 
neutrophils were made.  If neutrophils were more than 90% of the cell population then only 
the diagnosis of neutrophils was made.  The prostates were also examined for the presence of 
edema which was characterized by expansion of the interstitial spaces between the glandular 
acini with eosinophilic proteinaceous material present.   
Statistical Analysis- Dam means (vs. litter means, because half litters were crossed) were 
calculated for PPS, as well as male offspring body and tissue weights.  Data were evaluated 
for age and treatment effects by analysis of variance (ANOVA) using least-squares 
regression model (LSM) (Statistical Analysis System (SAS), SAS Institute, Inc. Cary, NC).  
Means were evaluated and treatment groups compared to each other.  Means and adjusted 
means relative to body weight were calculated for organ weights.  These means were 
compared with control means and among treatment groups. Body weights, serum hormone 
concentrations, and MPO concentrations were analyzed by one-way ANOVA.  Visual 
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evidence of prostate abnormalities was analyzed in a contingency table using Fisher’s exact 
test in Graphpad Instat (Graphpad Software, San Diego, CA).   Prostate pathology 
distribution and severity scores were analyzed for treatment and age effect by t-test and 
Dunnett’s multiple comparison in JMP (SAS).  Significant treatment effects were indicated 
when p<0.05. 
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Results 
Growth and Puberty- The male offspring in the ATR-ATR group were significantly smaller 
(p<0.001) at PND4 when compared to offspring in the C-C and C-ATR groups (8.6+0.1g 
ATR-ATR vs. 9.2+0.1g C-C, 9.0+0.2g ATR-C, and 9.2+0.1g C-ATR).  Although 
statistically significant, the offspring were only found to have a 6.5% reduction in weight, 
and this is within normal biological size variation.  This small decrement in weight was also 
reported in ATR-ATR exposed female siblings (Chapter 4), but is not due to lack of weight 
gain in utero (Chapter 5). At weaning, PND22, the treatment groups were all similar in body 
weight (56.9+1.0g C-C, 54.6+1.1g ATR-C, 54.6+1.0 g C-ATR, and 56.0+0.9g ATR-ATR).  
Body weights in the C-ATR males were reduced 8.4%, but other males were not different at 
PND120 (Table 1).  Animals from the ATR-C group were significantly smaller (p<0.05) than 
animals in the control and C-ATR groups at PND220 (Table 1).   
Male offspring were evaluated for preputial separation (PPS) as a physical indication 
of puberty.  Control males displayed PPS on PND 41.3+0.3 (Fig. 1A).  A significant 2 ½ day 
delay was seen only in males in the ATR-ATR group (43.7+0.5, p<0.01).  This delay was 
also significant when compared to males in the remaining groups.  Body weights at time of 
PPS were decreased in the ATR-ATR animals (p<0.01 vs. C-C, Fig. 1B).  While a significant 
reduction in body weight was not seen in the remaining ATR groups, there was a trend for 
body weight reduction (3-7%) at time of puberty, in addition to a 1.5 day (p=0.07) delay in 
mean day of PPS in the C-ATR group. 
Reproductive Tissue Weights- Reproductive tissues and pituitaries were removed from 
male rats on PND 120 or 220.  There were no significant weight differences among the 
groups for pituitary glands in rats euthanized at PND120 (Table 1).  The pituitary glands 
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from the prenatally ATR exposed males weighed significantly more than those taken from 
controls at PND220, regardless of when the exposure occurred.  However, when controlling 
for body weight of the animals in the distinct treatment groups, pituitary gland weights of 
animals in the ATR-C and ATR-ATR treatment groups were significantly increased 
compared to control animals (p<0.03).   
Significant changes in weight were not detected or present for other male 
reproductive tissues from the various ATR exposures (Table 1, whether or not body weight 
was a covariate), there was a consistently significant difference in lateral prostate weights at 
both time points.  At PND120, the lateral prostates of the ATR-ATR offspring group 
weighed significantly more (p<0.01) than those in any other group (Fig. 2).  When lateral 
prostate weights were compared using body weight as a covariate, they were still found to be 
significantly different (p<0.01) when compared to all other groups.  The average ATR-ATR 
lateral prostate weight was 49% higher than control.  At PND220, lateral prostate weights 
were significantly increased in animals within all ATR exposure groups compared to control 
animals, 45-110%.  When adjusted for BW (statistical differences shown in Fig. 2), animals 
in ATR-C and ATR-ATR groups had significantly increased lateral prostate weights 
(p<0.01).  While lateral prostate weights from the ATR-ATR males were significantly 
different from all other groups (p<0.03), weights from males in the ATR-C group were 
considered different from C-C and ATR-ATR (p<0.03).  The greater average body weight in 
the PND220 C-ATR group reduced the apparent significance of the lateral prostate weight 
effect. 
At necropsy, seven of ten offspring in the ATR-ATR group had macroscopic 
abnormalities characterized by nodular pale white foci present on the outer surface of the 
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lateral prostates at PND120 (three on right lateral, four on left lateral prostate, Table 2) which 
was statistically different from C-C and ATR-C group as both lacked macroscopic 
alterations.  The C-ATR group had four of ten males with macroscopic prostate alterations.  
All were found on the right lateral prostate.  At PND220, visible abnormalities were present 
in all ATR exposed groups.  The majority were found on the right lateral prostate.  As shown, 
ATR-C males had 22% and ATR-C had 40% displaying macroscopic nodules.  ATR-ATR 
had 56% with alterations which was significantly different from C-C group which had none 
visible foci.    
Histopathology- At PND120, the distribution of inflammation in the lateral prostates of 
males from the C-ATR group was significantly increased compared to control males (p<0.05, 
Fig 3, Table 3) which was localized to focal areas of the tissue.  Affected glands had high 
multiple acini affected with inflammation present in the interstitial space and the acinus, and 
micro-abscesses (Fig. 3).  The C-ATR and ATR-ATR glands had neutrophils as the 
predominant inflammatory cell.  They were more prominent in the ventral prostate (Figure 4) 
in all dose groups, and associated with a higher incidence of inflammation in the ventral 
prostate sections at PND120 (Table 3).  The inflammation in the ventral prostate was not 
dose related and presented a wider tissue distribution than the lateral prostates.  The severity 
of inflammation in the ventral prostate was not affected by ATR exposure.   
At PND220, no significant increases in prostate inflammation were present (Table 4), 
however, the incidence, distribution, and severity of inflammation in the ventral prostate 
were decreased compared to that present at PND120.  The lateral prostates were not different 
form control.  There was no increase in incidence or severity of prostate inflammation over 
time following ATR exposure.      
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Myeloperoxidase Assay (MPO)-The MPO was assayed separately for PND120 and 220, 
and the values of the internal standards varied by less than 1% between runs. The positive 
and negative controls used in the assay resulted in the expected values. While total lateral 
prostate weights were increased at both PND120 and 220, MPO assay data showed that the 
inflammation in the left lateral prostates of offspring of treated dams was not different from 
controls at PND120 (Table 5).  Even though, ATR-ATR males had 14% more MPO than 
control males, the difference lacked statistical significance.  This increase was consistent 
with the observed increase in macroscopic alterations in that group of animals.  A general 
increase in MPO concentration was noted in the lateral prostates within a treatment group 
between PND120 and 220.  A significant decrease was seen between MPO concentrations in 
the ATR-ATR group and C-C group (p<0.002) at PND220.  ATR-C animals had MPO 
concentrations similar to C-C while those in C-ATR groups were lower.  This is inconsistent 
with the observations of visible abnormalities, but could possibly be explained by the use of 
the left lateral prostate and not the right in which the majority of visible abnormalities were 
observed at necropsy or because neutrophils were not always the predominant inflammatory 
cell present.   
Serum Hormone Measurements- Serum hormone concentrations of total testosterone, 
androstenedione, estrone, and prolactin by RIA are presented in Table 6.  There were no 
statistically significant differences in serum hormone concentration among the groups at 
PND120 for testosterone, androstenedione, estrone, and prolactin.  However, there was a 35-
40% increase in mean testosterone levels in C-ATR and ATR-ATR males when compared to 
control males, but these levels were within what is regarded to be a physiological range.  The 
same males from these two groups also had slightly increased (7-10%) androstenedione 
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levels.  These increases were not statistically different.  All three ATR exposed groups had 
non-significant increases in estrone (10-20%) and prolactin (14-31%) levels.   
By PND220 (Table 6), testosterone and estrone levels for all animals had decreased from 
PND120 levels, but ATR exposed animals’ hormone levels still remained higher than 
controls.  Testosterone levels in all ATR exposed groups were 20-60% higher than control 
levels.  ATR-C and C-ATR males had slightly increased (26-29%) androstenedione levels vs. 
controls.  Steroid hormone ratios, particularly those controlled by aromatase and 17-β 
hydroxysteroid dehydrogenase, were evaluated but no statistical differences were found at 
either time point.  Prolactin levels in all ATR-exposed animals were significantly lower than 
those in the C-C group (33-55%).  Prolactin levels in the ATR-ATR group were less than 
half of that measured in controls.  These ATR-exposed animals also had enlarged pituitary 
glands at PND220 (Table 1). 
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Discussion 
These studies demonstrated that a five-day exposure to 100 mg ATR/kg BW/d during 
late gestation resulted in effects present at seven months after the exposure period had ended 
in Long Evans rat offspring.  The developing lateral prostate and anterior pituitary gland 
appeared to be sensitive to the effects of a brief prenatal or a residual lactational exposure to 
ATR.  ATR from lactational exposure appeared to work in combination with in utero 
exposure to enhance delays in puberty, serum prolactin, pituitary weight, and lateral prostate 
weight compared to gestational exposure alone.  Similar to what was observed for mammary 
gland (Rayner et al., 2004), continual exposure of the developing offspring to ATR is not 
required for altered gland development (prostate enlargement) or altered hormone status in 
later life.  The males exposed to ATR only during gestation had enlarged prostates and 
anterior pituitary glands at seven months of age and decreased serum prolactin.  Lactational 
exposure appeared to enhance the effects of gestational exposure resulting in prostate 
enlargement three months earlier.  Lactational exposure only (C-ATR group) increased 
distribution of inflammation in the lateral prostate.  The inflammation caused by ATR does 
not progress or become more severe over time.  Therefore, it is not possible to predict from 
these data the full effects that perinatal ATR exposure may manifest in the adult, aged rat 
prostate. 
Studies have shown that peripubertal ATR exposures delayed puberty (Stoker et al., 
2000, Trentacoste et al., 2001) and lactational ATR exposures increased the incidence and 
severity of lateral prostate inflammation at PND120 (Stoker et al., 1999a).  The present study 
also demonstrated a delay in puberty in males with combined gestational and lactational 
exposure.  The female siblings of these males exposed gestationally and lactationally and 
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those exposed only through lactation also displayed delayed puberty.  However, the females 
had increased weights at time of puberty (Chapter 4).  It is possible that the lower body 
weight of the males contributed to the delayed puberty observed as suggested by Kennedy 
and Mitra (1967).  Our data also agrees with previous reports (Laws et al., 2000; Stoker et 
al., 2000) that the amount of atrazine needed to induce pubertal delays is much lower than 
the 100 mg/kg/d dose administered, because the 5 day dosing of the dams in our study ceased 
on GD19 and pups exposed to only the milk of those dams were affected (1 ½ day delay). 
In our studies, we did observe lateral prostate inflammation in 120 day old control 
pups following suckling from dams with prenatal ATR exposure (potentially through 
lactational exposure). This effect was insignificant at the later time point suggesting the 
inflammation may be a transient effect, or that much longer exposures to increased 
circulating prolactin (and potentially steroid hormones) are needed to increase the incidence 
and severity of the effects on the prostate. Only males exposed through lactation had 
increased distribution of inflammation in the lateral prostate was consistent with Stoker et al., 
(1999a).  However, neither prenatal nor postnatal ATR exposure increased inflammation in 
the ventral prostate in our study and the combined exposure did not lead to increased 
inflammation of either prostatic lobe.  The visual lateral prostate abnormalities noted at 
necropsy actually were increased by both pre-and postnatal ATR exposure (Table 2), but 
were located on the surface of the gland and may not have penetrated deep within the gland, 
as relatively small focal areas seem to be affected in the lateral prostate. The five slides per 
animal for pathological examination (step-sectioned through gland) covered a small portion 
of the entire gland and it is possible that we may have missed inflamed sites located deeper 
or more superficial in the gland.  We also used a conservative approach in assessing 
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“inflammation” as 2 of the 5 slides had to reveal evidence of inflammation before we scored 
it as a positive.  With that said, many reported prostate inflammation studies score a single 
slide for pathology.  It is possible that not having both lateral prostate glands (one used for 
MPO and one for pathology) available for evaluation could have increased variability and 
caused the MPO concentrations and pathology to disagree.  Judging by the visible lesions 
seen in our study, the lateral lobes of the prostate were not affected equally. Furthermore, the 
inconsistencies of a predominance of neutrophils in the affected prostate glands (at either 
timepoint) suggests that the inflammation may be more of a chronic state in some animals, 
and not an acute response as would be suggested by polymorphonuclear cells (neutrophils) at 
the inflammation site. This, too, would potentially cause a disagreement between the 
pathology results and MPO outcomes.    Future studies should section and evaluate the entire 
prostate gland and not rely strictly on MPO if the response is not known to have an acute 
neutrophil response. 
The present study on early life ATR exposure evaluated circulating hormone 
concentrations at about 4 and 7 months of life.  We detected hormone levels that were both 
consistent and that differed from previous work. Stoker and colleagues (1999c) found no 
statistical differences in steroid hormones at PND120 when they examined male Wistar rats 
treated PND22-32 with pimozide, bisphenol A, or estradiol.  They did find that prolactin 
levels in their treated animals were higher at PND29. By PND120, serum prolactin levels 
were not different between the groups.   Males exposed to pimozide and bisphenol A also 
had increased lateral prostate weights at PND120.  Perinatal methoxychlor exposure was 
shown to increase anterior pituitary prolactin levels (but not serum prolactin levels) and 
lateral prostate weights at PND90 (Stoker et al., 1999b).  In males exposed to ATR via 
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lactation, Stoker et al., (1999a) reported significantly lower concentrations of serum prolactin 
in PND120 males from dams exposed to 50 mg/kg ATR cotreated with ovine prolactin, but 
there were no lateral prostate differences among the treatment groups, suggesting that the 
addition of exogenous prolactin alleviated the adverse effects of ATR on pup prostate 
development.  Stoker and colleagues (2000) found no differences in steroid or pituitary 
hormones at PND120 and no differences in lateral prostate weights at PND120 in male 
Wistar rats exposed to varying amounts of ATR during PND23-53.  Our hormonal 
observations began at PND120, and no statistical differences were noted at that time, 
although trends for increase in testosterone and prolactin were noted.  However by PND220, 
there was a decrease in serum prolactin and coincidently an increase in anterior pituitary 
gland weight in males born to ATR treated dams.  While ATR has not been classified as an 
estrogen mimic, it is considered to be an endocrine disruptor and has been shown to suppress 
prolactin and luteinizing hormone (Cooper et al., 2000).  ATR may disrupt placental and 
early postnatal hormones leading to permanent changes in early prostate development 
resulting in growth with age, as observed by the lateral prostate weight increases in the 
present study.   
The results of the present study suggest that the developing lateral prostate glands in 
Long Evans rata are sensitive to gestational, and lactational ATR exposure.  A combination 
of pre- and early postnatal ATR exposures delayed puberty, enhanced lateral prostate gland 
effects, and decreased serum prolactin.  The exposure parameters responsible for the pubertal 
outcomes are consistent with what we previously reported for the female siblings (Chapter 
4).  However, the males may have been more sensitive to ATR as they also exhibited slight 
decrements in body weight at the time of puberty that was not observed in the female pups. 
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 Table 1. Effect of 100 mg/kg ATR* on reproductive organ weights at PND120 and 
PND220 
PND120 C-C1 ATR-C C- ATR ATR-ATR 
Body Wt(g) 661.6 + 17.3 623.4 + 18.5 605.7 + 13.9a 616.0 + 18.3 
Pituitary(mg) 10.08 + 0.66 9.65 + 0.71 9.64 + 0.49 10.34 + 0.34 
Left Testis(g) 1.99 + 0.04 1.98 + 0.03 1.87 + 0.08 1.88 + 0.07 
Right Testis(g) 1.92 + 0.04 1.92 + 0.03 1.87 + 0.04 1.85 + 0.07 
Seminal Vesicle Wet(g) 1.64 + 0.25 1.45 + 0.10 1.43 + 0.08 1.58 + 0.07 
Seminal Vesicle Dry(g) 0.728 + 0.04 0.698 + 0.04 0.700 + 0.02 0.774 + 0.03 
Ventral Prostate(mg) 524.0 + 42.4 469.9 + 33.6 451.1 + 28.0 532.3 + 32.9 
     
PND220     
Body Wt(g) 777.3 + 26.6 703.5 + 23.5ab 804.1 + 31.5 739.3 + 10.8 
Pituitary(mg) 8.41 + 0.98 10.38 + 1.05c 10.52 + 0.81 12.9 + 0.72de
Left Testis(g) 1.97 + 0.06 1.89 + 0.07 2.01 + 0.06 2.10 + 0.07 
Right Testis(g) 1.92 + 0.06 1.85 + 0.07 1.99 + 0.05 2.03 + 0.07 
Seminal Vesicle Wet(g) 1.67 + 0.12 1.74 + 0.09 1.92 + 0.15 1.86 + 0.10 
Seminal Vesicle Dry(g) 0.775 + 0.04 0.851 + 0.03 0.944 + 0.05 0.819 + 0.05 
Ventral Prostate(mg) 545.5 + 26.9 576.5 + 23.8 579.6 + 44.1 525.3 + 56.3 
ATR= atrazine, PND= post natal day.  Data presented as dam mean + SE. 1Dam-Milk source. 
PND120- Dam N=5-6, with n= 10 offspring per exposure group. 
PND220- Dam N=4-5, with n = 8-10 offspring per exposure group. 
a Significant treatment effect by ANOVA; p<0.05 vs. C-C. 
b Significant treatment effect by ANOVA; p<0.01 vs. C-ATR. 
Analysis  indicated is shown for BW as covariate. 
c Significant treatment effect by ANOVA; p<0.03 vs. C-C. 
d Significant treatment effect by ANOVA; p<0.01 vs. C-C. 
e Significant treatment effect by ANOVA; p<0.03 vs. C-ATR 
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 Table 2.  Visual evidence of prostate abnormalities at necropsy 
Dam-Milk Source PND 120 PND220   
C-C 0/10 0/8   
ATR-C 0/10 2/9   
C-ATR 4/10 4/10   
ATR-ATR   7/10a 5/9b     
Data presented as # of animals exhibiting prostate abnormalities/ total # of  
animals per group.   
PND120- Dam N=5-6, with n= 10 offspring per exposure group. 
PND220- Dam N=4-5, with n = 8-10 offspring per exposure group. 
Analysis of abnormalities- 2 sided p- values 
a p=0.003 vs. C-C &C-ATR. 
b p =0.03 vs. C-C.  
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Table 3.  Prostate pathology on PND120 
Lateral prostate inflammation:     
Total Incidence 
Group*  Incidence Distribution Distribution Severity Severity Neutrophils 
 
Inflammation 
     (total) (affected)  (total) (affected)  
  
  
 
C-C  0/10   0  0 0 0 0 8/10 
ATR-C 0/10 0 0 0 0 0 8/10 
C-ATR 3/10 0.5 + 1.0a 1.7 + 1.2 1.1 + 2.1 3.7 + 2.3 2/3 7/10 
ATR-ATR   1/10 0.1 + 0.3 1.0 0.5 + 1.5 5.0  
 
1/1 6/10 
 
Ventral prostate inflammation:  
 Incidence Distribution Distribution Severity Severity Neutrophils 
 
 
     (total) (affected)   (total) (affected)  
C-C  8/10   1.1 + 0.07 1.4 + 0.5 1.2 + 0.9 1.5 + 0.7 3/8  
ATR-C 8/10 1.7 + 1.3 2.1 + 1.0 1.1 + 1.1 2.0 + 0.8 4/8  
C-ATR 7/10 1.4 + 1.2 2.0 + 0.8 1.3 + 0.9 1.9 + 0.4 2/7  
ATR-ATR   6/10 1.1 + 1.1 1.8 + 0.8 1.0 + 1.1 1.7 + 0.8 1/6  
* Group= Dam-Milk Source Data presented as dam mean + SE. PND120- Dam N=5-6, with n= 10 offspring per exposure group. 
All significant effects vs. Control.  Total Incidence=lateral and ventral lobes. a Significant treatment effect by t-test; p<0.05.  
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Table 4.  Prostate pathology on PND220 
Lateral prostate inflammation:    Total Incidence 
Group*  Incidence Distribution Distribution Severity    Severity Neutrophils Inflammation
     (total) (affected)   (total) (affected)   
C-C  1/8   0.1 + 0.4  1.0 0.5 + 1.4 4.0 1/1 2/8 
ATR-C  2/9 0.3 + 0.7 1.5 + 0.7 0.9 + 1.8 4.0 + 1.4 2/2 4/9 
C-ATR  3/10 0.2 + 0.6 2.0 0.5 + 1.6 5.0 1/3 2/10 
ATR-ATR   2/9 0.2 + 0.4 1.0 0.8 + 1.8 4.0 2/2 4/9 
 
Ventral prostate inflammation: 
 
 
Incidence     Distribution Distribution Severity Severity Neutrophils
     (total) (affected)   (total) (affected)   
C-C  1/8   0.1 + 0.4 1.0 0.1 + 0.4 1 1/1  
ATR-C  2/9 0.2 + 0.4 1.0 0.4 + 1.0 2.0 + 1.4 0/2  
C-ATR  1/10 0.1 + 0.3 1.0  0.3 + 0.9 3 1/1  
ATR-ATR   3/9 0.4 + 0.7 1.3 + 0.6 0.9 + 1.4 2.6 + 0.6 1/3  
* Group= Dam-Milk Source Data presented as dam mean + SE. PND220- Dam N=4-5, with n = 8-10 offspring per exposure group. Total Incidence=lateral and ventral 
lobes. 
 
 
 
 Table 5.  Concentration (ng/ml) of myeloperoxidase in left prostate at PNDs 120 and 
220 
 C-C1 ATR-C C- ATR ATR-ATR 
PND120 44.5 + 2.75 41.3 + 1.83 45.3 + 2.50 51.9 + 3.61 
PND220 224.1 + 29.1 228.7 + 35.6 155.3 + 22.8 84.7 + 16.2a
Data presented as dam mean + SE.   1Dam-Milk source. PND120- Dam N=5-6, with n= 10 offspring per exposure 
group. PND220- Dam N=4-5, with n = 8-10 offspring per exposure group. a Significant treatment effect by ANOVA; 
p<0.01 vs. C-C. 
 
 
 
Table 6.  Serum hormone concentration at PND120 and PND220 
PND120 C-C1 ATR-C C- ATR ATR-ATR 
Testosterone(ng/ml) 1.00 + 0.17 1.04 + 0.24 1.41 + 0.29 1.35 + 0.31 
Androstenedione(ng/ml) 0.360 + 
0.04 
0.353 + 
0.04 
0.395 + 
0.05 
0.386 + 
0.04 
Estrone(pg/ml) 43.5 + 3.01 52.1 + 4.82 50.4 + 4.30 47.9 + 3.80 
Prolactin(ng/ml) 2.97 + 0.39 4.10 + 0.71 3.31+ 0.34 3.38 + 0.39 
     
PND220     
Testosterone(ng/ml) 0.613 + 
0.18 
0.982 + 
0.22 
0.737 + 
0.14 
0.819 + 
0.15 
Androstenedione(ng/ml) 0.318 + 
0.05 
0.410 + 
0.03 
0.400 + 
0.04 
0.315 + 
0.05 
Estrone(pg/ml) 16.9 + 2.21 20.7 + 2.79 21.4 + 2.96 25.1 + 2.91 
Prolactin(ng/ml) 5.72 + 0.86 3.81 + 0.38a 3.86 + 
0.55a
2.55 + 0.19b
Data presented as dam mean + SE. 1Dam-Milk source. PND120- Dam N=5-6, with n= 10 offspring per exposure 
group. PND220- Dam N=4-5, with n = 8-10 offspring per exposure group. a Significant treatment effect by ANOVA; 
p<0.02 vs. C-C. b Significant treatment effect by ANOVA; p<0.01 vs. C-C. 
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Figure 1.  Effect of gestational exposure to 100 mg/kg BW/day on age and weight at time of 
preputial separation (PPS).  (A) Age (days) at the time of PPS.  Data presented as dam mean 
+ SE.  Groups listed as dam-milk source. Significant treatment effect by ANOVA (LSM).  
aDifferent from C-C, p<0.0001.  (B) Dam mean + SE of body weight (g) at the time of PPS.  
aDifferent from C-C, p<0.01. 
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Figure 2.  Total lateral prostate weight at PNDs 120 & 220.  Data presented as dam mean + 
SE (mg). Groups listed as dam-milk source. Significant treatment effect by ANOVA (LSM).  
aDifferent from C-C, ATR-C, and C-ATR, p<0.001. b Different from C-C p<0.03.  cDifferent 
from C-C, ATR-C, and C-ATR, p<0.03. 
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  Figure 3.  Histological sections of lateral prostates at PND120.  Groups listed as dam-milk 
source. (A, B) C-C offspring displaying few inflammatory cells. (C, D) C-ATR offspring 
found to have statistically significant distribution and severity of inflammation.  Note the 
infiltration (arrow) of inflammatory cells and micro-abscess (ma) formation.  A, C at 100X; 
B, D at 200X magnification.  
A  C-C B   C-C 
ma
C C-ATR D  C-ATR
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Figure 4.  Histological sections of ventral prostates at PND120. (A, B) C-C offspring. (C, D) 
ATR-C offspring. The ATR-C prostate shown represents severe inflammation given a grade 
of 3 in this prostatic lobe. A, C at 100X; B, D at 200X magnification. 
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